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ABSTRACT 
 
Purpose: This study compares overall survival (OS) and biochemical failure-free 
survival (bFFS) in low- and intermediate-risk prostate cancer patients that received 
brachytherapy [low-dose-rate brachytherapy (LDR-BT) or high-dose-rate brachytherapy 
with external beam radiation therapy (HDR-BT+EBRT)] versus external beam radiation 
therapy (EBRT) alone.  
 
Materials/Methods: Patient data was obtained from the ProCaRS database, which 
contains 7974 prostate cancer patients treated at four Canadian institutions.  Propensity 
score (PS) matching was used to generate matched cohorts with balanced baseline 
prognostic factors. 
  
Results/Conclusions: Final PS matches included two 1:1 intermediate-risk patient 
matches, LDR-BT vs. EBRT (total n = 254) and HDR-BT+EBRT vs. EBRT (total 
n=388), and a 4:1 (LDR-BT:EBRT) low-risk match (total n=400).  Hazard ratios for OS 
were 0.79 (p=0.69), 0.64 (p=0.47), and 1.41 (p=0.50), respectively.  Hazard ratios for 
bFFS were 0.22 (p=0.001), 0.48 (p=0.007), and 0.35 (p=0.004), respectively. 
 
Conclusions: PS matching showed BT significantly improved bFFS but not OS in 
matched prostate cancer patients. 
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1.0 Introduction 
 
  Prostate cancer is the most commonly diagnosed non-cutaneous malignancy and 
is the third leading cause of cancer-related death in Canadian men (Canadian Cancer 
Society 2012).  Primary radiation therapy (RT) treatment of prostate cancer has been 
shown to provide similar local control and survival benefits compared to surgical 
management for patients with localized disease (Thompson 2007).  Treatment options for 
patients with low-risk prostatic disease include either conservative management through 
active surveillance, or definitive therapy via radical prostatectomy (RP), external beam 
radiation therapy (EBRT), or brachytherapy (BT).  Increased risk of local recurrence and 
distant metastasis following single modality therapy for patients with intermediate- or 
high-risk prostate cancer has led to increased use of adjuvant hormone therapy 
accompanied by dose escalated RT regimens (Thompson 2007).  Intensity modulated 
radiation therapy (IMRT) prescription doses of  >80 Gy have been explored for patients 
at higher risk of disease recurrence.  However, standard prescription doses from primary 
EBRT treatments tend to range from 70-80 Gy given in 1.8 to 2.0 Gy fractions 
(Washington 2004).   
 
 BT options available to men with prostate cancer include low dose rate 
brachytherapy (LDR-BT) and high dose rate brachytherapy (HDR-BT).  Permanent seed 
LDR-BT is generally given as a monotherapy, while HDR-BT boost has been explored as 
concurrent therapy with EBRT (HDR-BT+EBRT) (Thompson 2007).  Higher doses are 
achievable using highly conformal BT treatments compared to EBRT treatments, with 
total doses of ≥115Gy delivered using permanent seed LDR-BT implants (Nag 1999).  
Biologically equivalent dose (EQD2Gy), which is a standardized equivalent EBRT dose 
given in 2 Gy fractions, has been used to describe the total combined dose given with 
HDR-BT+EBRT treatments (Morton 2011).  Modern HDR-BT+EBRT treatments giving 
two fractions of 10 Gy HDR-BT with 45 Gy EBRT have an estimated total EQD2Gy of 95 
Gy (Morton 2011).  
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 Currently, a lack of high quality randomized controlled trial (RCT) data on 
prostate cancer RT survival outcomes are available in the literature.  No definitive RCT 
data exists directly comparing two or more RT treatments.  As a result, comparative 
evidence has been predominately generated from observational data.  However, RT 
survival comparisons in several of these non-experimental studies do not control for the 
effects of adjuvant hormone therapy and they tend to assess heterogeneous patient 
populations composed of low-, intermediate- and high-risk patients.  Novel comparisons 
of the effectiveness of the different RT modalities available within each prostate cancer 
risk-stratum are warranted, specifically aimed at isolating the effects of RT in the absence 
of hormone therapy.        
 
 The goal of this study was to assess primary RT survival outcomes of overall 
survival (OS) and biochemical failure-free survival (bFFS) in individual prostate cancer 
risk categories.  This study used propensity score (PS) matching analysis to control for 
the effects of baseline prognostic factors on survival as well as to create separate, unique 
cohorts of entirely low-risk and intermediate-risk patients for analyses.  There were three 
matched comparisons made.  LDR-BT was compared with EBRT in separate low-risk 
and intermediate-risk cohorts, while combination HDR-BT+EBRT was compared with 
EBRT in an intermediate-risk cohort only. 
 
 
 
 
 
 
 
 
 
 
 
 
3	  
	  
2.0 Prostate Cancer 
 
2.1  Introduction 
 
In Canada, prostate cancer is the most commonly diagnosed non-cutaneous cancer 
in men, with an estimated 26,500 new cases reported in 2012 (Canadian Cancer Society 
2012).  The incidence of prostate cancer has risen steadily since 1980, with the exception 
of two rapid rises in incidence, the first peaking in 1993 and the second in 2001.  
Increased early detection of prostate cancer due to intensified prostate specific antigen 
(PSA) screening has been linked to both peaks in prostate cancer incidence.  The first 
peak in prostate cancer incidence, in 1993, coincided with the introduction of the PSA 
blood test, while the second peak, in 2001, occurred during a time of increased public 
awareness and promotion of PSA screening following the prostate cancer diagnosis of 
then Canadian Minister of Health, Allan Rock (Fradet 2009).  Both sharp rises in prostate 
cancer incidence were followed by equally significant declines.  Currently, the incidence 
of prostate cancer has remained relatively constant in Canada, with an estimated 
incidence of 121 per 100,000 men in 2012 (Canadian Cancer Society 2012). 
 
In contrast to incidence, death from prostate cancer is less common.  Prostate 
cancer has the third highest mortality rate among all cancers in Canadian men.  In 2012, 
prostate cancer was estimated to account for roughly 10% of all cancer-related deaths in 
Canadian men (Canadian Cancer Society 2012).  The lower yearly mortality rate relative 
to incidence rate is attributable to the generally slow growing nature of prostate cancer, 
with diagnoses predominantly occurring in men with early stage disease.  Overall, 
prostate cancer has a good prognosis, with 5-year survival rates of  >90% for low-risk 
patients (Rubin 2001).  The trend in prostate cancer mortality has been relatively stable 
over time.  More recently, there has been a slight decline in prostate cancer mortality at a 
rate of 4.3% per year, from 2001 to 2007 (Canadian Cancer Society 2012).  Early 
detection and improvements in the quality of care are popular explanations for this recent 
decrease in prostate cancer mortality (Fradet 2009).  
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Prostate cancer incidence varies by geographical region, with the highest rates 
reported in North America and the lowest rates in Asia (Curado 2007).  Reduced dietary 
fat intake commonly found in oriental cuisine is thought to be responsible for these lower 
prostate cancer incidence rates seen in Asian countries (Fleshner 2004).  Aside from the 
obvious requirement of being male, there are numerous additional factors that can 
increase an individual’s risk for developing prostate cancer.  Increased age has been 
associated with prostate cancer risk, with the majority of patients presenting over the age 
of 60 (Rubin 2001).  African American and Hispanic men are at higher risk than 
Caucasians for prostate cancer (Hoffman 2001), as are men with at least one familial 
relative diagnosed with the disease (Bratt 2002).  Chemical exposure to tobacco as well 
as certain pesticides increases risk for prostate cancer, while exposure to antioxidants, 
such as genistein (soy beans), lycopene (tomatoes), and vitamin E, could potentially be 
protective (Damber 2008).  Conventionally studied etiological factors, such as alcohol 
consumption, obesity and reduced physical activity, do not appear to increase risk for 
prostate cancer.  Although benign prostatic hypertrophy (BPH) presents with similar 
symptoms as prostate cancer, no study has been able to show a causal association 
between BPH and the development of prostate cancer (Rubin 2001). 
 
The natural history of disease progression for prostate cancer originates as a 
mutation occurring in normal human cells.  Prostate cancer can develop locally from cells 
originating in prostatic tissues, or distantly, as a result of metastasis from cancers of the 
lung, skin, colon or lymphatic tissues.  Prostate cancer spreads locally by invading 
surroundings tissues, specifically the seminal vesicles, bladder, rectum, and pelvic soft 
tissues.  Distant spread of prostate cancer tends to follow a sequential pattern, beginning 
with regional dissemination predominantly to the pelvic lymph nodes.  Regional spread is 
followed by distant metastasis, usually to the bone.  Although prostate cancer is a slow 
growing malignancy, metastasis to the bone and other organs including the liver, lung 
and occasionally, the brain, can eventually result in death (Rubin 2001). 
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 2.2  Clinical Detection and Diagnosis 
 
 Most men with prostate cancer are asymptomatic and are diagnosed by an 
elevated PSA blood test.  PSA is a serine protease enzyme that is secreted by prostatic 
epithelial cells.  The primary function of PSA is to keep semen in a fluidic state prior to 
ejaculation (Balk 2003).  Trace levels of PSA are normally detectable in peripheral blood 
serum, with higher concentrations found in the prostatic lumen.  Localized disease, such 
as prostate cancer or BPH, can cause an increased amount of PSA to leak out of the 
prostatic lumen into the peripheral blood stream.  Standard PSA screening tests use a 
serum total PSA threshold of 4.0 ng/mL to indicate the need for further biopsy evaluation 
(Balk 2003).  However, controversy exists over the specificity of this PSA threshold, as 
aggressive, organ confined, prostate cancer is diagnosed in roughly 50% of individuals 
with low levels of serum PSA, ranging from 0 to 4ng/mL (Schröder 2000).  
 
 Additional methods have been proposed to help improve the accuracy of PSA 
screening.  One such method uses age-specific reference ranges (ASRRs) to account for 
rising PSA levels as men age.  The recommended PSA serum concentration using ASRRs 
starts from 0 to 2.5 ng/mL, for younger men aged 40 to 49 years and increases up to a 
maximum range of 0 to 6.5 ng/mL, for older men aged 70 and above (Oesterling 1993).  
There are two main theoretical advantages of using ASRRs.  The first advantage is that 
ASRRs innately diagnose an increased number of prostate cancers in younger men.  This 
means that a higher number of men, who are likely to require some form of interventional 
therapy, are properly identified.  The second advantage of ASRRs is that fewer diagnoses 
are made in older men who are unlikely to die of their disease.  This reduces the number 
of unnecessary biopsies and additional investigations in older individuals (Crawford 
1999).   
 
 There are additional approaches to improving PSA measurement accuracy.  One 
approach is to standardize PSA blood concentration relative to the prostate volume, also 
known as the PSA density.  This technique attempts to differentiate benign elevated PSA 
levels from those caused by prostate cancer (Benson 1994).  Measuring the change in 
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PSA over time, or PSA velocity, has also been identified as a means of screening for 
prostate cancer.  A PSA velocity showing a yearly increase of 0.75 ng/mL is the most 
common criteria indicating a positive test result (Kadmon 1996).  Limitations of PSA 
velocity are that it requires previous knowledge of PSA measurements and is unable to 
account for natural fluctuations in PSA serum concentration over time (Kadmon 1996).  
The PSA found in prostate cancer cells tends to avoid inactivation via proteolytic 
cleavage.  This results in a lower fraction of free-PSA, or inactivated PSA, relative to 
total PSA in the peripheral blood.  The fraction of free-PSA to total PSA can be measured 
and is known as the PSA index.  A PSA index ≤25% in patients with total PSA 
measurements ranging from 4-10 ng/mL has been shown to increase risk for prostate 
cancer (Catalona 1998).  
 
Controversy exists regarding the overall benefit of PSA screening for prostate 
cancer in otherwise healthy men.  Although, PSA screening has increased the number of 
men diagnosed with early stage, low-risk prostate cancer, it has not been found to 
significantly reduce prostate cancer-specific mortality or all-cause mortality in men 
(Andriole 2009).  In fact, over diagnosis from PSA screening can increase the morbidity 
for men, including increased stress and anxiety over the need for more invasive tests and 
treatments.  One recent European randomized trial containing 162,243 men estimated that 
1410 men would need to be PSA screened to prevent one death from prostate cancer 
(Schröder 2009).  
 
In addition to screening, PSA testing can be used on follow-up examination to 
monitor efficacy of primary therapy.  Elevated PSA has long been established as an 
indicator for clinical relapse following RP or RT (Kuriyama 1981).  As low levels of PSA 
are normally detectable following RT, there have been multiple definitions for a rising 
PSA used to indicate treatment failure.  The most current Radiation Therapy Oncology 
Group (RTOG) and American Society for Therapeutic Radiology and Oncology 
(ASTRO) definition for biochemical failure following primary RT is a PSA rise of 2 
ng/mL, or more, above the nadir, or the lowest recorded PSA value (Roach 2006).  This 
definition replaced the previous RTOG-ASTRO recommendation of three consecutive 
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rises in PSA after the nadir as indicative of biochemical failure (Roach 2006).  Neither of 
these definitions accounts for the benign rises in PSA (also known as ‘PSA bounce’) that 
has been documented following BT radiation in prostate cancer patients (Mehta 2013).  
Current studies on PSA bounce have been unable to identify the etiology of this 
phenomenon (Chira 2013, Mehta 2013).  
 
Besides PSA screening, clinical detection of prostate cancer can occur as a result 
of other investigations.  One common presentation of prostate cancer is an abnormal 
nodular growth found on digital rectal examination (DRE).  Although the specificity and 
sensitivity of using DRE alone to accurately diagnose prostate cancer has been 
questioned (Byar 1972), the combination of patient history, serum PSA measurement, 
and DRE are commonly used to assess prostate cancer risk and help shape biopsy 
decision making (Rubin 2001).  In rare instances, a prostate cancer diagnosis can occur 
following transurethral resection of the prostate (TURP) for urinary obstructive 
symptoms.  However, pre-existing urinary obstructive symptoms have not been found to 
be associated with decreased survival among men with prostate cancer (Brawn 1994).  
Trans-rectal ultrasound (TRUS) guided biopsy is performed for definitive diagnosis of 
prostate cancer in the instance of elevated PSA or abnormal DRE.  Other routine tests 
such as chest x-ray, bone scans and computerized tomography (CT) scans or magnetic 
resonance imaging (MRI), are not involved in the diagnosis of prostate cancer, but are 
instead used for staging disease (Rubin 2001).  
 
 2.3  Classification and Histopathology 
 
The prostate is made of both glandular and non-glandular tissues that are 
contained within the prostatic capsule.  The glandular tissues are classified into three 
major zones, the peripheral zone, central zone and transitional zone.  Each classified zone 
has unique histological architecture and function.  The peripheral zone accounts for 70% 
of the glandular tissue and is the most common site for development of multifocal 
prostate carcinomas.  The central zone is a conical shaped structure that makes up 
roughly 25% of the glandular tissue and is relatively resistant to prostate cancers and 
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other prostatic diseases.  Finally, the transitional zone, which makes up the remaining 
5%-10% of the glandular tissue, is the site most associated with the development of BPH 
(McNeal 1988).   
 
Histologically, adenocarcinoma accounts for roughly 95% of all clinically 
diagnosed prostate cancers, most commonly originating in the peripheral zone.  
Additional histological subtypes that can occur within the prostate include: small cell 
(anaplastic) carcinoma, lymphoma, sarcoma, basal cell carcinoma, and transitional cell 
carcinoma (Rubin 2001).  The most widely used histologic grading system for prostate 
cancer was first introduced by Gleason and Mellinger (Gleason 1974), and is called the 
Gleason score.  A discrete value ranging from 1 to 5 is used in the creation of the Gleason 
score, with higher values indicating increasing degree of malignancy of histologic 
pattern.  The total Gleason score is the sum of the two most common histologic patterns, 
resulting in a discrete numerical value ranging from 2 to 10.  Prostate cancer patients with 
higher Gleason scores tend to have a poorer prognosis, as Gleason score is correlated 
with both pathological staging and survival (Rubin 2001). 
 
2.4  Prostate Cancer Staging 
 
 The most commonly used prostate cancer staging system is the American Joint 
Committee on Cancer (AJCC), TNM classification system.  TNM is an acronym that 
describes the size and extent of the primary tumor (T), spread to regional lymph nodes 
(N) and distant metastasis (M).  Once histological finding of prostate cancer is confirmed, 
TNM classification can be used to both clinically and pathologically stage the disease.  
Clinical staging for prostate cancer occurs prior to the delivery of any definitive therapy, 
using information from several preliminary diagnostic tests, such as serum PSA level, 
DRE, and imaging.  Alternatively, pathological staging is performed following surgical 
resection of the prostate, seminal vessels and pelvic lymph nodes with histological 
examination of the resected specimens for involvement with prostate cancer.  Clinical 
and pathological staging is used to assess the extent of the disease and aid in treatment 
decision-making (Fleming 1997). 
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 Several revisions to the AJCC TNM staging definitions for prostate cancer have 
occurred since their creation in 1977.  The most dramatic change occurred in 1997, where 
the T-stage category T2 from the “T” portion of the TNM staging, went from three 
subcategories to two subcategories (Fleming 1997).  Implementation of the 1997 TNM 
system ended in 2002, when the AJCC guidelines were changed back to their original 
definitions (Greene 2002).  This major change in T-staging for patients treated from the 
years 1997 to 2002 is problematic in prostate cancer research, as comparisons between 
studies using different TNM definitions can be challenging.  The current TNM staging 
system implemented in 2010 by the AJCC (Edge 2009) is shown in Tables 1 and 2. 
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Table 1:  AJCC TNM clinical and pathological staging definitions. 
 
Primary Tumor (T) 
 
Clinical 
 
TX:  Primary tumor cannot be assessed 
T0:  No evidence of primary tumor 
T1:  Clinically inapparent tumor neither palpable nor visible by imaging 
 T1a: Tumor incidental histologic finding in 5% or less of tissue resected 
 T1b:  Tumor incidental histologic finding in more than 5% of tissue resected 
 T1c:  Tumor identified by needle biopsy (for example, because of elevated PSA) 
T2:  Tumor confined within prostate 
 T2a:  Tumor involves one-half of one lobe or less 
 T2b:  Tumor involves more than one-half of one lobe but not both lobes 
 T2c:  Tumor involves both lobes 
T3:  Tumor extends through the prostate capsule 
 T3a:  Extracapsular extension (unilateral or bilateral) 
 T3b:  Tumor invades seminal vesicles(s) 
T4:  Tumor is fixed or invades adjacent structures other than seminal vesicles, such as 
external sphincter, rectum, bladder, levator muscles, and/or pelvic wall 
 
Pathologic (pT) 
 
pT2:  Organ confined 
 pT2a:  Unilateral, one-half of one side or less 
 pT2b:  Unilateral, involving more than one-half of side but not both sides 
 pT2c:  Bilateral disease 
pT3:  Extraprostatic extension 
 pT3a:  Extraprostatic extension or microscopic invasion of bladder neck 
 pT3b:  Seminal vesicle invasion 
pT4:  Invasion of rectum, levator muscles, and/or pelvic wall 
 
Regional Lymph Nodes (N) 
 
Clinical 
 
NX:  Regional lymph nodes were not assessed 
N0:  No regional lymph node metastasis 
N1:  Metastasis in regional lymph node(s) 
 
Pathologic 
 
pNX:  Regional nodes not sampled 
pN0:  No positive regional nodes 
pN1:  Metastases in regional node(s) 
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Distant Metastasis (M) 
 
M0:  No distant metastasis 
M1:  Distant metastasis 
 M1a:  Nonregional lymph node(s) 
 M1b:  Bone(s) 
 M1c:  Other site(s) with or without bone disease 
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Table 2:  AJCC prostate cancer anatomical stage/prognostic groupings. 
 
 
Stage I  
 
T1a-T1c, N0, M0, PSA < 10, Gleason ≤ 6 
T2a, N0, M0, PSA < 10, Gleason ≤ 6     
T1-2a, N0, M0, *PSA X, βGleason X 
 
Stage IIA 
 
T1a-T1c, N0, M0, PSA < 20, Gleason = 7 
T1a-T1c, N0, M0, 10 ≤ PSA < 20, Gleason ≤ 6 
T2a, N0, M0, 10 ≤ PSA < 20, Gleason ≤ 6  
T2a, N0, M0, PSA < 20, Gleason = 7 
T2b, N0, M0, PSA < 20, Gleason ≤ 7  
T2b, N0, M0, *PSA X, βGleason X  
 
Stage IIB 
 
T2c, N0, M0, any PSA, any Gleason 
T1-T2, N0, M0, PSA ≥ 20, any Gleason 
T1-T2, N0, M0, any PSA, Gleason ≥ 8 
 
Stage III 
 
 T3a-T3b, N0, M0, any PSA, any Gleason 
 
Stage IV 
 
T4, N0, M0, any PSA, any Gleason 
Any T, N1, M0, any PSA, any Gleason 
Any T, any N, M1, any PSA, any Gleason 
 
*PSA X = PSA not assessed 
β Gleason X = Gleason not assessed 
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   2.5  Risk Stratification and Treatment Options  
 
 Historically, prostate cancer patients have been grouped into three prognostic risk 
categories, low-, intermediate- and high-risk.  The three risk categories are used to predict 
risk of disease recurrence and metastasis as well as tailor therapy (Rubin 2001).  The 
combination of serum PSA, Gleason score and T-stage are the most universally accepted 
prognostic factors used to stratify patient risk, with all three prognostic factors being 
independently associated with increased risk of disease progression (Partin 1997).  
Although there is currently a debate whether updating the Genitourinary Radiation 
Oncologists of Canada (GUROC) three-category, risk-stratification system for prostate 
cancer is warranted, the current consensus requirements remain unchanged (Lukka 2001, 
Rodrigues 2012).  Table 3 shows the current GUROC consensus requirements for 
prostate cancer, three-category risk stratification (Lukka 2001) and the most commonly 
used treatment options for patients in each risk category (Keyes 2013, Rubin 2001, 
Thompson 2007).  
 
 As highlighted in Table 3, there is a wide range of treatment options available to 
prostate cancer patients in each risk category.  Currently, there are three primary 
treatment modalities that are used with curative intent for men with prostate cancer, RP, 
EBRT and BT (Thompson 2007).  All three treatments can be used alone, for patients 
with clinically localized disease, or they can be used in combination with other therapies 
for locally advanced, high-risk patients.  Due to the slow growing nature of prostate 
cancer, active surveillance, or the process of observing a patient until their disease 
reaches a critical stage before providing therapy, is a unique option available to low-risk 
patients.  Although observation is an attractive option for older men with low-risk cancer, 
it is not suitable for those in the intermediate- or high-risk categories, as these individuals 
have disease generally requiring intervention (Keyes 2013).  In the case of metastatic 
disease, patients usually are no longer given primary therapies with curative intent.  
Androgen deprivation therapy (ADT) is a hormone therapy predominantly used alone or 
in combination with small doses of radiation to palliate patients with metastatic prostate 
cancer.  ADT can also be used in the adjuvant setting for patients with locally confined 
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disease (Rubin 2001).  Although the decision on treatment modality primarily depends on 
patient risk category, other factors such as the patient age, comorbid conditions, and 
personal preference can determine treatment choice  (Keyes 2013, Rubin 2001, 
Thompson 2007).  
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Table 3:  GUROC consensus requirements and treatment options by prostate cancer risk.  
Risk 
Category 
GUROC Consensus  Standard Treatment Options 
Low Must have all of the 
following: 
• PSA ≤ 10 ng/mL 
• Gleason Score ≤ 6 
• Stage T2a or less 
Observation (active surveillance or watchful 
waiting); 
Radical prostatectomy +/- nerve sparing; 
External beam radiation only; 
Brachytherapy only 
 
Intermediate Must have all of the 
following if not low-risk: 
• PSA ≤ 20ng/mL 
• Gleason Score < 8 
• Stage T1/T2 
 
Radical prostatectomy +/- lymphadenectomy; 
External beam radiation +/- ADT; 
Brachytherapy +/- ADT; 
External beam radiation + brachytherapy +/- 
ADT 
High Must have at least one of 
the following: 
• PSA > 20ng/mL 
• Gleason Score ≥ 8 
• Stage ≥ T3a 
Prostatectomy +/- lymphadenectomy + 
External beam radiation + ADT; 
External beam radiation only + ADT; 
External beam radiation + brachytherapy + 
ADT; 
ADT only 
 Abbreviations: ADT = androgen deprivation therapy; PSA= prostate specific 
antigen; GUROC= Genitourinary Radiation Oncologists of Canada 
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 2.6  Surgical Management of Prostate Cancer  
 
RP has been established as an appropriate monotherapy for treatment of clinically 
localized prostate cancer (Thompson 2007).  RP involves complete removal of the 
prostate gland, seminal vesicles and part of the vas deferens.  Commonly, RP is 
performed using an open retropubic or perineal incision, with both techniques yielding 
similar recurrence rates and survival (Lance 2001).  Due to high rates of impotency and 
incontinence associated with RP, a nerve-sparing surgical technique can be performed on 
men with favorable tumor and patient characteristics.  This technique has been found to 
yield desirable results in men, with up to 70% reporting returned potency following 
surgery (Catalona, 1999).  The overall improvement of symptoms from nerve-sparing 
surgery depends on patient selection.  The lowest rates of impotency following RP 
reported in the literature tend to include younger, healthier men, with less advanced 
disease (Talcott 1997).  Pelvic lymphadenectomy is generally performed concurrently 
with RP in patients at high risk for nodal spread (Rubin 2001).  An advantage of RP over 
other treatment options is that complete removal of the prostate gland will result in cure 
when disease is truly localized.  However, when disease has spread outside of the prostate 
gland, additional therapies must be considered to reduce risk of recurrence (Thompson 
2007). 
 
There are a number of acute and chronic side effects from RP that can impact 
patient quality of life.  Erectile dysfunction (ED) is common in men following RP, with 
varying degrees of severity.  Factors that can influence the severity of ED include: 
whether nerve-sparing surgery was used, patient age, the patient’s ability to achieve and 
maintain erections prior to surgery, and the use of ED medications such as Sildenafil 
(Viagra) following surgery (Kundu 2004, Stanford 2000, Walsh 2000).  Urinary 
incontinence, urethral stricture, rectal pain and rectal incontinence are additional 
complications that can occur following RP (Benoit 2000).  Short-term morbidities from 
the surgical procedure are rare, but include myocardial infarction, thrombosis, wound 
infection and death (Shabbir 2005).   
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 2.7 Radiation Therapy Management of Prostate Cancer 
   
2.7.1 Introduction 
 
RT is the therapeutic delivery of ionizing radiation with the aim of reducing or 
eliminating disease.  The biological mechanism of how the radiation dose is deposited in 
the tissue is quite complex.  On the cellular level, charged particles (protons and 
electrons) and uncharged particles (photons and neutrons) excite water molecules, which 
create secondary reactive molecules called free radicals.  These free radicals damage the 
deoxyribonucleic acid (DNA) within the cell, leading to apoptosis, or cell death.  Because 
radiation damages both cancer cells and normal cells, there is a constant trade-off 
between delivering adequate dose to the tumor target and attempting to spare the 
surrounding tissues.  Cells that are actively dividing are known to be more sensitive to 
radiation than slower growing cells.  This feature of radiation allows it to be very 
effective in treating cancers with high rates of growth.  Additionally, dose fractionation 
(partitioning of dose) and ensuring adequate tissue oxygenation take advantage of the 
radiobiology of tumor cells and have been shown to improve the therapeutic effect of RT 
treatments (Washington 2004).  
 
With respect to RT management of prostate cancer, EBRT and BT are standard 
treatment options (Rubin 2001).  No definitive randomized controlled trial data exists 
directly comparing either RT treatment modality to RP with respect to patient important 
outcomes.  Observational data have demonstrated that both EBRT and BT provide local 
control and survival benefits similar to RP in men with regionally localized prostate 
cancer (Thompson 2007).  Two large observational studies suggest both BT and EBRT 
are superior to RP with respect to ED and urinary incontinence, but inferior in preventing 
bowel toxicities (Martin 2008, Resnick 2013).   
 
Higher doses of radiation have been shown to improve probability of cure 
following RT treatment for prostate cancer (Washington 2004).  However, the incidence 
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of gastrointestinal (GI) and genitourinary (GU) side effects increases when higher 
volumes of the pelvis are irradiated.  Possible acute GI side effects from RT treatments 
include proctitis, diarrhea, abdominal cramps, rectal bleeding and fecal incontinence.  GU 
side effects include cystitis, frequency, dysuria, hematuria, urethral stricture and loss of 
potency or ED.  EBRT can cause irritation to the skin in the treatment field, ranging from 
mild erythema and pruritus, to dry or moist desquamation.  Rectal injury is uncommon 
from TRUS-guided BT, although it can occur.  Fatigue is also a common side effect for 
men receiving RT treatments for prostate cancer (Rubin 2001). 
 
2.7.2  External Beam Radiation Therapy (EBRT) 
 
EBRT has been established as a form of radiation therapy delivery that provides 
excellent local control and relatively low risk of long-term morbidity for prostate cancer 
patients.  EBRT uses high-energy photons that penetrate tissue and deliver radiation dose 
to the tumor target.  EBRT machines deliver focused beams of radiation at different 
angles so that the highest dose reaches the tumor, while shielding is used to spare 
surrounding tissues.  Currently, there is no consensus on what standard EBRT dose 
prescription, treatment technique or fractionation schedule should be used to treat 
prostate cancer.  A typical EBRT treatment course for a prostate cancer patient involves 
daily treatments given over approximately 6 to 8 weeks.  In cases where there is a high 
probability of local or regional spread, whole pelvis EBRT is generally given, with doses 
of 46-50 Gy prescribed to the pelvic lymph nodes and 54-56 Gy to the seminal vesicles 
(Washington 2004).   
 
The development of 3D conformal and IMRT treatment planning and delivery 
techniques has allowed higher doses to be delivered to patients with improved accuracy. 
One randomized controlled trial containing 393 patients with low- to intermediate-risk 
prostate cancer found conformal EBRT doses of 79 Gy reduced PSA biochemical 
recurrence by >15% compared to doses of ≤70 Gy (p < 0.001).  However, there was no 
statistically significant difference in overall survival or long-term side effects between the 
groups at 5-years (Zeitman 2005).  Long-term follow-up of another randomized trial with 
19	  
	  
low- to high-risk patients found similar results, with a high dose of 78 Gy leading to non-
failure rates of 70% compared to 64% in the 70 Gy group at 6-years (p <0.03) (Pollack 
2002).  Currently, there is a lack of quality evidence to indicate whether dose escalation 
is beneficial for low-risk prostate cancer patients.  Observational data and subgroup 
analysis from a randomized controlled trial have found doses >70 Gy to significantly 
reduce biochemical recurrence in men with PSA > 10ng/mL, but not in those with PSA < 
10ng/mL (Hanks 1998, Pollack 2002).  
 
As a single modality therapy, EBRT can be used to treat patients with low-, 
intermediate- and high-risk of recurrence.  An advantage of EBRT over RP is that it can 
be prescribed for patients who are unfit for surgery (Rubin 2001).  Post-operative RT to 
the pelvic lymph nodes and prostate bed following RP has become a frequently 
prescribed treatment of high-risk prostate cancer.  One large, European randomized 
controlled trial, found immediate post-operative RT improves biochemical progression-
free survival (hazard ratio = 0.49; 95% CI, 0.41-0.59) at > 10-years in patients with high-
risk prognostic features (capsular perforation, positive surgical margins, or seminal 
vesicle invasion) compared to delayed management (Bolla 2012).  A separate American 
randomized trial with 425 men, with a median follow-up of 10.5 years, reported 
significantly reduced PSA relapse (hazard ratio = 0.43; 95% CI, 0.31-0.58) and disease 
recurrence (hazard ratio = 0.62; 95% CI, 0.46-0.82) with postoperative EBRT compared 
to observation, but found no statistically significant difference in overall survival 
(Thompson 2006).  Additionally, EBRT can be used to treat bone metastases originating 
from prostate cancer.  Single fraction EBRT doses of 8 Gy have been shown to be 
equally effective at relieving pain symptoms from metastatic bone lesions compared to 
multiple fraction doses (20 Gy in 5 fractions or 30 Gy in 10 fractions), with roughly 60% 
of patients experiencing relief of their pain (Sze 2004). 
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2.7.3  Brachytherapy (BT) 
 
 The second radiation therapy option available to prostate cancer patients is BT.  
The term brachytherapy originates from the Greek word “brachys” meaning “short 
distance” therapy (Devlin 2007).  For prostate cancer patients, BT involves the surgical 
implantation of small radioactive sources (seeds) in and around the prostate.  These 
radioactive sources decay creating alpha, beta and gamma particles, which ionize cellular 
molecules (including DNA), depositing dose similar to EBRT (Beltas 2007).  BT is a 
highly conformal therapy; meaning the radiation dose delivered is tightly confined to the 
cancer target, with surrounding tissues only receiving relatively low doses.  The 
conformal dose achievable with BT can be attributed to the short-range radiation 
produced by the implanted sources, which have a steep dose fall-off with distance (Khan 
2003).  As a result, BT can achieve higher doses to the tumor target compared to EBRT 
and still adequately spare the surrounding tissues (Washington 2004).  
 
For prostate cancer, TRUS guided LDR-BT can be used alone as a single 
modality treatment or to boost radiation dose to the primary tumor following EBRT.  
LDR-BT treatments usually involve a one-day, outpatient surgical procedure, where 
radioactive sources are permanently implanted within the prostate bed (Keyes 2013).  
This is one advantage of LDR-BT, as the time commitment for patients is much less than 
EBRT.  Postoperative recovery following LDR-BT is quick in comparison to RP, with 
the potential for patients to undergo spinal, instead of general anesthetic (Keyes 2013).  
The effective treatment time for LDR-BT, or the time it takes for the permanent LDR-BT 
sources to fully decay and deposit the total dose, can last up to 9 months depending on 
the radioactive isotope used (Ling 1992).   
 
Commercially available iodine-125 (I-125) and palladium-103 (Pd-103) are the 
most common radioisotopes used for LDR-BT.  Standard minimum prescription doses of 
144 Gy for I-125 and 115-120 Gy for Pd-103 are recommended by the American 
Brachytherapy Society for permanent seed LDR-BT (Nag 1999).  An additional isotope, 
cesium-131, has also been explored for LDR-BT monotherapy use in the United States, 
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with a prescribed dose of 115 Gy (Kehwar 2009).  For radiation boost following 40 to 50 
Gy EBRT, LDR-BT doses of 100-110 Gy I-125 and 80-90 Gy Pd-103 are recommended 
(Nag 1999).  Studies have shown that patients with favorable risk factors treated with 
either I-125 or Pd-103 LDR-BT have biochemical free recurrence rates >90% at 5-years 
(Blasko, 2000; Grimm 2001).  No association has been found between radioisotope type 
and BT treatment efficacy (Merrick 2001, Rodrigues 2013). 
 
HDR-BT is an additional radiation therapy technique available to men with 
prostate cancer.  HDR-BT differs from LDR-BT with respect to the treatment delivery 
process and overall treatment time.  HDR-BT sources have a higher dose per unit time 
than LDR-BT sources.  As a result, HDR-BT treatments are usually delivered in multiple 
fractions to allow for optimal normal tissue repair (Nag 1994).  Handling of HDR-BT 
sources can be dangerous due to the potential of rapid overexposure.  The invention of 
automated devices that insert and remove the HDR-BT sources remotely (referred to as 
afterloading units), have allowed physicians to safely perform HDR-BT treatments from 
outside the treatment room (Henschke 1963).  Prior to prostate HDR-BT treatment 
delivery, the patient is placed under epidural or spinal anesthesia, while temporary 
catheter tubes are surgically implanted throughout the target volume.  Following patient 
recovery, CT imaging is used to create an optimized treatment plan, accounting for the 
location of the implanted catheters, while maximizing dose to the target volume and 
limiting dose to the surrounding tissues.  During HDR-BT treatment delivery, radiation 
dose is delivered as the HDR-BT source “dwells” inside the patient at computer 
calculated points along the implanted catheters.  These pre-calculated dwell points are 
planned so that they optimize radiation dose uniformity throughout the target volume 
(Slessinger 2010).  Although the treatment time required for HDR-BT delivery via 
remote afterloading units can vary depending on the total dose prescribed and source 
strength, it generally lasts approximately 10 to 20 minutes (Keyes 2013).  For an average 
size prostate, the use of 15 to 20 implanted catheters has been found to provide adequate 
tumor dose coverage for HDR-BT treatments (Charra-Brunaud 2003).  
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Iridium-192 (Ir-192) is the most common radioisotope used in HDR-BT.  Prostate 
HDR-BT is predominantly used concurrently with EBRT to boost dose to the primary 
tumor in men with intermediate- to high-risk disease.  Original HDR-BT boost treatment 
regimens developed in the 1980’s gave two Ir-192 HDR-BT treatments of 15 Gy each, 
following 40-50 Gy pelvic RT (Nag 1994).  More modern HDR-BT treatments tend to 
have lower doses of either 10 Gy fractions delivered over two treatments with concurrent 
45 Gy EBRT, or a single 15 Gy HDR-BT treatment given with 37.5 Gy EBRT (Morton 
2011).  In general, HDR-BT+EBRT dose regimens reported in the literature have 
estimated EQD2Gy doses 25% to 50% higher than standard fraction, 74 Gy EBRT (Fowler 
2005, Morton 2011).  Monotherapy HDR-BT has been shown to have similar 
biochemical control as LDR-BT with potentially reduced urinary and rectal toxicities in 
low-risk patients (Grills 2004).  However, more studies are required to determine the full 
utility of monotherapy HDR-BT in the treatment of prostate cancer.  
  
2.8  Additional Treatment Options 
 
2.8.1  Observation (Active Surveillance/Watchful Waiting) 
 
 Evidence from autopsy series estimates roughly 20-30% of men over the age of 
70 years old will have asymptomatic, undiagnosed prostate cancer (Sanchez-Chapado  
2003; Stamatiou 2006).  The use of PSA screening likely has increased the over diagnosis 
and over treatment of prostate cancers, especially in men with low-risk disease (Klotz 
2013).  In general, conservative management for patients with low-volume, low-risk 
prostate cancer is provided using active surveillance protocols.  Recommendations for 
patients under active surveillance are to perform serial PSA tests, DRE exams and annual 
biopsy while they are followed (Klotz 2013).  A positive test result from a rising PSA or 
evidence of histological progression initiates decision on definitive, curative therapy.  
This differs from watchful waiting protocols, where patients are passively followed until 
clinical symptoms present, usually indicative of disseminated disease.  Therefore, 
patients who receive watchful waiting tend to not undergo curative therapy because, by 
the time they are symptomatic, they have metastatic disease and so, instead, they are 
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palliated at the appropriate time.  This is why active surveillance is preferred for 
individuals with low-risk prostate cancer, so that patients have the potential of being 
spared unnecessary morbidity from radical therapies, yet still preserving the chance for 
cure (Klotz 2012).   
  
No randomized data exists comparing active surveillance to RP or RT in entirely 
low-risk patients.  However, two recent RCTs have attempted to compare watchful 
waiting to RP in men with prostate cancer, yielding conflicting results (Bill-Axelson 
2011, Wilt 2012).  The first of these trials, named the Prostate Cancer Intervention 
Versus Observation (PIVOT) trial, contained 731 men diagnosed with prostate cancer 
from 1994 to 2002.  Results from the PIVOT trial indicated that there was no OS 
difference between watchful waiting compared to RP with a reported hazard ratio of 0.88 
(95% CI 0.71 to 1.08) (Wilt 2012).  The results of the PIVOT trial were contradictory to 
the second trial, that found RP to be superior to watchful waiting, reporting a relative risk 
of death of 0.75 (95% CI 0.61 to 0.92) after 15-year follow-up of 695 prostate cancer 
patients (Bill-Axelson 2011).  Both of these trials included patients with low-, 
intermediate- and high-risk prostate cancers, making it difficult to compare efficacy of 
observation versus RP in entirely low-risk patients.  Lower level evidence from cohort 
studies suggest active surveillance provides acceptable treatment outcomes for low-risk 
patients.  One Canadian, single arm cohort study found that out of 450 low-risk patients 
treated with active surveillance, 30% were upgraded to higher risk disease and given 
either RT or RP, with only 1% dying from prostate cancer during a 10-year follow-up 
(Klotz 2012).  Due to the lack of evidence, common practice guidelines consider RP, 
EBRT, BT and active surveillance as equal options for patients with low-risk cancer, but 
not those in the higher risk categories (Keyes 2013, Rubin 2001). 
 
2.8.2  Hormone Therapy 
 
Hormone manipulation using ADT is the standard single modality therapy 
reserved for patients with metastatic prostate cancer (Loblaw 2007).  The primary goal of 
ADT is to block the stimulating effects of testosterone (androgen) on the prostate gland 
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and cause the prostate cancer to regress.  The testes produce over 90% of the total 
circulating testosterone, with the additional 5-10% produced by the adrenal glands (Rubin 
2001).  Reduction of testosterone produced by the testes can be achieved surgically, with 
bilateral orchiectomy, or medically, through the use of luteinizing hormone-releasing 
hormone (LHRH) agonists or antagonists that block the production of sex hormones. 
LHRH agonists have been found to lower testosterone levels below 50ng/mL, which is 
generally achievable through surgical castration.  Therefore, both therapies are 
considered equally effective (Rubin 2001).  The use of antiandrogens to reduce the 
remaining testosterone produced by the adrenal glands can be used in combination with 
the above-mentioned ADTs and is termed combined androgen blockade (CAB).  
However, single ADTs such as LHRH agonists and orchiectomy tend to be preferred over 
CAB due to the higher costs associated with CAB and the lack of evidence suggesting 
any survival benefits.  Additionally, CAB can cause increased severity in patient side 
effects, such as decreased libido, fatigue, diarrhea and anemia (Eisenberger 1998).   
 
In addition to the treatment of metastatic disease, ADT is used to treat men with 
non-metastatic prostate cancer.  ADT given with definitive primary therapy, such as RP 
or RT, is recommended for men with locally advanced disease (Rubin 2001).  Long-term 
follow-up of one randomized trial from the RTOG found that ADT with EBRT led to 
improved local-control and disease free-survival compared to EBRT alone in patients 
with T3-4 or N1 stage prostate cancer (Lawton 2001).  In a separate RCT carried out 
jointly by the United States National Cancer Institute and the United Kingdom Medical 
Research Council, called the PR3 trial, demonstrated that the addition of ADT to RT 
provided improved OS compared with ADT alone after six-year follow-up of 1205 men, 
with a reported hazard ratio of 0.77 (95% CI 0.61 to 0.98, p=0.03) (Warde 2011).  
Another trial from the European Organization for Research and Treatment of Cancer 
found that the 5-year OS was 78% in patients receiving EBRT plus ADT for 3 years 
compared to 62% in the EBRT only arm (p<0.001).  This study contained a cohort of 412 
men with advanced stage, non-metastatic prostate cancer (Bolla 2002).  Six-month 
androgen suppression following EBRT has been shown to provide similar improvements 
in survival in a randomized study of intermediate- to high-risk patients (D’Amico 2004).  
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Although the benefits of ADT use in the treatment of men with unfavorable prognostic 
features are well documented, there is no definitive evidence to indicate its effectiveness 
in clinically localized, low-risk prostate cancer.  Observational data indicates that 
hormone therapy given with RT significantly reduces PSA biochemical recurrence in 
intermediate- and high-risk patients, but not in men with low-risk disease, when 
compared to RT alone (D’Amico 2000).  Neoadjuvant ADT can be used to reduce tumor 
bulk prior to RT or surgery leading to improved local control, as well as identify patients 
with hormone sensitive prostate cancer (Lee 1999).   
 
Roughly 10-20% of men do not respond to initial ADT management and are 
identified as having castration resistant disease (Rubin 2001, Tannock 2004).  Given 
enough time, of the remaining men that do initially respond to ADT, the majority will 
eventually develop hormone refractory prostate cancer, manifesting symptoms of 
treatment failure.  Many chemotherapy agents have been studied to help treat patients 
with castration resistant prostate cancer, of which taxane derivatives are the most 
effective (Tannock 2004).  The addition of up-front chemotherapy to ADT management 
of hormone sensitive prostate cancer has shown no clinical benefit (Gravis 2013). 
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3.0 Comparative Effectiveness Research (CER) 
 
3.1  Introduction 
 
 Comparative Effectiveness Research (CER) contrasts the advantages and/or 
disadvantages that are afforded to patients receiving different therapies.  CER generates 
new evidence in the form of experimental or observational studies, or synthesizes 
evidence from previous studies through systematic review.  The primary goal of CER is 
to improve the quality of care provided to patients by creating or compiling evidence, 
which can later be used to help guide clinical decision-making (Luce 2010).    
 
 Historically, the term CER gained popularity in the United States, through a 
government initiative to improve the quality and transparency of their comparative 
studies (Wilensky 2006, VanLare 2010).  In Canada, the term CER is now becoming 
more frequently used and familiar with Canadian researchers when describing their 
comparative studies in multiple health care fields (Whicher 2009, Sun 2014).  
Commonly, the term Evidence-Based Medicine (EBM) has been used synonymously 
with CER, due to the similarities between terms.  However, there are some differences 
between the definitions of EBM versus CER.  For example, both EBM and CER are 
focused on evidence synthesis through systematic review, however, EBM is more 
focused on using this evidence to drive decision-making and create practice guidelines, 
while CER is more focused on improving the evidence created in the primary studies.  
Therefore, CER is more concerned with answering both the effectiveness and value 
questions of “does it work in a clinical setting?” and “is it worth it?” while EBM takes it 
once step further by answering the efficacy and clinical practice driven questions of  “will 
it work?” and “should we our change practice?” (Luce 2010).  As a result, CER shifts the 
focus towards the creation of quality primary evidence generation in experimental and 
observational studies, which is later used in the EBM decision-making process. 
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 3.2 CER in Experimental Studies  
 
 RCTs are generally considered to be the gold standard in CER.  A properly 
designed RCT allows researchers to compare different therapies, while also minimizing 
the effects of all known and unknown confounding variables, which are, on average, 
made equal following randomization.  In oncology, RCTs have advanced the care for 
patients by enabling investigators to answer important questions regarding the efficacy of 
a particular therapy aimed at driving EBM decision-making.  RCTs also provide insight 
into which subgroups of patients might benefit the most from treatment as well as allow 
for prospective follow-up of patient reported side effects aimed at improving quality of 
life.  Pragmatic RCTs, or experimental studies that are implemented under routine 
clinical conditions, fall under the category of CER, as they typically compare the 
effectiveness of a drug or therapy compared to the alternative standard of care given to 
patients.  Additionally, pragmatic RCTs tend to be focused on important outcomes 
instead of surrogate end points (Hahn 2012).   
 
 Although pragmatic RCTs are the foundation of CER, there are some limitations 
that can make RCTs in general less appealing to researchers.  RCTs can be costly to 
conduct, may require a large number of patients to detect small differences in treatment 
effect, may take a long time to finish depending on patient accrual time and the outcomes 
investigated, and tend to have highly selected patient enrollment that may not be 
representative of actual clinical populations (Friedman 2010).  Due to these limitations, 
obtaining evidence through other means, such as systematic reviews or observational 
studies, can become exceedingly valuable for policy makers (Hahn 2012). 
 
 3.3 CER in Observational Studies  
 
  3.3.1 Introduction 
  
 Although RCTs have long been considered the first choice for evidence 
generation in medicine, due to their high level of internal validity and ability to provide 
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the least biased estimates of risk, there are many instances where results from 
experimental studies are not indicative of real-life application.  Observational studies are 
a source of evidence generation that can answer research questions that are less suited for 
an RCT.  For example, observational studies can be more appropriate in instances of rare 
diseases, when it is unethical to randomly assign the intervention of interest, when it is 
impossible to randomize the factor of interest (eg. a genetic factor), or when it is 
impractical to assign the intervention (Friedman 2010).  Additionally, observational 
studies have the advantage of being less costly and labor intensive to carry out than an 
experimental study and can provide initial evidence to support the implementation of a 
future RCT (Dreyer 2010).   
 
 In CER, observational studies play an important role in the generation of primary 
evidence for practice guideline construction and policy driven decision-making.  The use 
of administrative data in observational studies has the advantage of being inexpensive to 
use, contains information on very large populations and provides information on 
outcomes requiring a longer follow-up time (Hershman 2012).  However, limitations in 
observational studies exist, which if not properly accounted for can lead to erroneous 
results.  The inability to randomly allocate patients to different therapies can lead to 
confounding, which occurs when there are imbalances between confounding variables 
among patient groups (Hershman 2012).  A confounding variable is defined as a variable 
that is associated with the primary variable of interest (independent variable) and 
associated with the outcome of interest (dependent variable), but is not an intermediate 
variable in the causal pathway between the independent variable and dependent variable 
(Szklo 2014).  Adjustment for confounding is very important, as an imbalance in 
confounders has the potential to change the magnitude or even direction of estimated 
treatment effect.  However, a properly designed study using appropriate analytical 
methods can help reduce the confounding bias, or inaccurate estimates of the association 
between treatment and outcome that is caused by confounding variables (Hershman 
2012).   
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  3.3.2 Instrumental Variable Analysis 
  
 Instrumental variable analysis is an analytical approach that can be used in 
observational studies to overcome imbalances between confounding variables among 
treatment groups.  An instrumental variable “C” estimates the effect of a separate 
independent variable “A” on the outcome variable “B” without requiring the 
measurement of any confounders that bias the effects of A on B.  For C to be a true 
instrumental variable, it must satisfy the following assumptions: each patient’s outcome 
is not affected by treatment status of other individuals, C is correlated with A, C is not 
directly or indirectly associated with B, and all effects of C on B are manifested through 
the effects of C on A (Angrist 1996).  In theory, the use of an instrumental variable 
attempts to balance all known and unknown confounding variables by using a 
characteristic that influences the treatment a patient receives, but does not have any sway 
on outcome, therefore providing an unbiased means of measuring treatment effect.  Thus, 
a well-chosen instrumental variable can balance unmeasured confounding in a non-
experimental study in a way similar to that of an RCT (Rassen 2009).  However, 
validating whether an instrumental variable is appropriate can be challenging, especially 
when there are unforeseen associations between the instrumental variable and outcome, 
or when the correlation between the instrumental variable and treatment assignment is 
weak (Armstrong 2012).  Some common instrumental variables found in the literature 
include: rates of treatment use by region, physician prescription preferences, distance 
from hospital or treatment facility, density of health care providers by geographical area, 
health care provider costs, and changes in health care infrastructure (Hershman 2012).  
 
  3.3.3 Regression-Based Modeling  
 
 Multivariable regression modeling is a traditional analytical approach used in 
observational studies to account for confounding bias.  Regression-based modeling 
allows investigators to estimate the association between a treatment and outcome, while 
keeping other covariates in the model constant (Szklo 2014).  As long as the number of 
outcomes of interest in the study sample is large, regression modeling using either, linear 
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regression for continuous outcomes, or logistic regression for binary outcomes, has the 
advantage of adjusting for a substantial number of confounding variables.  Additionally, 
advanced, multi-level modeling techniques are able to adjust for correlated observations, 
when clustering of patient outcomes occurs within single institutions in multi-institutional 
studies (Armstrong 2012).  However, there are some limitations to regression-based 
models, some of which include: they do not account for confounders which are not 
included in the model, they are unable to provide accurate estimates of association when 
there is insufficient overlap among covariates between treatment groups, and they are 
bound by the assumptions of the regression model chosen (Vittinghoff 2012). 
 
  3.3.4 Matching 
 
 Matching is another analytical tool used to control for the influences of 
confounding variables.  Although matching is predominately used in case-control studies, 
it has also been used in cohort studies in oncology to control for multiple prognostic 
factors pertaining to survival (Coen 2012, Khor 2013, Pickle 2010, Szklo 2014).  There 
are many different types of matching techniques that have been developed.  Matching 
directly on an individual-by-individual basis is the most common, where subjects are 
matched so that both individuals have the same baseline-measured covariates.  Direct 
individual matches are generally made based on both categorical variables (eg. male vs. 
female) and continuous variables using cutoff ranges (eg. age ≤ 65 years, or > 65 years) 
(Szklo 2014).  Frequency matching is another common technique found in comparative 
studies, where matched patients are selected based on the distribution of covariates in 
each group (Szklo 2014).  Minimum Euclidean distance measure matching is a more 
complex technique that has been developed to match patients.  Matching using minimum 
Euclidean distance measures is based on the distance two subjects are apart in their 
combination of covariates represented in a standardized score (Smith 1977).  An example 
of a simple match using minimum Euclidean distance measures is shown in Figure 1, 
where patient matches (group #1 and groups #2) are considered based on the covariates 
of age and PSA concentration in a two-dimensional diagram.  Minimum distance 
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matching can be expanded to include multiple variables in ‘n’ dimensional space (Szklo 
2014). 
 
 There are many advantages and disadvantages in using matching compared to 
other analytical techniques.  For example, results from matched designs are easily 
interpretable and are able to provide balance in confounding baseline prognostic factors 
within the treatment groups.  Additionally, matching allows for an increase in statistical 
power when strong confounders are used to create the matches (Szklo 2014).  However, 
matching does have several disadvantages, some of which include: reduced sample size 
when matches are made based on a large number of variables, association and interaction 
assessment between variables used in the matching process is no longer possible, highly 
selected matched cohorts can lead to a reduction in the external validity, and possible loss 
of statistical efficiency when variables used to match subjects are not strongly correlated 
with exposure or outcome (Thompson 1982, Szklo 2014). 
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Fig. 1. Diagram demonstrating matching according to minimum distance method. 
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  3.3.5 Propensity Score (PS) Matched Analysis 
 
 Propensity score (PS) matching is an analytical tool that has been used in 
observational studies to account for the effects of confounding.  Similar to minimum 
distance matching, subjects are matched based on having a similar score (known as their 
propensity score), which is the estimated probability that an individual would receive a 
particular treatment given their specific combination of baseline covariates (Rosenbaum 
1983).  Multivariable logistic regression modeling is used to generate the PS for each 
patient, with treatment assignment as the dependent variable regressed on baseline 
prognostic factors found to impact the outcome of interest (Austin 2007).  Matching 
based on correctly specified propensity score models has been demonstrated to provide 
balance in baseline prognostic factors in groups of patients receiving different therapies 
in a wide range of settings (Rubin 1996).  Once PS matching is completed and adequate 
balance in baseline prognostic factors is achieved, investigators can then compare 
differences in the occurrence of outcomes between treatment groups.  Popular in 
oncology, PS matching has been used in a variety of oncology research, including studies 
on cancers of the lung, breast, colon, brain, and prostate (Chen 2011, Ganz 2011, Khor 
2013, O’Conner 2011, Rodrigues 2013, Verstegen 2013, Wong 2006).  Similar to other 
matching techniques, PS matching has the advantage of being an active attempt at 
balancing baseline prognostic factors in groups of patients that can yield a high-level of 
internal validity in an observational study.  However, PS matching has the disadvantage 
of only being able to provide balance in known confounders that are included in the PS 
model.  Thus, balance in confounders, that are either unknown to the investigator or are 
unavailable to be included in the PS model, cannot be achieved in a PS matched study 
like it could be in a RCT (Armstrong 2012). 
  
 3.4 CER in Prostate Cancer Radiation Therapy Literature 
 
 As was previously discussed, experimental studies are regarded as the highest 
form of evidence generation in the CER literature.  To date, a relatively small number of 
RCTs exist that have aimed to generate evidence comparing treatment outcomes in 
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prostate cancer.  There are a number of relatively small RCTs comparing surgery to other 
treatment options, including two RCTs comparing RP vs. watchful waiting (Bill-Axelson 
2005, Wilt 2012), an RCT comparing RP vs. BT (Gilberti 2009) and an RCT comparing 
RP vs. EBRT (Paulson 1982).  Additionally, there are several RCTs that compare 
differences within a single radiation therapy modality, including studies comparing 
different EBRT dose fractionation sizes (Lukka 2005, Pollack 2006, Yeoh 2006), EBRT 
escalated doses (Kuban 2008, Peeters 2006, Zietman 2005), I-125 vs. Pd-103 BT implant 
sources (Merrick 2007), and BT+EBRT dose regimens (Wallner 2005).  However, there 
is no definitive RCT data available that compares differences in effectiveness between 
two or more primary prostate cancer RT treatment modalities.  No RCT exists that 
compares survival outcomes or side effects in EBRT vs. permanent implant BT 
treatments, or BT alone vs. combination BT+EBRT treatments.  There is a single 
institutional RCT that compares outcomes of combination HDR-BT+EBRT vs. EBRT 
alone (Sathya 2005), however, due to some limitations, the evidence generated in this 
study can only be considered of lower quality.  
 
 In their study, Sathya et al compared 35 Gy Ir-192 permanent seed BT implants 
with adjuvant 40 Gy in 20 fractions EBRT to EBRT alone delivered to a total dose of 66 
Gy in 33 fractions.  A total of 138 patients treated at the Hamilton Regional Cancer 
Centre, Hamilton, ON, Canada, from 1992 to 1997 were adequately randomized to 
receive HDR-BT+EBRT (n=70) or EBRT only (n=68).  OS and bFFS differences 
between groups were assessed with a median follow-up of 8 years.  Results from this 
study indicated that HDR-BT+EBRT led to statistically significantly improved bFFS 
compared to EBRT alone (hazard ratio=0.42; p=0.024), but there was a non-statistically 
significant difference in OS (hazard ratio=1.36; p=0.54).   
 
 There were several study limitations in the RCT by Sathya et al.  Intention-to-treat 
was violated, as 19 patients in the HDR-BT+EBRT group and 15 patients in the EBRT 
group were not included in the final analysis.  Therefore, the balance of known and 
unknown confounders following randomization was no longer present in their final 
analysis.  Additionally, the study had the limitation of being a relatively small, single 
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institutional study that included a combination of intermediate- and high-risk patients in 
their comparison.  Subgroup analysis did show that HDR-BT+EBRT significantly 
improved bFFS in both intermediate- and high-risk subgroups, however this analysis was 
exploratory, making it difficult to assess whether this result is universal across all prostate 
cancer risk categories, including low-risk.  Finally, EBRT dose was relatively low in this 
RCT at only 66 Gy.  EBRT doses ≥ 72 Gy have been shown to improve survival 
outcomes for localized prostate cancer compared to lower doses (Kupelian 2000).   
   
 There are two active RCTs that potentially could improve the quality of evidence 
directly comparing RT treatment options.  One of these trials, named the Effectiveness of 
Prostate Cancer Treatments, or the E-PROSTCaT trial (http://www.clinicaltrials.gov - 
#NCT01492751), compares quality of life measures and survival outcomes in prostate 
cancer patients treated with RP, EBRT or LDR-BT.  However, results of the E-
PROSTCaT trial are not expected until at least 2015.  The other trial (#NCT00063882), 
sponsored by the RTOG (RTOG trial #0232) and the National Cancer Institute, compares 
EBRT+BT vs. BT alone in intermediate-risk patients, with results expected in 2017.  
Both of these trials are in the data analysis stage and are no longer recruiting patients.  An 
additional trial was proposed by the British Columbia Cancer Agency to compare EBRT 
vs. LDR-BT (#NCT00407875), however, this trial was terminated due to low patient 
accrual.  
 
 Low patient accrual is one plausible explanation as to why RCTs comparing 
prostate cancer therapies are nonexistent in the literature.  Differences between the 
various prostate cancer treatment modalities are known to impact final treatment choice 
(Rubin 2001).  Radiation treatments are less invasive than surgery.  Several studies have 
demonstrated that the risk of GU or GI side effects are not universal across surgical or RT 
treatment options (Martin 2008, Resnick 2013, Rubin 2001).  The risk of impotency has 
been identified as a strong indicator for treatment choice in young, sexually active men, 
with the majority finding it difficult to consent to receiving a therapy that might increase 
their risk of losing potency (Rubin 2001).  Additionally, the time commitment for 
patients receiving primary radiation can be quite different depending on treatment 
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chosen.  For example, dose escalated IMRT treatment delivery can last over 8-weeks in 
duration, while permanent BT implantation is delivered on a single day, outpatient basis 
(Washington 2004, Keyes 2013).  Thus, the advantages and disadvantages of each 
therapy could theoretically reduce the number of patients who are willing to enter a trial 
that randomizes them into receiving one RT treatment over another, as patients usually 
have strong preferences in their treatment selection (Rubin 2001). 
 
 Although the available RCT generated CER comparing outcomes from two or 
more RT modalities is quite sparse, a large number of observational comparative studies 
exist in the literature.  Thirty-seven observational CER studies directly comparing 
prostate cancer primary RT outcomes were identified upon literature review, 29 of which 
were retrospective studies (Abel-Waheb 2008, Aoki 2009, Beyer 2000, Burdick 2009, 
Coen 2012, D’Amico 1998, da Silva Franca 2010, Deutsch 2010, Eade 2008, Elliot 2007, 
Gelbium 2000, Goldner 2012, Gondi 2007, Huang 2010, Klein 2009, Khor 2013, Krestin 
2000, Kupelian 2004, Nieder 2008, Ojha 2010, Pe 2009, Pickles 2010, Pinkawa 2010, 
Vassil 2010, Wong 2009, Zelefsky 1999, Zelefsky 2008, Zelefsky 2011, Zhou 2009) and 
eight were prospective studies (Davis 2001, Ferrer 2008, Joseph 2008, Kalakota 2010, 
Lee 2001, Lev 2009, Smith 2009, Talcott 2003).  Methods used to adjust for confounding 
included various forms of regression modeling in 30 studies (Abel-Wahab 2008, Aoki 
2009, Beyer 2000, Burdick 2009, D’Amico 1998, d Silva Franca 2010, Deutsch 2010, 
Eade 2008, Elliot 2007, Ferrer 2008, Gelbium 2000, Goldner 2012, Gondi 2007, Huang 
2010, Kalakota 2010, Klein 2009, Kupelian 2004, Nieder 2008, Ojha 2010, Pe 2009, 
Pinkawa 2010, Smith 2009, Talcott 2003, Vassil 2010, Wong 2009, Zelefsky 1999, 
Zelefsky 2008, Zelefsky 2011, Zhou 2009) and matching in four studies (Coen 2012, 
Khor 2013, Krestin 2000, Pickles 2010).  No study on primary radiation outcomes 
involved the use of instrumental variable analysis, and three studies reported unadjusted 
results, making no effort to account for confounding variables (Davis 2001, Joseph 2008, 
Lee 2001).  A summary of these observational studies on primary RT outcomes as well as 
the RCT by Santhya et al are shown in Appendix I.  A description of the literature search 
strategy for CER articles directly comparing primary RT outcomes is described in 
Appendix II. 
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 With respect to survival outcomes, biochemical failure was assessed in the highest 
number of observational studies, totaling 20 (Beyer 2000, Burdick 2009, Coen 2012, 
D’Amico 1998, da Silva Franca 2010, Deutsch 2010, Eade 2008, Goldner 2012, Gondi 
2007, Klein 2009, Khor 2013, Krestin 2000, Kupelian 2004, Pe 2009, Pickles 2010, 
Pinkawa 2010, Vassil 2010, Wong 2009, Zelefsky 1999, Zelefsky 2011).  However, a 
number of limitations in the bFFS comparisons existed in these studies.  For example, 
different biochemical failure definitions were used, including the original RTOG-ASTRO 
definition of three consecutive PSA rises following nadir (Roach 2006) in four studies 
(Gondi 2007, Krestin 2000, Kupelian 2004, Zelefsky 1999), and the more currently 
accepted ASTRO-Phoenix definition of a PSA rise of 2ng/mL, or more, following nadir 
(Roach 2006) in 16 studies (Burdick 2009, Coen 2012, da Silva 2010, Deutsch 2010, 
Eade 2008, Goldner 2012, Gondi 2007, Klein 2009, Khor 2013, Pe 2009, Pickles 2010, 
Pinkawa 2010, Vassil 2010, Wong 2009, Zelefsky 2011).  This made it difficult to 
compare results of biochemical failure in older studies compared to more modern ones.  
Biochemical failure was also included as part of a composite outcome, failure-free-
survival (FFS), in one additional study, defined as the initiation of secondary therapy, 
positive biopsy post-treatment, PSA rise of 10 ng/dL or more even without three 
consecutive elevations, or development of metastasis (Beyer 2000).  Additionally, 
follow-up was short in the majority of these studies, with only eight studies having a 
follow-up time ≥ 8-years (Beyer 2000, Burdick 2009, Coen 2012, Deutsch 2010, Goldner 
2012, Klein 2009, Khor 2013, Zelefsky 2011).  Only four of these studies with longer 
follow-up included patients from multiple cancer centres (Coen 2012, Deutsch 2010, 
Goldner 2012, Klein 2009) and only three studies accounted for differences in ADT use 
between treatment groups (Coen 2012, Klein 2009, Khor 2013).     
  
 One additional issue with the majority of observational studies using bFFS as 
their primary outcome (Burdick 2009, Coen 2012, da Silva Franca 2010, Deutsch 2010, 
Eade 2008, Goldner 2012, Gondi 2007, Klein 2009, Khor 2013, Krestin 2000, Kupelian 
2004, Pe 2009, Pickles 2010, Pinkawa 2010, Vassil 2010, Wong 2009, Zelefsky 1999, 
Zelefsky 2011), was that comparisons were made in populations composed of mixed low, 
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intermediate and high-risk patients.  This made it difficult to distinguish how PSA failure 
from the compared RTs would be affected within each prostate cancer risk category. 
There were only eight studies that assessed comparative cohorts made up of a singular 
prostate cancer risk category; five assessed entirely low-risk patients (Eade 2008, 
Goldner 2012, Pe 2009, Zelefsky 1999, Zelefsky 2011) and three assessed intermediate-
risk patients (Gondi 2007, Klein 2009, Vassil 2010).  Three of the five low-risk studies 
compared ASTRO-Phoenix bFFS differences in patients receiving LDR-BT vs. EBRT 
with ≥ 5-years of follow-up time (Goldner 2012, Pe 2009, Zelefsky 2011).  In the low-
risk studies by Goldner et al and Pe et al, both compared 74 Gy EBRT to 144 Gy I-125 
permanent implant LDR-BT.  Goldner et al reported no clinically significant difference in 
bFFS between groups, reporting 5-year survival percentages of 94% (LDR-BT, n=667) 
and 91% (EBRT, n=170), while Pe et al reported similar 5-year survival percentages of 
96% (LDR-BT, n=171) vs. 95% (EBRT, n=189), p=0.70.  The low-risk study by 
Zelefsky et al (2011) reported results of a comparison between high dose 81 Gy IMRT 
(n=448) vs. the same LDR-BT dose regimen of 144 Gy (n=281).  Their results 
demonstrated a statistically significant difference in 5-year bFFS of 95% (LDR-BT) vs. 
89% (EBRT), p=0.04.  Although efforts were made to account for confounding, through 
Cox proportional hazard regression adjustment, in all of the low-risk prostate cancer 
studies comparing ASTRO-Phoenix defined bFFS, two of the studies did not account for 
differences in ADT use (Goldner 2012, Zelefsky 2011), and another study by Pe et al, 
reported results from their single institution with a relatively short median follow-up of 
37 months in their BT cohort.   
 
 In the intermediate-risk studies that compared ASTRO-Phoenix bFFS, 144 Gy 
LDR-BT was compared to EBRT doses ranging from 70-80 Gy (Vassil 2010), or a 
singular dose prescription of 81 Gy (Klein 2009).  Vassil et al reported a non-statistically 
significant difference in bFFS comparing LDR-BT (n=256) vs. EBRT (n=305) with a 
hazard ratio of 0.99 (95% CI 0.62-1.58, p=0.97).  Similarly, Klein et al reported non-
statistically significant bFFS 8-year actuarial percentages of 82% (LDR-BT, n=204) vs. 
75% (EBRT, n=321), p>0.05.  Again, attempts to account for confounding though Cox 
regression adjustment was performed in both studies, however, one of the studies made 
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the mistake of classifying the prostate cancer etiological factor ‘race’ as a prognostic 
factor in their adjustment (Vassil 2010).  Race is known to be a risk factor for the 
development of prostate cancer, but is not known to impact treatment prognosis (Rubin 
2001).  Since race is thus not a classical confounding variable, as it is not associated with 
the outcome of interest, some authors feel that it should not be included in the regression 
model (Szklo 2014).  Klein et al, accounted for the confounder ADT use in their study by 
eliminating all ADT patients, this was not done by Vassil et al.  However, Klein et al did 
not report age differences between groups, and made no reference to adjusting for this 
strong confounder in their analysis.   
 
 Attempts to ascertain results comparing bFFS in separate risk categories were 
attempted in five studies through subgroup analyses (Coen 2012, Deutsch 2010, Khor 
2013, Pickles 2010, Wong 2009).  Beyond that cautious interpretation of subgroup 
analysis is universally recommended, due to the increased likelihood of chance findings 
(Friedman 2010), there were some additional limitations found in these exploratory 
analyses.  For example, one study did not account for ADT (Deutsch 2010), while 
another study did not account for either ADT or age (Wong 2009).  There were also some 
limitations in two additional matched studies, one using conventional 1:1 case-by-case 
matching (Pickles 2005) and the other using propensity score matching (Khor 2013).  In 
their single institutional, Canadian study, Pickles et al compared bFFS in a cohort of low- 
and intermediate-risk patients, receiving either 145 Gy I-125 LDR-BT (n=139) or 52-72 
Gy EBRT (n=139).  Although matching did bring balance to comparison groups with 
respect to most of the important prognostic factors, including ADT, the confounding 
variable age was curiously not used in the matching process.  This led to a >7 year 
median age gap between treatment groups.  In their subgroup analysis, Pickles et al 
reported 5-year bFFS actuarial percentages of 94% (LDR-BT) vs. 88% (EBRT), p<0.001, 
for low-risk patients, and 100% (LDR-BT) vs. 78% (EBRT), p=0.02, for intermediate-
risk patients, respectively.  In another single institutional study from Australia, Khor et al 
compared 19.5 Gy Ir-192 with 46 Gy adjuvant EBRT (HDR-BT+EBRT) to 74 Gy EBRT 
alone using propensity score matched analysis (total n=688, matched ratio 1:1).  Their 
cohort was comprised of intermediate- and high-risk patients, and PS matching was 
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performed based on the variables of age, ADT use and prostate cancer risk category.  
Results from subgroup analysis showed a statistically significant improvement in bFFS in 
the HDR-BT+EBRT compared to the EBRT patients with intermediate-risk disease 
(hazard ratio=0.44, 95% CI 0.28-0.70, p<0.001), but a non-statistically significant 
difference in the high-risk patients (hazard ratio=0.82, 95% CI 0.52-1.28).  
 
  The outcome of OS was assessed in a relatively low number of studies found in 
the literature (Coen 2012, Klein 2009, Zhou 2009, Wong 2009).  Coen et al reported a 
non-statistically significant difference in OS (secondary outcome) between high dose 
protons with adjuvant EBRT vs. EBRT alone, with 8-year actuarial percentages of 93% 
vs. 96% (p=0.45).  Zhou et al reported a significant difference between BT (n=664) and 
EBRT (n=876), with 5-year OS percentages of 82% and 72% (p<0.001), respectively.  
However, the type of BT (HDR or LDR) and source type (I-125, Pd-103, Ir-192) was not 
reported by Zhou et al, as well as total dose, fractionation schedule or ADT use.  This 
made it difficult to decipher the exact comparison being made.  Klein et al reported a 
borderline statistically significant difference in their LDR-BT vs. EBRT comparison of 
OS in entirely intermediate-risk patients, with 8-year actuarial percentages of 94% (LDR-
BT) vs. 81% (EBRT).   
   
 There were a number of additional primary outcomes that were investigated in the 
prostate cancer CER RT literature, including late GI or GU side effects (Aoki 2009, Elliot 
2007, Gelbium 2000, Kalakota 2010, Zelefsky 2008), patient reported quality of life 
(Davis 2001, Ferrer 2008, Huang 2010, Joseph 2008, Lee 2001, Lev 2009, Smith 2009, 
Talcott 2003) and secondary cancers (Abel-Waheb 2008, Nieder 2008, Ojha 2010).  
However, our CER study only focuses on overall survival and biological failure 
outcomes.  For reference, the results from these studies are available in Appendix I. 
 
 Upon literature review, it was clear that the CER comparing primary RT survival 
outcomes is lacking.  Most studies that were found compared primary RT survival 
outcomes in a mixture of low-, intermediate- and high-risk patients, with very few studies 
comparing treatment differences within one prostate cancer risk group.  A short follow-
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up time and poor adjustment for ADT use between comparative groups were also 
important limitations that were seen.  The goal of this study is to help improve the quality 
of CER evidence by retrospectively comparing primary RT survival outcomes in 
separately matched prostate cancer risk groupings, in the absence of ADT use.    
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4.0 Research Study 
 
 4.1 Primary Study Objectives  
 
1a) To compare overall survival rates between prostate cancer patients who received 
either external beam radiation alone or brachytherapy with or without adjuvant 
external beam radiation as their primary mode of treatment.  
 
1b) To compare overall survival rates for propensity score matched low-risk prostate 
cancer patients that received external beam radiation alone or low dose rate 
brachytherapy. 
 
1c) To compare overall survival rates for propensity score matched intermediate-risk 
prostate cancer patients that received external beam radiation alone or 
brachytherapy (low dose rate brachytherapy alone or high dose rate brachytherapy 
with adjuvant external beam radiation). 
 
1d) To compare overall survival rates for propensity score matched high-risk prostate 
cancer patients that received external beam radiation alone or brachytherapy (low 
dose rate brachytherapy alone or high dose rate brachytherapy with adjuvant 
external beam radiation).  
 
 4.2 Secondary Study Objectives  
 
2a) To compare biochemical failure-free survival rates between prostate cancer 
patients who received either external beam radiation alone or brachytherapy with 
or without adjuvant external beam radiation as their primary mode of treatment.  
 
2b) To compare biochemical failure-free survival rates for propensity score matched 
low-risk prostate cancer patients that received external beam radiation alone or 
low dose rate brachytherapy. 
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2c) To compare biochemical failure-free survival rates for propensity score matched 
intermediate-risk prostate cancer patients that received external beam radiation 
alone or brachytherapy (low dose rate brachytherapy alone or high dose rate 
brachytherapy with adjuvant external beam radiation). 
 
2d) To compare biochemical failure-free survival rates for propensity score matched 
high-risk prostate cancer patients that received external beam radiation alone or 
brachytherapy (low dose rate brachytherapy alone or high dose rate brachytherapy 
with adjuvant external beam radiation).  
 
 4.3  Study Hypothesis 
 
The overall hypothesis of this study is that brachytherapy with or without 
adjuvant external beam radiation provides superior overall survival and biochemical-
failure-free survival compared with external beam radiation alone as a primary treatment 
option for prostate cancer patients. 
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5.0 Methods 
 
 5.1 Summary of Methods 
 
1. Conducted a literature review to obtain expert knowledge on prostate cancer 
radiation and propensity score matching methodology. 
 
2. Established a theoretical casual framework for the mechanism of action of 
radiation treatment on survival by modeling a directed acyclic graph (DAG) 
 
3. Performed ProCaRS database quality assurance to ensure patients were 
correctly risk-stratified. 
 
4. Obtained low-, intermediate-, and high-risk study populations from the 
ProCaRS database using appropriate inclusion and exclusion criteria. 
 
5. Selected preliminary comparison populations in each risk strata based on 
sample size. 
 
6. Selected the covariates used to create the propensity score models for each 
comparison group based on literature review and availability in the ProCaRS 
database. 
 
7. Performed propensity score matching on all final comparison populations. 
 
8. Chose the best match for each comparison group based on an assessment of 
confounding covariate balance following propensity score matching. 
 
9. Assessed overall survival and biochemical failure-free survival for each 
comparison using the Kaplan Meier method. 
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5.2 Case Definitions 
 
 The primary goal of this study was to determine whether BT treatment options 
were superior to EBRT in providing a survival benefit for prostate cancer patients.  The 
exposure and outcome definitions used for this study are shown in Table 4. 
 
Table 4:  Exposure and outcome definitions. 
 
Exposures (E): 
 
E1) EBRT exposure definition:  
• Any EBRT treatment given (3D conformal or IMRT) that met the minimum 
radiation dose requirements.    
• The minimum EBRT dose requirements are further described in 
section 5.5.   
• Possible radiation therapy treatments that fell under this category:   
• EBRT only. 
 
E2) Brachytherapy exposure definition: 
• Any primary RT treatment option that involved either LDR-BT or HDR-BT 
with or without EBRT. 
• LDR-BT exposure was defined as any patient who underwent iodine-125 or 
palladium-103 permanent seed LDR-BT.   
• HDR-BT was defined as any patient who received iridium-192 HDR-BT.   
• Minimum dose requirements for both LDR-BT and HDR-BT with or 
without EBRT are further described in section 5.5.  
• Possible radiation therapy treatments that fell under this category: 
• LDR-BT only. 
• HDR-BT + EBRT. 
• LDR-BT + EBRT. 
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Outcomes (O): 
 
O1) Overall survival: 
• The time from which a patient ends radiation treatment until death.  Death 
could be from any cause. 
O2) Biochemical failure-free survival: 
• The time from which a patient ends radiation treatment until biochemical 
failure.  Biochemical failure was defined using ASTRO-RTOG Phoenix II 
definition of a PSA rise by 2 ng/mL or more above the nadir PSA (Roach 
2006).  To eliminate the possibility of false positive biochemical failure in the 
BT group because of PSA bounce (Mehta 2013), a PSA of ≥ 0.5 ng/mL on 
last known follow-up was an additional requirement for biochemical failure in 
BT patients (Rodrigues 2013). 
 
5.3 Theoretical Causal Framework/Directed Acyclic Graph (DAG)  
 
 A Directed Acyclic Graph (DAG), which is a visual representation of the possible 
causal mechanisms (including confounding) that can lead to the primary outcome of 
interest (Szklo 2014), was used to establish a causal framework for this study.  The DAG 
model was used to visualize all probable associations that were thought to exist between 
the known confounding variables and both the primary independent and dependent 
variables.  The visual representation of the causal mechanisms in the DAG model was 
used to establish which confounders were most appropriate to control for (Szklo 2014).  
Following literature review, five variables were identified as the strongest patient 
confounders of the association of prostate cancer radiation treatment and survival, age, T-
stage, PSA concentration, Gleason total, and adjuvant hormone therapy use (see Section 
2.0, “Prostate Cancer”).  Age and hormone therapy were included in the DAG model 
individually, while T-stage, PSA concentration, and Gleason total were combined as 
‘tumor factors’ for simplicity.  
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 An additional variable identified as a confounder of surgical management of 
prostate cancer and survival, with the potential to be a confounder of prostate cancer RT 
outcomes, was the percentages of prostate cancer found in core biopsies (Hinkelammert 
2013).  The percentage of positive cores was added to the variable ‘tumor factors’ in the 
DAG model.  Finally, the effect of treatment variation across centres (‘treatment centre 
factors’) and the effects of any changes in radiation therapy practice (‘time trends’), 
which have both previously been shown to influence RT outcomes (Cooperberg 2010), 
were accounted for in the DAG model.  
 
 All backdoor paths in the DAG model, which are the possible causal pathways 
created between the primary independent variable and the dependent variable via their 
associations with known confounders, regardless of the direction of association (Szklo, 
2014), were used to help determine which confounders were to be adjusted for in our 
analyses.  The DAG representing the theoretical causal framework for the mechanism of 
action of radiation treatment on overall survival (OS) including all backdoor paths is 
shown in Figure 2. 
 
 The variables age, tumor factors, hormone therapy, treatment centre and time 
trends were all identified as confounders to be accounted for in this study.  Controlling 
for these factors blocked all backdoor paths, including the ensured blocking of backdoor 
paths 1, 2, 5, 8 and 11 (Fig. 2).  No colliders, or variables where two pathways meet (ie. 
‘variable a’ à ‘collider variable b’ ß ‘variable c’), were identified in the DAG model, 
meaning that all of the above variables could be adjusted for without introducing further 
bias, assuming there was no unknown confounding (Cole 2002). 
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Fig. 2. Directed acyclic graph (DAG) for examining effects of radiation type on OS. 
 
Possible Backdoor Paths: 
 
1) Radiation Treatment Type ß Age à OS 
2) Radiation Treatment Type ß Tumor Factors à OS 
3) Radiation Treatment Type ß Tumor Factors ß Hormone Therapy à OS 
4) Radiation Treatment Type ß Tumor Factors ß Hormone Therapy ß Time 
Trends à Treatment Centre Factors à OS 
5) Radiation Treatment Type ß Hormone Therapy à OS 
6) Radiation Treatment Type ß Hormone Therapy ß Time Trends à Treatment 
Centre Factors à OS 
7) Radiation Treatment Type ß Hormone Therapy à Tumor Factors à OS 
8) Radiation Treatment Type ß Treatment Centre à OS 
Treatment	  Centre	  Factors	  
	  Radiation	  Treatment	  Type	  
Time	  Trends	  
	  OS	  
	  Tumor	  Factors	  	  	  
Age	  	  
Hormone	  Therapy	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9) Radiation Treatment Type ß Treatment Centre ß Time Trends à Hormone 
Therapy à OS 
10) Radiation Treatment Type ß Treatment Centre ß Time Trends à Hormone 
Therapy à Tumor Factors à OS 
11) Radiation Treatment Type ß Time Trends à OS 
12) Radiation Treatment Type ß Time Trends à Hormone Therapy à OS 
13) Radiation Treatment Type ß Time Trends à Hormone Therapy à Tumor 
Factors à OS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50	  
	  
5.4 The Prostate Cancer Risk Stratification (ProCaRS) Database  
 (Data Source) 
 
 Patient information from the Prostate Cancer Risk Stratification (ProCaRS) 
database was used as the data source for this study.  The ProCaRS database contains 
primary RT outcome data on 7974 prostate cancer patients treated at four major cancer 
institutions (Princess Margaret Hospital, Toronto, Ontario, Canada; l’Université Laval, 
Quebec, Canada; McGill University, Montréal, Canada; and the British Columbia Cancer 
Agency, British Columbia, Canada) (Rodrigues 2013).  Following a review of the most 
current guidelines for prostate cancer risk stratification (Rodrigues 2012), the creation of 
the ProCaRS database was sanctioned by the GUROC in an attempt to advance research 
in prostate cancer RT outcomes and methodology.  Results from recursive partitioning 
risk stratification modeling using the ProCaRS data suggested that a six category prostate 
cancer risk stratification system, including categories of extreme-low-, low-, 
intermediate-low-, intermediate-high-, high- and extreme-high-risk, should replace the 
current GUROC three-category system of low-, intermediate- and high-risk (Rodrigues 
2013).  Multivariable Cox proportional hazard regression using ProCaRS data indicated 
that BT was a significant predictor in the outcome of bFFS (Rodrigues 2012).  The results 
from this initial analysis led to the current study, using PS matched analysis to compare 
EBRT versus BT outcomes of OS and bFFS in homogenous cohorts of entirely low-risk, 
intermediate-risk and high-risk patients.  For the purpose of this investigation, the 
previously described original GUROC three-category risk stratification system (Lukka 
2001) was used to stratify patients into low-, intermediate- and high-risk categories prior 
to PS matching and analysis (see Section 2.5, Table 3 for the GUROC low-, intermediate- 
and high-risk category requirements).   
 
 All available variables in the ProCaRS database as well as brief descriptions are 
displayed in Appendix III. 
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5.5 Selection of Study Populations for Propensity Score Matches 
 
  5.5.1 Initial Patient Selection Process and Sample Size Assessment 
 
 The initial process used to select all RT treatment comparison groups prior to 
propensity score matching is outlined in Figure 3.  
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7913 Men registered in ProCaRS database with complete GUROC 
staging information 
 
 
 
 
 
 
 
 3928 Low-risk prostate 
cancer patients 
 2883 Intermediate-risk 
prostate cancer patients 
 1102 High-risk prostate 
cancer patients 
 
  
 
  
 
 
 
 
   
 3017 Low-risk patients 
received primary 
radiotherapy alone  
 1635 Intermeidate-risk 
patients received primary 
radiotherapy alone  
 323 High-risk patients 
received primary 
radiotherapy alone  
 
    
 
 
 
 
 
 
   
 Low-Risk (n=2887): 
- 30 Received HDR+EBRT 
- 2446 Received LDR-BT 
- 411 Received EBRT 
 Intermediate-risk (n=1412): 
- 450 Recived HDR+EBRT 
- 47 Received LDR+EBRT 
- 252 Received LDR-BT 
- 663 Received EBRT 
 High-risk (n=289): 
- 16 Received HDR+EBRT 
- 1 Received LDR+EBRT 
- 4 Received LDR-BT 
- 268 Received EBRT 
 
    
 
 
 
 
 
 
 
 
   
 Low-Risk (n=2857): 
- 2446 Received LDR-BT 
- 411 Received EBRT 
 Intermediate-risk (n=1365): 
- 450 Recived HDR+EBRT 
- 252 Received LDR-BT 
- 663 Received EBRT 
  
 
                   X 
 
  
Further selection 
considerations specific to 
low-risk comparison is 
shown in Fig. 4 
  
Further selection 
considerations specific to 
intermediate-risk comparison 
is shown in Fig. 5 
   
Fig. 3. Initial patient selection process. 
Excluded men treated with hormones 
Separated men by GUROC risk classification 
Excluded men with missing data on baseline characteristics (age, 
PSA, Gleason, T-stage) and outcome measures (OS and BFFS) 
Excluded 
LDR+EBRT due 
to small sample 
size 
Excluded 
HDR+EBRT due 
to small sample 
size  
Discontinued work 
on high-risk 
patients due to low 
numbers receiving 
brachytherapy  
7974 Men registered in ProCaRS database 
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 Patients were separated by GUROC prostate cancer risk category into three 
homogenous groups of low-risk, intermediate-risk, or high-risk.  Patients receiving 
hormone therapy were removed from the comparison groups, as ADT has been 
previously established as a strong confounder of prostate cancer RT survival outcomes 
(Bolla 2002, D’Amico 2004, Lawton 2001).  Patients with missing data on important 
baseline characteristics including age, PSA concentration, Gleason total pattern and T-
stage, as well as outcome data on OS and bFFS were excluded.  This was done to ensure 
that all patients had data on the most important baseline variables and outcomes used in 
all propensity score models and matched analyses.  Following these exclusions the total 
numbers of individuals receiving each RT treatment option was assessed.  Adequate 
sample size was found in low-risk patients that received either LDR-BT (n=2446) or 
EBRT alone (n=411) and intermediate-risk patients who had HDR-BT+EBRT (n=450), 
LDR-BT (n=252), or EBRT alone (n=663).  There were insufficient numbers of low-risk 
patients that received HDR-BT+EBRT (n=30) and intermediate-risk patients that 
received LDR-BT+EBRT (n=47); these patients were excluded prior to propensity score 
matching.  Due to the lack of high-risk patients treated with any of the BT modalities (ie. 
HDR-BT or LDR-BT with or without EBRT), work on the high-risk patient population 
was abandoned.  Before PS matching, some additional selection considerations for the 
low-risk and intermediate-risk patient populations were considered separately and are 
discussed in section 5.5.2 and 5.5.3, respectively.  The SAS code used to create the initial 
patient populations shown in Figure 3 can be seen in Appendix V and Appendix VI. 
 
  5.5.2 Patient Selection for Low-Risk Propensity Score Match  
 
 The patient selection process for PS matching specific to the low-risk prostate 
cancer comparison is shown in Figure 4.  The SAS coding for this selection process is 
shown in Appendix VI. 
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Fig. 4. Low-risk comparison group selection process (cont. from fig. 3). 
 
 
Low-risk frequencies (n= 2857): 
- 2446 Men received LDR-BT 
- 411 Men received EBRT 
- 0 Men excluded due to missing data on radiation dose 
- 45 Men excluded for receiving EBRT total dose 5250 cGy 
- 29 Men excluded for receiving EBRT total dose 6000 cGy 
- 23 Men excluded for receiving EBRT total dose 6400 cGy 
- 153 Men excluded for receiving EBRT total dose 6600 cGy 
- 1 Man excluded for receiving EBRT total dose 6728 cGy 
- 56 Men excluded for receiving EBRT total dose 6800 cGy 
- 138 Men excluded for receiving LDR-BT dose <14400 cGy 
- 
Minimum required 
radiation dose: 
EBRT ≥ 70 Gy 
LDR-BT ≥ 144 Gy 
Low-risk frequencies (n = 2412): 
- 2308 Men received LDR-BT 
- 104 Men received EBRT  
Excluded men with 
missing data on T2b 
TNM staging year 
- 58 Men excluded from LDR-BT group due to missing data on 
T2b TNM staging year 
- 
Low-risk frequencies (n=2354): 
- 2250 Men received LDR-BT 
- 104 Men received EBRT 
Assessed additional covariates for 
Propensity Score (PS) model: centre, 
RT start year, percent positive cores 
RT start restricted to 
years 1999-2006 
FINAL Low-risk comparison group used in PS match (n=1820): 
- 1716 Men received LDR-BT  
- 104 Men received EBRT 
- 30 Men excluded from LDR-BT group treated 
prior to 1999 
- 504 Men excluded from LDR-BT group treated 
after 2006 
- 
- Variables centre and percent positive 
cores were not included in PS model 
- RT start year was added to PS model 
- 
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  Radiation Dose Considerations for Low-Risk Comparison: 
  
 To ensure a fair comparison was made between low-risk radiation treatment 
modalities, a minimum radiation dose requirement of 70 Gy for the EBRT group and 144 
Gy for the LDR-BT group was required to be included in the PS match.  These doses 
were chosen based on literature review.  Currently, a debate exists as to whether the 
benefits of dose escalation in low-risk patients is as beneficial compared to intermediate 
or high-risk patients.  Two randomized trials found in subgroup analysis that dose 
escalation up to 78 Gy provides a benefit in low-risk patients (Kuban 2008, Zietman 
2005), while a separate trial found no significant difference between 68 Gy and 78 Gy in 
their subgroup analysis (Peeters 2006).  Due to the lack of quality evidence to support 
EBRT doses exceeding 70 Gy for low-risk prostate cancer, a required EBRT dose of ≥ 70 
Gy for all low-risk patients was chosen for this study.  Additionally, the minimum dose 
of 144 Gy given with I-125 LDR-BT was chosen based on standard treatment 
recommendations (Nag 1999).  Although a large number of patients that received EBRT 
doses < 70 Gy were excluded (n=307), the benefits of EBRT dose escalation on survival 
are well documented (Hanks 1999, Zelefsky 1998, Kupelian 2000).  Therefore, a 
minimum EBRT dose of at least 70 Gy was required in this comparison group to ensure 
that an adequate EBRT dose was being compared to the higher doses given with LDR-
BT.  There were no patients eliminated from the low-risk population due to missing data 
on RT dose. 
 
  TNM Staging Considerations for Low-Risk Comparison:   
 
 Low-risk patients with T2b T-stage with missing data on TNM staging year were 
removed prior to PS matching.  This ensured that there were no patients with bilateral 
disease in the patient cohort, which would have categorized them as being intermediate-
risk.  Palpable bilateral disease is defined as T2b using the 1997 AJCC TNM staging 
definitions and T2c using the more current definitions adopted after 2002 (Fleming 1997, 
Greene 2002, Edge 2009).  This excluded 58 men from the LDR-BT group.   
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  Additional Variable Assessment for Low-Risk Propensity Score Model:  
 
 All variables used in the PS models were required for a patient to receive a PS and 
be used in the PS matches.  An assessment was made whether including additional 
variables in the low-risk PS model would impact patient numbers available for PS 
matching.  Some of the additional covariates considered for inclusion in the low-risk PS 
model prior to matching included: percent positive cores, treatment centre, and RT start 
year.  The variable ‘percent positive cores’ was not included in the PS model, as this 
would have prevented 17 EBRT patients and 1078 LDR-BT patients from receiving a PS 
(roughly 16% and 48% of the remaining EBRT and LDR-BT populations, respectively).  
Additionally, the variable ‘treatment centre’ was also not included due to the distribution 
of RT treatment modalities provided by the various cancer centres.  For example, cancer 
centres 1, 2 and 3 provided data on low-risk patients treated with LDR-BT, while only 
centres 1 and 2 gave data on EBRT.  Therefore, if the variable ‘treatment centre’ was 
included in the PS model, all LDR-BT patients from cancer centre 3 (n=942) would 
receive no PS and could not be matched.  Finally, RT start year was included in the PS 
model.  Restricting RT start dates was viable because all low-risk EBRT treatments 
occurred during the years 1999-2006, with ample numbers of low-risk LDR-BT patients 
receiving treatment over that same timeframe.  In total, 104 EBRT and 1716 LDR-BT 
patients made up the eventual population used for the low-risk PS match.    
 
  5.5.3 Patient Selection for Intermediate-Risk Propensity Score  
   Matches 
 
 The patient selection process for PS matches specific to the intermediate-risk 
prostate cancer comparisons are shown in Figure 5.  The SAS coding for this selection 
process is shown in Appendix V. 
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Intermediate-risk frequencies (n= 1365): 
- 450 Men received HDR+EBRT 
- 252 Men received LDR-BT 
- 663 Men received EBRT 
- 6 Men excluded in HDR+EBRT group due to 
missing data on RT dose 
- 17 Total men excluded in HDR+EBRT group 
with unusual radiation dose: 
  - 1 excluded for receiving 1000 cGy + 4400 cGy 
  - 1 excluded for receiving 1800 cGy + 4400 cGy 
  - 3 excluded for receiving 1900 cGy + 4400 cGy 
  - 1 excluded for receiving 2000 cGy + 4200 cGy 
  - 2 excluded for receiving 2000 cGy + 4600 cGy 
  - 8 excluded for receiving 2000 cGy + 4500 cGy 
  - 1 excluded for receiving 2000 cGy + 4700 cGy 
- 398 Total men excluded due to low EBRT dose: 
   - 38 excluded for receiving 5250 cGy 
   - 51 excluded for receiving 6000 cGy 
   - 3 excluded for receiving 6200 cGy 
   - 15 excluded for receiving 6400 cGy 
   - 225 excluded for receiving 6600 cGy 
   - 1 excluded for receiving 6660 cGy 
   - 37 excluded for receiving 6800 cGy 
   - 25 excluded for receiving 7000 cGy 
   - 1 excluded for receiving 7200 cGy 
   - 1 excluded for receiving 7250 cGy 
- 1 Man excluded with unusual EBRT dose of 
7524 cGy 
- 12 Men excluded for low LDR dose <144 cGy 
 
Minimum required radiation dose: 
HDR+EBRT (5 most common): 
- 10 Gy + 50 Gy 
- 15 Gy + 40 Gy 
- 15 Gy + 44 Gy 
- 19 Gy + 45 Gy 
- 20 Gy + 44 Gy 
LDR ≥ 144 cGy 
EBRT ≥ 74 cGy 
 
Excluded men with 
missing data on 
T2b TNM staging 
year 
- 35 Men excluded from HDR+EBRT group due to missing data 
on T2b TNM staging year 
- 1 Man excluded from LDR-BT group due to missing data on 
T2b TNM staging year 
- 
Intermediate-risk frequencies (n= 932): 
- 427 Men received HDR+EBRT 
- 240 Men received LDR-BT 
- 265 Men received EBRT  
Intermediate-risk frequencies (n= 896): 
- 392 Men received HDR+EBRT 
- 239 Men received LDR-BT 
- 265 Men received EBRT  
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Fig. 5. Intermediate-risk comparison group selection process (cont. from fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed additional covariates for 
Propensity Score (PS) model: centre, 
RT start year, percent positive cores 
and Gleason total 4+3 vs 3+4 
Excluded patients with 
Gleason total pattern 2 to 5 
- 10 Total men excluded for having Gleason total 2 
to 5 
  - 2 Men excluded from HDR+EBRT group 
  - 8 Men excluded from LDR-BT group  
- 
- Variables centre, RT start year, percent 
positive cores and Gleason total 4+3 vs 
3+4 were not included in PS model 
- 
FINAL Intermediate-risk comparison 
group #2 used in PS match (n=496): 
- 231 Men received LDR-BT  
- 265 Men received EBRT 
FINAL Intermediate-risk comparison 
group #1 used in PS match (n=655): 
- 390 Men received HDR+EBRT  
- 265 Men received EBRT  
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  Radiation Dose Considerations for Intermediate-Risk Comparisons: 
  
 Similar to low-risk, a minimum radiation dose was required to be included in the 
intermediate-risk PS matches.  LDR-BT minimum dose remained the same as in the low-
risk cohort, at ≥ 144 Gy.  Current literature suggests EBRT doses of at least 72 Gy 
provide improved survival outcomes for localized prostate cancer compared to lower 
doses (Kupelian 2000).  The minimum EBRT dose chosen for this study was slightly 
higher than this recommendation, at ≥ 74 Gy because only two intermediate-risk patients 
received doses of at least 72 Gy but less than 74 Gy.  This allowed for an increase in 
minimum dose and ensured that dose escalation was used for all EBRT patients in the 
intermediate-risk PS matches.  HDR-BT+EBRT doses were limited to the five most 
common dose regimens found in the ProCaRS database (Fig 5).  There were an additional 
six men removed from the HDR-BT+EBRT population due to missing data on RT dose. 
 
  TNM Staging Considerations for Intermediate-Risk Comparisons: 
 
 Intermediate-risk patients with T2b T-stage with missing data on TNM staging 
year were excluded prior to PS matching.  This was done for similar reasons as in the 
low-risk category, to ensure that patients with T-stage T2b were correctly identified as 
having either unilateral or bilateral disease (Fleming 1997, Greene 2002, Edge 2009).  
There were 35 T2b staged men from the HDR-BT+EBRT group and a single T2b staged 
man from the LDR-BT group that were excluded because of missing data on TNM 
staging year. 
  
  Variable Assessment for Intermediate-Risk Propensity Score Models: 
   
 Again, similar to the low-risk cohort, the additional variables of treatment centre, 
RT start year, and percent positive cores were assessed for inclusion in the PS models.  
The variable ‘treatment centre’ was not included in the PS models for the same reason as 
in the low-risk cohort.  For intermediate-risk patients, cancer centres 1 and 2 provided 
treatment data on LDR-BT and EBRT, cancer centre 3 on LDR-BT and HDR-BT+EBRT, 
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and centre 4 gave data exclusively on HDR-BT+EBRT.  RT start year was not included 
in the PS models due to a wide range of years that each treatment modality was given, 
LDR-BT was given from the year 1994 to 2010, EBRT from 1999-2006, and HDR-
BT+EBRT from 2001 to 2010.  This precluded the possibility of restricting treatment 
year for the PS modeling.  The percentage of positive cores was not included in the PS 
models due to a large proportion of men (310 in the HDR-BT+EBRT group, 70 in the 
LDR-BT group, and 26 in EBRT group) who had missing data on this variable.   
 
 Additionally, an assessment was made whether Gleason total 7 in the 
intermediate-risk cohort could be further subdivided into sub-patterns 3+4 vs. 4+3.  
Current evidence suggests that Gleason pattern 4+3 compared to Gleason pattern 3+4 can 
lead to a worse survival prognosis for men with prostate cancer (Wright 2009).  
Unfortunately, splitting Gleason 7 into two sub categories was not possible for the 
intermediate-risk PS modeling, as there were a large number of patients receiving BT 
with missing sub-pattern data (306 men in the HDR-BT+EBRT group and 59 in the 
LDR-BT group).  Therefore, Gleason pattern 7 was kept as a single category in the 
intermediate-risk PS models. 
 
 Finally, following an assessment of the distribution of Gleason total pattern in the 
intermediate-risk patient population, it was discovered that all patients with Gleason 
totals of 2, 3, 4 or 5 received BT and not EBRT.  These patients were removed prior to 
matching as including them would lead to difficulties in PS model convergence.  This 
was due to the category of Gleason total 2 to 5 predicting 100% probability of receiving 
BT in the PS model.  Thus, only patients with Gleason total 6 or 7 were included in the 
intermediate-risk matches.  
 
 5.6 Overview of Propensity Score Matching Methodology 
 
 Propensity score matching methodology described by Peter Austin (2007) in his 
systematic review entitled “Propensity-score matching in cardiovascular surgery 
literature from 2004 to 2006:  A systematic review and suggestions for improvement” 
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was used as a general guideline for the PS methods used in this study.  There were four 
steps involved in the PS matching and analysis in this study:  i) creating PS model(s); ii) 
performing PS matching; iii) statistical assessment of covariates balance following 
matching; iv) estimating treatment effects.   
 
  5.6.1 Creation of Final Propensity Score Models 
 
 As was previously discussed, the PS for each patient was estimated indicating 
their probability of receiving a particular treatment based on a number of baseline 
variables in a PS model (Heinze 2011).  Multivariable logistic regression modeling was 
used to create the PS models for this study.  RT treatment designation was the dependent 
variable in the logistic models, while the confounders for RT treatment outcomes were 
the independent variables.  The independent variables chosen for all PS models were 
chosen a priori and were all known to confound prostate cancer survival outcomes.  This 
followed current theory that variables used in PS models should predict outcome and not 
necessarily treatment given (Brookhart 2006).  Four out of the five main prognostic 
factors of prostate cancer radiation therapy were included in all PS models: age, T-stage, 
baseline PSA concentration and Gleason Total.  Due to the requirement that patients must 
have data on all variables in the PS model to receive a PS, baseline data on all four of 
these variables were required throughout the patient inclusion process.  The fifth main 
confounding factor of RT treatment and survival, hormone therapy, was accounted for by 
excluding all patients who received ADT from the cohorts prior to matching.   
 
 The prognostic factors of ‘percent positive cores’ and ‘treatment centre’ were not 
included in any of the PS models following initial sample size assessments.  RT start year 
was included in the low-risk PS model, but not in the intermediate-risk models due to 
reasons previously mentioned in sections 5.5.2 and 5.5.3.  All variables were included in 
the models as main effects with no interactions.  Although interactions have been used in 
PS modeling, there is no current method of assessing the balance created in the 
combinations of variables following matching (Heinze 2011).  The covariates age and 
baseline PSA were included as continuous variables in the PS models, while the 
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covariates T-stage, Gleason total and RT start year were included as categorical variables. 
In the low-risk comparison PS model, T-stage had two categories (any T1; T2), Gleason 
total had two categories (Gleason total 2 to 5 inclusive; Gleason total 6), and RT start 
year had eight categories (one for each year from 1999 to 2006).  In the intermediate-risk 
PS models, T-stage had three categories (any T1; unilateral T2; bilateral T2) and Gleason 
total had two categories (Gleason total 6; Gleason total 7).  The final PS model formulas 
with variable definitions for low-risk and intermediate-risk comparisons are shown in 
Table 5.  The SAS code for low-risk PS model is shown in Appendix IX.  The SAS codes 
for the intermediate-risk PS models are shown in Appendices VII and VIII. 
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Table 5:  Propensity score models and variable definitions. 
Low-risk model:  
LDR-BT vs. EBRT: 
Logit{π} = β0 + β1age  + β2PSA + β3Tstage + β4GleasonTotal + β5RTStartYr2000 + β6 
RTStartYr2001 + β7RTStartYr2002 + β8 RTStartYr2003 + β9RTStartYr2004 + β10 
RTStartYr2005 + β11RTStartYr2006  
 
Where Logit{π} = P(Y=1|age, PSA, Tstage, GleasonTotal, RTStartYr), Y={1 if LDR-
BT, 0 if EBRT only} 
 
Age = {age in years} 
PSA = {baseline PSA measured in ng/mL} 
Tstage = {1 if baseline T-stage = T2, 0 if baseline T-staging = any T1} 
GleasonTotal = {1 if Gleason total = 6, 0 if Gleason total = 2, 3, 4, or 5} 
RTStartYr 2000 = {1 if RT Start occurred in 2000, 0 otherwise} 
RTStartYr 2001 = {1 if RT Start occurred in 2001, 0 otherwise} 
RTStartYr 2002 = {1 if RT Start occurred in 2002, 0 otherwise} 
RTStartYr 2003 = {1 if RT Start occurred in 2003, 0 otherwise} 
RTStartYr 2004 = {1 if RT Start occurred in 2004, 0 otherwise} 
RTStartYr 2005 = {1 if RT Start occurred in 2005, 0 otherwise} 
RTStartYr 2006 = {1 if RT Start occurred in 2006, 0 otherwise} 
 
Intermediate-risk models: 
LDR-BT vs. EBRT: 
Logit{π} = β0 + β1age  + β2PSA + β3TstageT2unilateral + β4 TstageT2bilateral + 
β5GleasonTotal7  
 
Where Logit{π} = P(Y=1|age, PSA, Tstage, GleasonTotal), Y={1 if LDR-BT, 0 if EBRT 
only} 
 
Age = {age in years} 
PSA = {baseline PSA measured in ng/mL} 
TstageT2unilateral = {1 if unilateral T2 disease, 0 if any T1 or T2 bilateral disease} 
TstageT2bilateral = {1 if bilateral T2 disease, 0 if any T1 or T2 unilateral disease} 
GleasonTotal = {1 if Gleason total = 7, 0 if Gleason total = 6} 
 
HDR-BT+EBRT vs. EBRT: 
Logit{π} = β0 + β1age  + β2PSA + β3TstageT2unilateral + β4 TstageT2bilateral + 
β5GleasonTotal7  
 
Where Logit{π} = P(Y=1|age, PSA, Tstage, GleasonTotal, RTStartYr), Y={1 if HDR-
BT+EBRT, 0 if EBRT only} 
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Age = {age in years} 
PSA = {baseline PSA measured in ng/mL} 
TstageT2unilateral = {1 if unilateral T2 disease, 0 if any T1 or T2 bilateral disease} 
TstageT2bilateral = {1 if bilateral T2 disease, 0 if any T1 or T2 unilateral disease} 
GleasonTotal = {1 if Gleason total = 7, 0 if Gleason total = 6} 
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  5.6.2 Propensity Score Matching 
 
 To ensure that optimal matches were achieved, several matches were attempted in 
each comparison group.  Nearest-neighbor matching methodology also known as ‘greedy 
matching’ was used for all matches.  This meant that each randomly selected EBRT 
patient was matched to the nearest BT patient based on patient ‘score’ regardless of 
whether that patient would be a better overall candidate for a different match (Austin 
2007).  Sampling was done without replacement, meaning once a patient was matched 
they were no longer available for future matches (Szklo 2014).  An assessment of the 
total number of patients was performed prior to matching to determine what matching 
ratios would be attempted.  One-to-one matches were explored prior to one-to-many 
matches.  One-to-many matches were used only when there was sufficient sample size 
disparity between treatment groups (ie. if roughly a 1:2 ratio existed, a 1:2 match was 
explored).  In the intermediate-risk comparisons, 1:2 matches were attempted with the 
slightly larger treatment group acting as the control or ‘many’ group.  Due to the large 
number of BT patients available in the low-risk comparison group (n=1716), 1:2, 1:3, and 
1:4 matches were explored with EBRT patients matched to multiple LDR-BT patients.  A 
maximum ratio of 1:4 was chosen based on previous literature indicating matches with 
higher ratios beyond 1:4 are not usually attempted, as the gain in statistical power 
becomes insignificant (Silva 1999).  Although one-to-one-to-one PS matching has been 
documented (Rassen 2013), the statistical methodology used to assess covariate balance 
in three-way PS matches is not fully developed, therefore 1:1:1 (EBRT:LDR-BT:HDR-
BT+EBRT) matching in the intermediate-risk comparison grouping was not attempted. 
 
 A variety of caliper widths, or the range of PS values within which an acceptable 
match was allowed, were explored in this study.  Caliper widths ranging from as low as 
0.005 (Christakis 2003) to as high as 0.1 (Moss 2003) of a propensity score have been 
reported.  In a Monte Carlo simulation study, a caliper of 0.2 of a standard deviation of 
the logit of the propensity score was shown to lead to improved covariate balance 
compared to other common caliper widths (Austin 2009).  However, other 
recommendations have not yielded a consensus on which caliper size is most appropriate 
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for PS matching (Calideno 2008, Lunt 2013, Stuart 2010).  For the matches in this study, 
the initial caliper used was 0.2 of a standard deviation of the logit of the propensity score.  
These initial matches were compared concurrently with additional matches on the 
propensity score scale, which included a tight, previously utilized, caliper width of 0.025 
(Verstegen 2013), a moderate caliper width of 0.05, and a generous caliper width of 0.1.  
An assessment of the covariate balance and sample size was made to determine which 
matches were to be used in the final analyses.  The SAS codes used to generate the final 
matches were based on a previously described SAS code (Coca-Perralillon 2006) and are 
shown in Appendices VII, VIII and IX. 
 
  5.6.3 Statistical Assessment of Covariate Balance After Matching 
 
 Following PS matching, the balance created in each match was assessed 
statistically by comparing the standardized difference in the matched variables.  The 
advantage of using the standardized difference to assess balance over significance testing 
is that the standardized difference is unaffected by sample size or power (Heinze 2011).  
The formula used to calculate the standardized difference for continues variable was 
   
 Additionally, for dichotomous variables, the standardized difference formula used was 
   
For formula (1), x̅treatment and x̅control indicate the mean of the continuous variable in 
‘treated’ and ‘control’ subjects, while the s2treatment and s2control denote their variances.  In 
formula (2), for a dichotomous variable, the pT and pC are the proportion of treated and 
control patients, respectively (Heinze 2011).  For this study, the recommended 
standardized difference cut-point of >0.10 (Austin 2007) was used to indicate significant 
imbalance in the baseline covariates.  The use of the standardized difference statistic was 
chosen based on recommendations that a proper statistical test of balance should not be 
effected by sample size and is related to the sample population not a theoretical one, 
(1) 
(2) 
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which are not features of standard p-value testing (Imai 2008).  Previously described SAS 
code (Faries 2010) was used to generate the standardized differences assessing covariate 
balance in each treatment comparison and is shown in Appendix X. 
 
 The choice of which matches were used in the final analyses were based on the 
following criteria: 
 
1. Following matching all variables used in the PS model must have a standardized 
difference <0.10. 
2. One-to-one matches were assessed prior to one-to-many matches. 
3. A match must be identified in each comparison group having the ‘best’ 
distribution of balance among all variables.   
4. Side-by-side box plots and five number summaries of continuous variables in 
each matched cohort must be similar on visual inspection. 
5. If two or more matches were found to have similar balance in a comparison 
group, the match with the highest number of variables with the lowest 
standardized difference was chosen (indicating a tighter match). 
6. If two or more matches were found to have comparable balance in all variables, 
then the match with the larger sample size was chosen. 
7. If no suitable match was found (with standardized difference <0.10 in all matched 
variables) using the original calipers of 0.2 of a standard deviation of the logit of 
the propensity score, or 0.025, 0.05 or 0.1 of a propensity score, in either one-to-
one matches or one-to-many matches, then a tighter caliper match was performed 
starting with a caliper of 0.01 of a propensity score. 
 
  Selection of the Final Match for Analysis in Low-risk LDR-BT vs. EBRT  
  Cohort: 
 
 A summary of the sample sizes created using different matching criteria for the 
low-risk LDR-BT vs. EBRT cohort is shown in Table 6.  For the low-risk cohort 
comparing LDR-BT to EBRT, 1:1 matches did not achieve balance (standardized 
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difference <0.10) in PSA, Gleason total or RT start year, regardless of the caliper size 
used.  The matches using ratios (EBRT:LDR-BT) of 1:2 and 1:3 did not bring balance to 
RT start year.  However, balance was achieved in 1:4 matches using a caliper width of 
0.2 of a standard deviation of the logit of the propensity score and a caliper width of 
0.025 of a propensity score.  Due to the similar balance produced in both of these 
matches, the 0.2 of a standard deviation of the logit of the propensity score match using a 
1:4 ratio (EBRT:LDR-BT) was chosen for final analysis based on a slightly larger sample 
size (n=400).  Tables 7-10 give examples of the balance produced using different caliper 
widths in the low-risk LDR-BT vs. EBRT matches.   
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Table 6:  Sample size based on propensity score matching in low-risk cohort (pre-match 
n=1820). 
Caliper Ratio 
(LDR:EBRT) 
Total N  
0.025 1:1 206  
0.025 2:1 282  
0.025 3:1 332 
0.025 4:1 395 
0.05 1:1 206 
0.05 2:1 294  
0.05 3:1 384  
0.05 4:1 410  
0.1 1:1 208  
0.1 2:1 300  
0.1 3:1 376  
0.1 4:1 425  
0.2*1SDevLogit 1:1 206  
0.2*1SDevLogit 2:1 294  
0.2*1SDevLogit 3:1 340  
0.2*1SDevLogit 4:1 400  
 Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate 
brachytherapy; SDev = standard deviation 
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Table 7:  Baseline characteristics of variables used in low-risk propensity score match 
(pre-match n=1820) [1:1 Matches]. 
 Caliper: 0.2*1SDevLogit 
Ratio: 1 LDR : 1 EBRT 
Total N = 206 
Caliper: 0.025 
Ratio: 1 LDR : 1 EBRT 
Total N = 206 
Caliper: 0.1 
Ratio: 1 LDR : 1 EBRT 
Total N = 208 
 
VARIABLE LDR 
n = 103 
EBRT 
n = 103 
S.D. LDR 
n = 103 
EBRT 
n = 103 
S.D. LDR 
n = 104 
EBRT 
n =  104 
S.D. 
*Age – mean 
± SDev 
 
68.6 ± 
6.5 
68.8 ± 
6.4 
0.031 68.6 ± 
6.5 
68.9 ± 
6.6 
0.043 68.7 ± 
6.5 
69.0 ± 
6.6 
0.038 
*Baseline 
PSA – mean 
± SDev 
6.42 ± 
1.9 
6.07 ± 
2.4 
0.165 6.42 ± 
1.9 
6.04 ± 
2.4 
0.180 6.43 ± 
1.9 
6.06 ± 
2.4 
0.177 
*Gleason 
Total – n(%) 
    2-5 
    6 
     
 
 
4(3.9) 
99(96.1) 
 
 
 
7(6.8) 
96(93.2) 
 
 
 
0.130 
 
 
 
 
4(3.9) 
99(96.1) 
 
 
 
7(6.8) 
96(93.2) 
 
 
 
0.130 
 
 
 
 
4(3.9) 
100(96.2) 
 
 
 
7(6.7) 
97(93.3) 
 
 
 
0.129 
 
 
*T Stage – 
n(%) 
  T1 
  T2  
  
 
 
63(61.2) 
40(38.8) 
 
 
 
61(59.2) 
42(40.8) 
 
 
0.040 
 
 
 
 
63(61.2) 
40(38.8) 
 
 
 
60(58.3) 
43(41.8) 
 
 
0.059 
 
 
 
 
64(61.5) 
40(38.5) 
 
 
61(58.7) 
43(41.4) 
 
 
 
0.059 
 
 
*RT  Start 
Year – n(%) 
1999 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
 
 
 
5(4.9) 
19(18.5) 
4(3.9) 
28(27.2) 
28(27.2) 
11(10.7) 
4(3.9) 
4(3.9) 
 
 
8(7.8) 
18(17.5) 
5(4.9) 
27(26.2) 
28(27.2) 
7(6.8) 
6(5.8) 
4(3.9) 
 
 
0.120 
0.025 
0.048 
0.022 
0.000 
0.138 
0.090 
0.000 
 
 
5(4.9) 
19(18.5) 
4(3.9) 
28(27.2) 
28(27.2) 
11(10.7) 
4(3.9) 
4(3.9) 
 
 
7(6.8) 
18(17.5) 
5(4.9) 
28(27.2) 
28(27.2) 
7(6.8) 
6(5.8) 
4(3.9) 
 
 
0.083 
0.025 
0.047 
0.000 
0.000 
0.137 
0.090 
0.000 
 
 
5(4.8) 
19(18.3) 
4(3.9) 
28(26.9) 
29(27.9) 
11(10.6) 
4(3.9) 
4(3.9) 
 
 
8(7.7) 
18(17.3) 
5(4.8) 
28(26.9) 
28(26.9) 
7(6.7) 
6(5.8) 
4(3.9) 
 
 
0.119 
0.025 
0.047 
0.000 
0.022 
0.137 
0.090 
0.000 
 Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate 
brachytherapy; PSA = prostate specific antigen; S.D. = standardized difference; SDev = standard 
deviation 
 
*Variable(s) used in propensity-score computation procedures.  
Grey Box = Variable with S.D > 0.10.  
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Table 8:  Baseline characteristics of variables used in low-risk propensity score match 
(pre-match n=1820) [1:2 Matches]. 
 Caliper: 0.2*1SDevLogit 
Ratio: 2 LDR : 1 EBRT 
Total N = 294 
Caliper: 0.025 
Ratio: 2 LDR : 1 EBRT 
Total N = 282 
Caliper: 0.1 
Ratio: 2 LDR : 1 EBRT 
Total N = 300 
 
VARIABLE LDR 
n = 196 
EBRT 
n = 98 
S.D. LDR 
n = 188 
EBRT 
n = 94 
S.D. LDR 
n = 200 
EBRT 
n =  100 
S.D. 
*Age – mean 
± SDev 
 
68.5 ± 
6.0 
68.5 ± 
6.4 
0.011 
 
68.2 ± 
5.8 
68.2 ± 
6.4 
0.004 68.6 ± 
6.0 
68.6 ± 
6.0 
0.000 
*Baseline 
PSA – mean 
± SDev 
6.01 ± 
2.0 
5.95 ± 
2.4 
0.067 6.01 ± 
2.0 
5.87 ± 
2.4 
0.085 6.12 ± 
2.0 
6.00 ± 
2.4 
0.053 
*Gleason 
Total – n(%) 
    2-5 
    6 
     
 
 
13(6.6) 
183(93.4) 
 
 
7(7.1) 
91(92.9) 
 
 
 
0.020 
 
 
 
 
13(6.9) 
175(93.1) 
 
 
 
7(7.5) 
87(92.6) 
 
 
 
0.021 
 
 
 
 
14(7.0) 
186(93.0) 
 
 
 
7(7.0) 
93(93.0) 
 
 
 
0.000 
 
 
*T Stage – 
n(%) 
  T1 
  T2  
  
 
 
116(59.2) 
80(40.8) 
 
 
 
58(59.2) 
40(40.8) 
 
 
 
0.000 
 
 
 
113(60.1) 
75(39.9) 
 
 
55(58.5) 
39(41.5) 
 
 
0.033 
 
 
 
119(59.5) 
81(40.5) 
 
 
59(59.0) 
41(41.0) 
 
 
0.010 
 
 
*RT  Start 
Year – n(%) 
1999 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
 
 
16(8.2) 
30(15.3) 
6(3.1) 
50(25.5) 
55(28.1) 
19(9.7) 
11(5.6) 
9(4.6) 
 
 
8(8.2) 
18(18.4) 
5(5.1) 
26(26.5) 
24(24.5) 
7(7.1) 
6(6.1) 
4(4.1) 
 
 
0.000 
0.082 
0.103 
0.023 
0.081 
0.092 
0.023 
0.025 
 
 
 
15(8.0) 
26(13.8) 
6(3.2) 
47(25.0) 
55(29.3) 
19(10.1) 
11(5.9) 
9(4.8) 
 
 
7(7.5) 
17(18.1) 
5(5.3) 
24(25.5) 
24(25.5) 
7(7.5) 
6(6.4) 
4(4.3) 
 
 
0.020 
0.116 
0.106 
0.012 
0.084 
0.094 
0.022 
0026 
 
 
17(8.5) 
30(15.0) 
6(3.0) 
53(26.5) 
55(27.5) 
19(9.5) 
11(5.5) 
9(4.5) 
 
 
8(8.0) 
18(18.0) 
5(5.0) 
26(26.0) 
26(26.0) 
7(7.0) 
6(6.0) 
4(4.0) 
 
 
0.018 
0.081 
0.102 
0.011 
0.033 
0.091 
0.021 
0.025 
 Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate 
brachytherapy; PSA = prostate specific antigen; S.D. = standardized difference; SDev = standard 
deviation 
 
*Variable(s) used in propensity-score computation procedures.  
Grey Box = Variable with S.D > 0.10. 
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Table 9:  Baseline characteristics of variables used in low-risk propensity score match 
(pre-match n=1820) [1:3 Matches]. 
 Caliper: 0.2*1SDevLogit 
Ratio: 3 LDR : 1 EBRT 
Total N = 340 
Caliper: 0.025 
Ratio: 3 LDR : 1 EBRT 
Total N = 332 
Caliper: 0.1 
Ratio: 3 LDR : 1 EBRT 
Total N = 376 
 
VARIABLE LDR 
n = 255 
EBRT 
n = 85 
S.D. LDR 
n = 249 
EBRT 
n = 83 
S.D. LDR 
n = 282 
EBRT 
n =  94 
S.D. 
*Age – mean 
± SDev 
 
67.3 ± 
5.6 
67.3 ± 
6.0 
0.007 
 
67.2 ± 
5.7 
67.1 ± 
6.0 
0.007 
 
67.8 ± 
5.6 
68.1 ± 
6.2 
0.051 
 
*Baseline 
PSA – mean 
± SDev 
6.02 ± 
2.0 
5.86 ± 
2.4 
0.086 6.03 ± 
2.1 
5.86 ± 
2.4 
0.079 6.11 ± 
2.0 
5.95 ± 
2.4 
0.074 
*Gleason 
Total – n(%) 
    2-5 
    6 
     
 
 
15(5.9) 
240(94.1) 
 
 
 
6(7.1) 
79(92.9) 
 
 
 
0.048 
 
 
15(6.0) 
234(94.0) 
 
 
 
6(7.2) 
77(92.8) 
 
 
 
0.049 
 
 
 
17(6.0) 
265(94.0) 
 
 
 
6(6.4) 
88(93.6) 
 
 
 
0.015 
 
*T Stage – 
n(%) 
  T1 
  T2  
  
 
 
151(59.2) 
104(40.8) 
 
 
 
52(61.2) 
33(38.8) 
 
 
0.040 
 
 
148(59.4) 
101(40.6) 
 
 
 
52(62.7) 
31(37.4) 
 
 
0.066 
 
 
 
 
112(39.7) 
170(60.3) 
 
 
38(40.4) 
56(59.6) 
 
 
0.014 
*RT  Start 
Year – n(%) 
1999 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
 
 
 
17(6.7) 
30(11.8) 
12(4.7) 
66(25.9) 
76(29.8) 
26(10.2) 
15(5.9) 
13(5.1) 
 
 
6(7.1) 
14(16.5) 
5(5.9) 
21(24.7) 
22(25.9) 
7(8.2) 
6(7.1) 
4(4.7) 
 
 
0.016 
0.136 
0.053 
0.027 
0.088 
0.068 
0.047 
0.018 
 
 
16(6.4) 
30(12.1) 
12(4.8) 
60(24.1) 
77(30.9) 
26(10.4) 
15(6.0) 
13(5.2) 
 
 
7(8.4) 
13(15.7) 
5(6.0) 
19(22.9) 
22(26.5) 
7(8.4) 
6(7.2) 
4(4.8) 
 
 
0.077 
0.104 
0.053 
0.028 
0.098 
0.069 
0.049 
0.018 
 
 
21(7.5) 
38(13.5) 
12(4.3) 
76(27.0) 
81(28.7) 
26(9.2) 
15(5.3) 
13(4.6) 
 
 
 
6(6.4) 
16(17.0) 
5(5.3) 
24(25.5) 
26(27.7) 
7(7.5) 
6(6.4) 
4(4.3) 
 
 
0.042 
0.101 
0.050 
0.032 
0.024 
0.064 
0.045 
0.017 
 Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate 
brachytherapy; PSA = prostate specific antigen; S.D. = standardized difference; SDev = standard 
deviation 
 
*Variable(s) used in propensity-score computation procedures.  
Grey Box = Variable with S.D > 0.10. 
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Table 10:  Baseline characteristics of variables used in low-risk propensity score match 
(pre-match n=1820) [1:4 Matches]. 
 Caliper: 0.2*1SDevLogit 
Ratio: 4 LDR : 1 EBRT 
Total N = 400 
Caliper: 0.025 
Ratio: 4 LDR : 1 EBRT 
Total N = 395 
Caliper: 0.1 
Ratio: 4 LDR : 1 EBRT 
Total N = 425 
 
VARIABLE LDR 
n = 320 
EBRT 
n = 80 
S.D. LDR 
n = 316 
EBRT 
n = 79 
S.D. LDR 
n = 340 
EBRT 
n = 85  
S.D. 
*Age – mean 
± SDev 
 
66.9 ± 
5.4 
66.9 ± 
5.9 
0.012 66.9 ± 
5.4 
66.8 ± 
5.9 
0.022 67.3 ± 
5.4 
67.3 ± 
6.0 
0.009 
*Baseline 
PSA – mean 
± SDev 
5.89 ± 
2.1 
5.86 ± 
2.4 
0.013 5.87 ± 
2.1 
5.84 ± 
2.5 
0.011 5.89 ± 
2.1 
5.84 ± 
2.4 
0.021 
*Gleason 
Total – n(%) 
    2-5 
    6 
     
 
 
19(5.9) 
301(94.1) 
 
 
6(7.5) 
74(92.5) 
 
 
0.062 
 
 
19(6.0) 
297(94.0) 
 
 
6(7.6) 
73(92.4) 
 
 
0.063 
 
 
20(5.9) 
320(94.1) 
 
 
 
6(7.1) 
79(92.9) 
 
 
 
0.048 
*T Stage – 
n(%) 
  T1 
  T2  
  
 
 
185(57.8) 
135(42.2) 
 
 
 
49(61.3) 
31(38.8) 
 
 
 
0.070 
 
 
181(57.3) 
135(42.7) 
 
 
 
48(60.8) 
31(39.2) 
 
 
 
0.071 
 
 
196(57.7) 
144(42.4) 
 
 
51(60.0) 
34(40.0) 
 
 
0.048 
*RT  Start 
Year – n(%) 
1999 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
 
 
 
19(5.9) 
42(13.1) 
20(6.3) 
77(24.1) 
94(29.4) 
31(9.7) 
19(5.9) 
18(5.6) 
 
 
 
6(7.5) 
12(15.0) 
5(6.3) 
18(22.5) 
22(27.5) 
7(8.8) 
6(7.5) 
4(5.0) 
 
 
0.062 
0.054 
0.000 
0.037 
0.042 
0.032 
0.062 
0.029 
 
 
18(5.7) 
41(13.0) 
20(6.3) 
75(23.7) 
94(29.8) 
31(9.8) 
19(6.0) 
18(5.7) 
 
 
6(7.6) 
12(15.2) 
5(6.3) 
18(22.8) 
21(26.5) 
7(8.9) 
6(7.6) 
4(5.1) 
 
 
0.076 
0.064 
0.000 
0.023 
0.070 
0.033 
0.062 
0.028 
 
 
22(6.5) 
48(14.1) 
20(5.9) 
79(23.2) 
103(30.3) 
31(9.1) 
19(5.6) 
18(5.3) 
 
 
6(7.1) 
16(18.8) 
5(5.9) 
19(22.4) 
22(25.9) 
7(8.2) 
6(7.1) 
4(4.7) 
 
 
0.023 
0.127 
0.000 
0.021 
0.098 
0.031 
0.060 
0.027 
 
 Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate 
brachytherapy; PSA = prostate specific antigen; S.D. = standardized difference; SDev = standard 
deviation  
 
*Variable(s) used in propensity-score computation procedures.  
Grey Box = Variable with S.D > 0.10. 
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  Selection of the Final Match for Analysis in Intermediate-risk LDR-BT  
  vs. EBRT Cohort: 
  
 A summary of the sample sizes created using various matching criteria for the 
intermediate-risk LDR-BT vs. EBRT cohort is shown in Table 11.  One-to-one matches 
in the LDR-BT vs. EBRT cohort using all original caliper widths including our tightest 
calipers of 0.2 of a standard deviation of the logit of the propensity score as well as a 
width of 0.025 of a propensity score were unable to balance the variable T-stage to within 
a standardized difference of 0.10.  Two-to-one (EBRT:LDR-BT) matches were also 
unable to bring balance to T-stage, or balance the variables of baseline PSA or Gleason 
total.  However, an appropriate match was found when a 1:1 match with a tighter caliper 
of 0.01 of a propensity score was used (n=254).  This match was chosen for final analysis 
in the intermediate-risk LDR-BT vs. EBRT cohort.  Tables 12 and 13 give examples of 
the balance produced using different caliper widths in the intermediate-risk LDR-BT vs. 
EBRT matches.   
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Table 11:  Sample size based on propensity score matching in intermediate-risk LDR-BT 
vs. EBRT cohort (pre-match n=496). 
Caliper Ratio 
(LDR:EBRT) 
Total N  
0.01 1:1 254  
0.025 1:1 260  
0.025 1:2 207  
0.05 1:1 264  
0.05 1:2 216  
0.10 1:1 278  
0.10 1:2 225  
0.2*1SDevLogit 1:1 268  
0.2*1SDevLogit 1:2 219  
 Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate 
brachytherapy; SDev = standard deviation 
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Table 12:  Baseline characteristics of variables used in intermediate-risk LDR-BT vs. 
EBRT propensity score match (pre-match n=496) [1:1 Matches]. 
 Caliper: 0.2*1SDevLogit 
Ratio: 1 LDR : 1 EBRT 
Total N = 268 
Caliper: 0.025 
Ratio: 1 LDR : 1 EBRT 
Total N = 260 
Caliper: 0.1 
Ratio: 1 LDR : 1 EBRT 
Total N = 278 
VARIABLE LDR 
n = 134 
EBRT 
n = 134 
S.D. LDR 
n = 130 
EBRT 
n = 130 
S.D. LDR 
n = 139 
EBRT 
n = 139 
S.D. 
*Age – mean 
± SDev 
 
68.8 ±  
6.4 
68.5 ±  
6.1 
0.050 68.9 ± 
6.4 
68.5 ±  
6.1 
0.060 68.8 ±  
6.3 
68.6 ±  
6.1 
0.037 
*Baseline 
PSA –  
mean ± SDev 
7.77 ±  
2.9 
7.89 ±  
3.9 
0.035 7.79 ± 
3.0 
7.78 ±  
3.8 
0.004 7.66 ±  
3.0 
7.82 ± 
 3.8 
0.047 
*Gleason 
Total – n(%) 
    6 
    7   
 
 
 
34(25.4) 
100(74.6) 
 
 
32(23.9) 
102(76.1) 
 
 
0.035 
 
 
32(24.6) 
98(75.4) 
 
 
29(22.3) 
101(77.7) 
 
 
0.055 
 
 
37(26.6) 
102(73.4) 
 
 
33(23.7) 
106(76.3) 
 
 
0.066 
*T Stage – 
n(%) 
    Any T1 
    Low T2  
    High T2  
 
 
 
58(43.3) 
57(42.5) 
19(14.2) 
 
 
58(43.3) 
64(47.8) 
12(9.0) 
 
 
0.000 
0.105 
0.164 
 
 
56(43.1) 
56(43.1) 
18(13.9) 
 
 
55(42.3) 
63(48.5) 
12(9.2) 
 
 
0.016 
0.108 
0.149 
 
 
60(43.2) 
58(41.7) 
21(15.1) 
 
 
60(43.2) 
67(48.2) 
12(8.6) 
 
 
0.000 
0.130 
0.201 
 Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate 
brachytherapy; PSA = prostate specific antigen; S.D. = standardized difference; SDev = standard 
deviation  
 
*Variable(s) used in propensity-score computation procedures.  
Grey Box = Variable with S.D > 0.10. 
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Table 13:  Baseline characteristics of variables used in intermediate-risk LDR-BT vs. 
EBRT propensity score match (pre-match n=496) [Exploratory Matches]. 
 Caliper: 0.01 
Ratio: 1 LDR : 1 EBRT 
Total N = 254 
Caliper: 0.2*1SDevLogit 
Ratio: 1 LDR : 2 EBRT 
Total N = 219 
Caliper: 0.025 
Ratio: 1 LDR : 2 EBRT 
Total N = 207 
VARIABLE LDR 
n = 127 
EBRT 
n = 127 
S.D. LDR 
n = 73 
EBRT 
n = 146 
S.D. LDR 
n = 69 
EBRT 
n = 138 
S.D. 
*Age – mean 
± SDev 
 
68.7 ± 
6.6 
68.5 ± 
6.1 
0.029 71.4 ± 
5.7 
71.9 ±  
4.1 
0.093 71.4 ± 
5.8 
71.9 ± 
4.3 
0.107 
*Baseline 
PSA –  
mean ± SDev 
7.87 ± 
3.0 
7.70 ± 
3.8 
0.050 7.92 ± 
2.8 
8.64 ±  
3.9 
0.210 7.87 ± 
2.8 
8.77 ± 
3.8 
0.270 
*Gleason 
Total – n(%) 
    6 
    7 
    
 
 
30(23.6) 
97(76.4) 
 
 
27(21.3) 
100(78.7) 
 
 
0.057 
 
 
4(5.5) 
69(94.5) 
 
 
25(17.1) 
121(82.8) 
 
 
0.374 
 
 
44(63.8) 
25(36.2) 
 
 
95(68.8) 
43(31.2) 
 
 
0.495 
*T Stage – 
n(%) 
    Any T1 
    Low T2  
    High T2  
 
 
 
56(44.1) 
56(44.1) 
15(11.8) 
 
 
 
53(41.7) 
62(48.8) 
12(9.5) 
 
 
 
0.048 
0.095 
0.077 
 
 
27(37.0) 
39(53.4) 
7(9.6) 
 
 
46(31.5) 
83(56.9) 
17(11.6) 
 
 
0.116 
0.070 
0.067 
 
 
25(36.2) 
37(53.6) 
7(10.1) 
 
 
 
43(31.2) 
81(58.7) 
14(10.1) 
 
 
 
0.108 
0.102 
0.000 
 Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate 
brachytherapy; PSA = prostate specific antigen; S.D. = standardized difference; SDev = standard 
deviation  
 
*Variable(s) used in propensity-score computation procedures.  
Grey Box = Variable with S.D > 0.10. 
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  Selection of Final Match for Intermediate-risk HDR-BT+EBRT vs. EBRT  
  Cohort: 
 
 A summary of the sample sizes created by the various matching criteria for the 
intermediate-risk HDR-BT+EBRT vs. EBRT cohort is displayed in Table 14.  Matches in 
the intermediate-risk HDR-BT+EBRT vs. EBRT cohort using a 1:1 ratio and caliper 
widths of 0.2 of a standard deviation of the logit of the propensity score and widths of 
0.025 and 0.1 on the propensity score scale were able to balance all variables used in the 
match (standardized difference <0.10).  Out of these three 1:1 matches, the match using 
the 0.2 of a standard deviation of the logit of the propensity score was determined to be 
the closest match as it had the lowest standardized difference values in all but one 
variable (Gleason total).  This match (n=388) was chosen for the HDR-BT+EBRT vs. 
EBRT final analysis.  Exploratory matches using 1:2 ratios did not produce acceptable 
matches.  Tables 15 and 16 give examples of the balance produced using different caliper 
widths in the intermediate-risk HDR-BT+EBRT vs. EBRT matches.   
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Table 14:  Sample size based on propensity score matching in intermediate-risk HDR-
BT+EBRT vs. EBRT cohort (pre-match n=655). 
Caliper Ratio 
(HDR:EBRT) 
Total N  
0.025 1:1 382  
0.025 2:1 258  
0.05 1:1 390  
0.05 2:1 282  
0.10 1:1 406  
0.10 2:1 291  
0.2*1SDevLogit 1:1 388  
0.2*1SDevLogit 2:1 273  
 Abbreviations: EBRT = external beam radiation therapy; HDR = high dose rate 
brachytherapy with adjuvant external beam radiation; SDev = standard deviation 
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Table 15:  Baseline characteristics of variables used in intermediate-risk HDR-BT+EBRT 
vs. EBRT propensity score match (pre-match n=655) [1:1 Matches]. 
 Caliper: 0.2*1SDevLogit 
Ratio: 1 HDR : 1 EBRT 
Total N = 388 
Caliper: 0.025 
Ratio: 1 HDR : 1 EBRT 
Total N = 382 
Caliper: 0.1 
Ratio: 1 HDR : 1 EBRT 
Total N = 406 
VARIABLE HDR 
n = 194 
EBRT 
n = 194 
S.D. HDR 
n = 191 
EBRT 
n = 191 
S.D. HDR 
n = 203 
EBRT 
n = 203 
S.D. 
*Age – mean 
± SDev 
 
69.2 ± 
5.0 
69.2 ± 
5.5 
0.006 69.0 ± 
5.3 
68.9 ± 
5.6 
0.026 69.1 ± 
5.3 
69.2 ± 
5.7 
0.020 
*Baseline 
PSA – mean 
± SDev 
8.92 ± 
4.0 
8.62 ± 
4.1 
0.074 8.91 ± 
4.0 
8.60 ± 
4.2 
0.074 8.95 ± 
4.0 
8.61 ± 
4.1 
0.084 
*Gleason 
Total – n(%) 
    6 
    7 
     
 
 
27(13.9) 
167(86.1) 
 
 
30(15.5) 
164(84.5) 
 
 
0.044 
 
 
27(14.1) 
164(85.9) 
 
 
29(15.2) 
162(84.8) 
 
 
0.030 
 
 
28(13.8) 
175(86.2) 
 
 
32(15.8) 
171(84.2) 
 
 
0.056 
*T Stage – 
n(%) 
    Any T1 
    Low T2  
    High T2  
 
 
92(47.4) 
90(46.4) 
12(6.2) 
 
 
 
92(47.4) 
89(45.9) 
13(6.7) 
 
 
 
0.000 
0.010 
0.021 
 
 
90(47.1) 
89(46.6) 
12(6.3) 
 
 
 
88(46.1) 
90(47.1) 
13(6.8) 
 
 
 
0.021 
0.011 
0.021 
 
 
98(48.3) 
92(45.3) 
13(6.4) 
 
 
 
95(46.8) 
93(45.8) 
15(7.4) 
 
 
 
0.030 
0.010 
0.039 
 Abbreviations: EBRT = external beam radiation therapy; HDR= high dose rate 
brachytherapy with adjuvant external beam radiation therapy; S.D. = standardized difference; 
SDev = standard deviation  
 
*Variable(s) used in propensity-score computation procedures.  
Grey Box = Variable with S.D > 0.10. 
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Table 16:  Baseline characteristics of variables used in intermediate-risk HDR-BT+EBRT 
vs. EBRT propensity score match (pre-match n=655) [Exploratory Matches]. 
 Caliper: 0.2*1SDevLogit 
Ratio: 2 HDR: 1 EBRT 
Total N = 273 
Caliper: 0.025 
Ratio: 2 HDR : 1 EBRT 
Total N = 258 
Caliper: 0.2*1SDevLogit 
Ratio: 1 HDR: 2 EBRT 
Total N = 141 
VARIABLE HDR 
n = 182 
EBRT 
n = 91 
S.D. HDR 
n = 172 
EBRT 
n = 86 
S.D. HDR 
n =47 
EBRT 
n = 94 
S.D. 
*Age – mean 
± SDev 
 
65.6 ± 
4.9 
65.3 ± 
4.8 
0.067 65.4 ± 
5.2 
64.8 ± 
5.1 
0.114 73.0 ± 
3.9 
73.5 ± 
3.0 
0.146 
*Baseline 
PSA – mean 
± SDev 
8.33 ± 
3.8 
8.82 ± 
4.1 
0.125 8.38 ± 
3.8 
8.83 ± 
4.2 
0.114 9.76 ± 
4.3 
8.73 ± 
4.5 
0.234 
*Gleason 
Total – n(%) 
    6 
    7 
     
 
 
14(7.7) 
168(92.3) 
 
 
9(9.9) 
82(90.1) 
 
 
0.078 
 
 
12(7.0) 
160(93.0) 
 
 
9(10.5) 
77(89.5) 
 
 
0.124 
 
 
16(34.0) 
31(66.0) 
 
 
23(24.5) 
71(75.5) 
 
 
0.212 
*T Stage – 
n(%) 
    Any T1 
    Low T2  
    High T2  
 
 
126(69.2) 
52(28.6) 
4(2.2) 
 
 
 
59(64.8) 
29(31.9) 
3(3.3) 
 
 
 
0.094 
0.072 
0.078 
 
 
124(72.1) 
46(26.7) 
2(1.2) 
 
 
 
57(66.3) 
27(31.4) 
2(2.3) 
 
 
 
0.126 
0.103 
0.089 
 
 
9(19.2) 
28(59.6) 
10(21.3) 
 
 
 
16(17.0) 
60(63.8) 
18(19.2) 
 
 
 
0.055 
0.088 
0.053 
 Abbreviations: EBRT = external beam radiation therapy; HDR = high dose rate 
brachytherapy with adjuvant external beam radiation therapy; PSA = prostate specific antigen; 
S.D. = standardized difference; SDev = standard deviation  
 
*Variable(s) used in propensity-score computation procedures.  
Grey Box = Variable with S.D > 0.10. 
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  5.6.4 Estimating Treatment Effects (Statistical Analysis) 
 
 Once final matches were obtained in each of the compared cohorts, Kaplan-Meier 
survival curves stratified by treatment group (EBRT vs. BT option) were generated for 
OS and bFFS.  The Kaplan-Meier curves were created for both pre-matches and post-
matches.  The log-rank test was used to assess whether a significant difference in OS or 
bFFS existed in the pre-match cohorts.  Due to the lack of independence in the PS 
matched cohorts, Cox proportional hazard regression adjusted for clustering (stratified by 
matched pairs) was used to generate the reported p-value, instead of the log-rank test.  
Both visual tests and global tests for violation of the proportionality assumption in the 
Cox regression models were performed on each of the final PS matched cohorts.  Visual 
testing for violation of proportionality included Log-Minus-Log survival plots and 
Schoenfeld residual plots, while global testing included the Suprmum-Kolmogorov test 
(based on 1000 replications) and the Schoenfeld test.  If there was indication of a 
violation of the proportionality assumption in either the visual tests (ie. a lack of 
parallelism on the Log-Minus-Log survival plot or bending of the Schoenfeld residual 
plot), or global tests (ie. significance in either the Suprmum-Kolmogorov or Schoenfeld 
test), then an extended Cox model was explored by adding a time dependent covariate 
[Radiation type*Log(Survival)].  If the addition of the time dependent covariate was 
significant (p<0.05) to the Cox model, then the extended Cox regression p-value using 
the likelihood ratio test (with 2 degrees of freedom under the null) was reported.  If the 
addition of the time dependent variable was not significant, the p-value from the original 
Cox regression adjusted for clustering was reported.  In the event that results from model 
testing were inconclusive, we compared results from both adjusted and extended Cox 
models in sensitivity analysis.  If results from sensitivity analysis using both models were 
comparable, then the extended Cox regression p-value was reported.  The survival 
difference in all PS matches was tested against the null hypothesis of no difference 
between groups at the 5% level of significance.  The statistical methods used in this study 
follow current consensus for appropriate propensity score matched survival analysis 
(Austin, 2007, Kleinbaum 2012).  The SAS code used to create the Kaplan-Meier curves, 
the adjusted and extended Cox-models, the model assumption tests, and the significance 
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tests are shown in Appendix XI.  The visual plots and results from the global tests are 
shown in Appendix XII.  The extended Cox-modeling shown in Appendix XI was 
achieved using a previously described SAS code (Kleinbaum 2012). 
  
 5.7 Power and Sample Size Considerations 
 
 The sample sizes for each comparison was determined through the PS match 
selection process and was not considered prior to matching.  The statistical power to 
detect survival differences in each cohort was considered once the best matches with 
adequate covariate balance were chosen.  A range in the statistical power for each match 
was calculated using SAS 9.3 statistical software.  For all power calculations, sample size 
was fixed and an alpha of 0.05 was used.  In the low-risk comparison, the 4:1 (LDR-
BT:EBRT) match was accounted for in the power calculation.  Based on the hypothesis 
of this study, that in all comparisons the BT treatment options were expected to be 
superior to EBRT, ranges in statistical power for each cohort assumed BT would have a 
lower hazard than EBRT.  Statistical power was calculated using 5-year and ≥7-year 
bFFS actuarial percentages for prostate cancer patients treated with EBRT found in the 
literature.  Low-risk and intermediate-risk, 5-year bFFS percentages ranged from 84% 
(Goldner 2012) to 95% (Pe 2009) and 74% (Wong 2009) to 86% (Vassil 2010), 
respectively.  The 7- to 10-year bFFS percentages following EBRT ranged from 75% 
(Pickles 2010) to 89% (Zelefsky 2011) for low-risk and 75% (Klein 2009) to 81% 
(Kupelian 2004) for intermediate-risk patients.  The power calculations used in this study 
were based on non-matched designs, thus the reported power may actually be under 
estimating the true power.  A minimum hazard ratio of at least 0.40 in favor of LDR-BT 
was required for statistical power ≥ 0.8 in the low-risk LDR-BT vs. EBRT comparison 
and a hazard ratio of 0.35 in favor of LDR-BT in the intermediate-risk comparison.  A 
hazard ratio of at least 0.45 in favor of HDR-BT+EBRT was required in the HDR-
BT+EBRT vs. EBRT comparison.  Table 17 shows the estimated range in hazard ratios 
required for statistical power of at least 0.8 in all comparisons.  The SAS code used for 
the power calculations is shown in Appendix XIII.   
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Table 17:  Hazard ratio required for statistical power of 0.8 using literature EBRT bFFS 
percentages. 
Comparison 
Sample 
size  
5-year 
EBRT 
bFFS% 
7-to-10 year 
EBRT 
bFFS% 
HR range 
for power 
≥ 0.8 
Low-risk: LDR-BT vs. EBRT *400 95% - 84% 89% - 75% 0.25 - 0.40 
Intermediate-risk: LDR-BT vs. EBRT 254 86% - 74% 81% - 75% 0.30 - 0.35 
Intermediate-risk: HDR-BT+EBRT vs. EBRT 388 86% - 74% 81% - 75% 0.40 - 0.45 
 Abbreviations: EBRT = external beam radiation therapy; HDR-BT+EBRT = high dose 
rate brachytherapy with adjuvant external beam radiation therapy; HR = hazard ratio; LDR-
BT = low dose rate brachytherapy 
 *4:1 (LDR-BT:EBRT) match 
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6.0 Results 
 
 6.1 Descriptive Statistics of Propensity Score Matches 
 
 PS matching brought adequate balance to all variables used in each of the PS 
models.  The baseline characteristics of age, PSA, Gleason total and T-stage had 
standardized differences <0.10 in all matches as well as RT start year in the low-risk 
match.  However, PS matching was unable to bring balance to many of the variables not 
included in the PS models.  In the low-risk, 4:1 (LDR-BT:EBRT) PS match (n=400), the 
variables of ‘percent positive cores’ and ‘treatment centre’ were not balanced 
(standardized difference > 0.1).  Similarly, in the intermediate-risk matches, the variables 
of percent positive cores, treatment year, and treatment centre were unbalanced.  In 
intermediate-risk matches, Gleason pattern 4+3 vs. 3+4 was balanced in the 1:1 HDR-BT 
vs. EBRT match (n=388) but not in the 1:1 LDR-BT vs. EBRT match (n=254).  
 
 Median follow-up time was varied in the PS matched cohorts.  For the low-risk 
match, patients that received LDR-BT had a median follow-up of 82 months, while 
EBRT patients had a median follow-up of 87 months.  In the intermediate-risk, HDR-
BT+EBRT vs. EBRT cohort, HDR-BT+EBRT patients had a median follow-up of 32 
months, and EBRT patients had a median follow-up of 81.5 months.  Finally, in the 
intermediate-risk LDR-BT vs. EBRT match, LDR-BT patients had a median follow-up of 
49 months, while EBRT patients had a median follow-up of 83 months.  The descriptive 
statistics with standardized differences for all patients (low-risk and intermediate-risk) 
prior to matching as well as following PS matching are shown in summary Tables 18-20.   
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Table 18:  Baseline characteristics for all low-risk patients (n=1820) and patients matched 
on propensity scores (n=400), stratified by treatment type (LDR-BT vs. EBRT). 
 All Patients 
N=1820 
Matched Patients 
N= 400 
Caliper: 0.2*1SDevLogit 
Ratio: 4 LDR : 1 EBRT 
VARIABLE LDR + 
EBRT 
n = 1820 
LDR 
n = 1716 
EBRT 
n = 104 
S.D. LDR + 
EBRT 
n = 400 
LDR 
n = 320 
EBRT 
n = 80  
S.D. 
*Age – mean ± 
SDev, median, 
(min – max) 
63.32 ± 
7.07 
63.00 
(43.00 – 
84.00) 
62.97 ± 
6.96 
63.00 
(43.00 – 
83.00) 
68.98 ± 
6.59 
70.00 
(51.00 – 
84.00) 
0.886 66.93 ± 
5.49 
68.00 
(51.00 – 
80.00 
66.94 ± 
5.39 
68.00 
(51.00 – 
79.00) 
66.87 ± 
5.91 
67.00 
(51.00 – 
80.00) 
0.012 
*Baseline PSA 
– mean ± SDev, 
median, (min – 
max) 
5.44 ± 
2.12 
5.40 
(0.26 – 
10.00) 
5.40 ± 
2.10 
5.34 
(0.30 – 
10.00) 
6.06 ± 
2.36 
6.23 
(0.26 – 
10.00) 
0.295 5.88 ± 
2.14 
5.90 
(0.26 – 
10.00) 
5.89 ± 
2.06 
5.90 
(0.50 – 
9.80) 
5.86 ± 
2.44 
5.92 
(0.26 – 
10.00) 
0.013 
*Gleason Total 
– n(%) 
    2-5 
    6 
 
 
136 (7.5) 
1684(92.5) 
 
 
129 (7.5) 
1587(92.5) 
 
 
7 (6.7) 
97 (93.3) 
 
 
 
0.031 
 
 
25 (6.3) 
375 (93.7) 
 
 
19 (5.9) 
301 (94.1) 
 
 
 6 (7.5) 
74 (92.5) 
 
 
0.062 
*T Stage – n(%) 
    T1 
    T2  
 
 
1112(61.1) 
708 (38.9) 
 
1051(61.3) 
665 (38.8) 
 
61 (58.7) 
43 (41.4) 
 
0.053 
 
234 (58.5) 
166 (41.5) 
 
185 (57.8) 
135 (42.2) 
 
49 (61.3) 
31 (38.8) 
 
0.070 
*RT Start Year 
– n(%) 
1999 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
 
 
 
67 (3.7) 
138 (7.6) 
197 (10.8) 
236 (13.0) 
312 (17.1) 
314 (17.3) 
275 (15.1) 
281 (15.4) 
 
 
59 (3.4) 
120 (7.0) 
192 (11.2) 
208 (12.1) 
284 (16.6) 
307 (17.9) 
269 (15.7) 
277 (16.1) 
 
 
8 (7.7) 
18 (17.3) 
5 (4.8) 
28 (26.9) 
28 (26.9) 
7 (6.7) 
6 (5.8) 
4 (3.9) 
 
 
0.186 
0.320 
0.237 
0.380 
0.254 
0.345 
0.324 
0.419 
 
 
25 (6.3) 
54 (13.5) 
25 (6.3) 
95 (23.8) 
116 (29.0) 
38 (9.5) 
25 (6.3) 
22 (5.5) 
 
 
19 (5.9) 
42 (13.1) 
20 (6.3) 
77 (24.1) 
94 (29.4) 
31 (9.7) 
19 (5.9) 
18 (5.6) 
 
 
6 (7.5) 
12 (15.0) 
5 (6.3) 
18 (22.5) 
22 (27.5) 
7 (8.8) 
6 (7.5) 
4 (5.0) 
 
 
0.062 
0.054 
0.000 
0.037 
0.042 
0.032 
0.062 
0.029 
Percent 
Positive Cores 
– n(%) 
  <50% 
  >50% 
  [Missing] 
 
 
 
 
860 (80.1) 
214 (19.9) 
[746] 
 
 
 
800 (81.1) 
187 (19.0) 
[729] 
 
 
 
60 (69.0) 
27 (31.0) 
[17] 
 
 
 
0.282 
 
 
 
189 (76.5) 
58 (23.5) 
[153] 
 
 
 
147 (80.3) 
36 (19.7) 
[137] 
 
 
 
42 (65.6) 
22 (34.4) 
[16] 
 
 
 
0.336 
Treatment 
Centre – n(%) 
  1 
  2 
  3 
 
 
 
536 (29.5) 
687 (37.8) 
597 (32.8) 
 
 
495 (28.9) 
624 (36.4) 
597 (34.8) 
 
 
41 (39.4) 
63 (60.6) 
0 (0) 
 
 
0.224 
0.500 
1.033 
 
 
124 (31.0) 
170 (42.5) 
106 (26.5) 
 
 
91 (28.4) 
123 (38.4) 
106 (33.1) 
 
 
33 (41.3) 
47 (58.8) 
0 (0) 
 
 
0.271 
0.415 
1.000 
 Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate 
brachytherapy; LDR+EBRT = total cohort of low dose rate brachytherapy and external beam 
patients; PSA = prostate specific antigen; RT = radiation therapy; S.D. = standardized difference; 
SDev = standard deviation  
 *Variable(s) used in propensity-score computation procedures (if NO asterisk(*) 
shown, then not used in propensity-score model). 
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Table 19:  Baseline characteristics for all patients (n=496) and patients matched on 
propensity scores (n=254), stratified by treatment type in intermediate-risk LDR-BT vs. 
EBRT comparison. 
 All Patients 
N=496 
Matched Patients 
N = 254 
Caliper: 0.01 
Ratio: 1 LDR : 1 EBRT 
VARIABLE LDR + 
EBRT 
n = 496 
LDR 
n = 231 
EBRT 
n = 265 
S.D. LDR + 
EBRT 
n = 254 
LDR 
n = 127 
EBRT 
n = 127 
S.D. 
*Age – mean ± 
SDev, median, 
(min – max) 
68.31 ± 
6.82 
69.00 
(45.00 – 
83.00) 
65.88 ± 
7.24 
67.00 
(46.00 – 
83.00) 
70.42 ± 
5.64 
71.00 
(45.00 – 
82.00) 
0.700 68.63 ± 
6.33 
69.00 
(45.00 – 
83.00) 
68.72 ± 
6.56 
69.00 
(46.00 – 
83.00) 
68.54 ± 
6.12 
69.00 
(45.00 – 
82.00) 
0.029 
*Baseline PSA 
– mean ± SDev, 
median, (min – 
max) 
8.24 ± 
3.94 
7.46 
(0.46 – 
19.97) 
7.49 ± 
3.39 
7.00 
(0.46 – 
18.00) 
8.89 ± 
4.26 
7.83 
(1.13 – 
19.97) 
0.361 7.78 ± 
3.40 
7.12 
(1.30 – 
18.00) 
7.87 ± 
2.99 
7.41 
(1.30 – 
18.00) 
7.70 ± 
3.77 
6.80 
(1.48 – 
17.00) 
0.050 
*Gleason Total 
– n(%) 
    6 
    7 
 
 
 
146 (29.4) 
350 (70.6) 
 
 
95 (41.1) 
136 (58.9) 
 
 
51 (19.3) 
214 (80.8) 
 
 
0.491 
 
 
57 (22.4) 
197 (77.6) 
 
 
30 (23.6) 
97 (76.4) 
 
 
27 (21.3) 
100(78.7) 
 
 
0.057 
*T Stage – n(%) 
    Any T1 
    Low T2  
    High T2  
 
 
212 (42.7) 
211 (42.5) 
73 (14.7) 
 
110 (47.6) 
79 (34.2) 
42 (18.2) 
 
102 (38.5) 
132 (49.8) 
31 (11.7) 
 
0.185 
0.320 
0.183 
 
109 (42.9) 
118 (46.5) 
27 (10.6) 
 
56 (44.1) 
56 (44.1) 
15 (11.8) 
 
53 (41.7) 
62 (48.8) 
12 (9.5) 
 
0.048 
0.095 
0.077 
Percent 
Positive Cores 
– n(%) 
  <50% 
  >50% 
  [Missing] 
 
 
 
 
240 (59.0) 
167 (41.0) 
[89] 
 
 
 
119 (70.8) 
49 (29.2) 
[63] 
 
 
 
121 (50.6) 
118 (49.4) 
[26] 
 
 
 
0.423 
 
 
 
140 (62.8) 
83 (37.2) 
[31] 
 
 
 
77 (72.6) 
29 (27.4) 
[21] 
 
 
 
63 (53.9) 
54 (46.2) 
[10] 
 
 
 
0.398 
Gleason 
Pattern – n(%) 
  3+3 
  3+4 
  4+3 
  [Missing] 
 
 
 
110 (24.8) 
251 (56.7) 
82 (18.5) 
[53] 
 
 
59 (33.2) 
100 (56.2) 
19 (10.7) 
[53] 
 
 
51 (19.3) 
151 {57.0) 
63 (23.8) 
[0] 
 
 
0.320 
0.016 
0.352 
 
 
47 (20.0) 
145 (61.7) 
43 (18.3) 
[19] 
 
 
20 (18.5) 
73 (67.6) 
15 (13.9) 
[19] 
 
 
27 (21.3) 
72 (56.7) 
28 (22.1) 
[0] 
 
 
0.069 
0.226 
0.214 
RT Start Year  
- n (%) 
1996 
1997 
1998 
1999 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
2007 
2008 
 
 
1 (0.2) 
2 (0.4) 
0 (0) 
16 (3.2) 
23 (4.6) 
47 (9.5) 
94 (19.0) 
80 (16.1) 
44 (8.9) 
56 (11.3) 
72 (14.5) 
15 (3.0) 
20 (4.0) 
 
 
1 (0.4) 
2 (0.9) 
0 (0) 
11 (4.8) 
6 (2.6) 
13 (5.6) 
13 (5.6) 
16 (6.9) 
19 (8.2) 
33 (14.3) 
56 (24.2) 
15 (6.5) 
20 (8.7) 
 
 
0 (0) 
0 (0) 
0 (0) 
5 (1.9) 
17 (6.4) 
34 (12.8) 
81 (30.6) 
64 (24.2) 
25 (9.4) 
23 (8.7) 
16 (6.0) 
0 (0) 
0 (0) 
 
 
0.093 
0.132 
0.000 
0.161 
0.185 
0.251 
0.685 
0.489 
0.043 
0.177 
0.525 
0.373 
0.435 
 
 
0 (0) 
0 (0) 
0 (0) 
3 (1.2) 
12 (4.7) 
23 (9.1) 
41 (16.1) 
35 (13.8) 
24 (9.5) 
33 (13.0) 
59 (23.2) 
5 (2.0) 
11 (4.3) 
 
 
0 (0) 
0 (0) 
0 (0) 
2 (1.6) 
2 (1.6) 
3 (2.4) 
6 (4.7) 
5 (3.9) 
12 (9.5) 
23 (18.1) 
50 (39.4) 
5 (3.9) 
11 (8.7) 
 
 
0 (0) 
0 (0) 
0 (0) 
1 (0.8) 
10 (7.9) 
20 (15.8) 
35 (27.6) 
30 (23.6) 
12 (9.5) 
10 (7.9) 
9 (7.1) 
0 (0) 
0 (0) 
 
 
0.000 
0.000 
0.000 
0.073 
0.300 
0.480 
0.653 
0.596 
0.000 
0.308 
0.827 
0.286 
0.436 
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2009 
2010 
 
15 (3.0) 
11 (2.2) 
15 (6.5) 
11 (4.8) 
0 (0) 
0 (0) 
0.373 
0.316 
3 (1.2) 
5 (2.0) 
3 (2.4) 
5 (3.9) 
0 (0) 
0 (0) 
0.220 
0.286 
 
Treatment 
Centre – n(%) 
1 
2 
3 
 
 
 
 
130 (26.2) 
313 (63.1) 
53 (10.7) 
 
 
 
93 (40.3) 
85 (36.8) 
53 (22.9) 
 
 
 
37 (14.0) 
228 (86.0) 
0 (0) 
 
 
 
0.619 
1.173 
0.777 
 
 
 
83 (32.7) 
152 (59.8) 
19 (7.5) 
 
 
 
65 (51.2) 
43 (33.9) 
19 (15.0) 
 
 
 
18 (14.2) 
109 (85.8) 
0 (0) 
 
 
 
0.859 
1.250 
0.593 
 Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate 
brachytherapy; LDR+EBRT = total cohort of low dose rate brachytherapy and external beam 
patients; PSA = prostate specific antigen; RT = radiation therapy; S.D. = standardized difference; 
SDev = standard deviation  
 *Variable(s) used in propensity-score computation procedures (if NO asterisk(*) 
shown, then not used in propensity-score model). 
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Table 20:  Baseline characteristics for all patients (n=655) and patients matched on 
propensity scores (n=388), stratified by treatment type in intermediate-risk HDR-
BT+EBRT vs. EBRT comparison. 
 All Patients 
N=655 
Matched Patients 
N=388 
Caliper: 0.2*1SDevLogit 
Ratio: 1 HDR : 1 EBRT 
VARIABLE Total 
Sample 
n = 655 
HDR+ 
EBRT 
n = 390 
EBRT 
n = 265 
S.D. Total 
Sample 
n = 388 
HDR+ 
EBRT 
n = 194 
EBRT 
n = 194 
S.D. 
*Age – mean ± 
SDev, median, 
(min – max) 
67.59 ± 
6.62 
69.00 
(45.00 – 
82.00) 
65.66 ± 
6.55 
66.00 
(47.00 – 
81.00) 
70.42 ± 
5.64 
71.00 
(45.00 – 
82.00) 
0.779 69.19 ± 
5.25 
70.00 
(55.00 – 
82.00) 
69.20 ± 
5.03 
70.00 
(57.00 – 
81.00) 
69.17 ± 
5.48 
70.00 
(55.00 – 
82.00) 
0.006 
*Baseline PSA 
– mean ± SDev, 
median, (min – 
max) 
8.51 ± 
4.06 
7.41 
(0.37 – 
19.97) 
8.26 ± 
3.91 
7.23 
(0.37 – 
19.96) 
8.89 ± 
4.26 
7.83 
(1.13 – 
19.97) 
0.155 8.77 ± 
4.06 
7.79 
(1.00 – 
19.76) 
8.92 ± 
4.01 
8.00 
(1.00 – 
19.76) 
8.62 ± 
4.13 
7.60 
(1.48 – 
19.60) 
0.074 
*Gleason Total 
– n(%) 
    6 
    7 
 
 
 
93 (14.2) 
562 (85.8) 
 
 
42 (10.8) 
348 (89.2) 
 
 
51 (19.3) 
214 (80.8) 
 
 
0.239 
 
 
57 (14.7) 
331 (85.3) 
 
 
27 (13.9) 
167 (86.1) 
 
 
30 (15.5) 
164 (84.5) 
 
 
0.044 
*T Stage – 
n(%) 
    Any T1 
    Low T2  
    High T2  
 
 
 
344 (52.5) 
263 (40.2) 
48 (7.3) 
 
 
242 (62.1) 
131 (33.6) 
17 (4.4) 
 
 
102 (38.5) 
132 (49.8) 
31 (11.7) 
 
 
0.485 
0.334 
0.273 
 
 
184 (47.4) 
179 (46.1) 
25 (6.4) 
 
 
92 (47.4) 
90 (46.4) 
12 (6.2) 
 
 
92 (47.4) 
89 (45.9) 
13 (6.7) 
 
 
0.000 
0.010 
0.021 
Percent 
Positive Cores 
– n(%) 
  <50% 
  >50% 
  [Missing] 
 
 
 
 
173 (53.9) 
148 (46.1) 
[334] 
 
 
 
52 (63.4) 
30 (36.6) 
[308] 
 
 
 
121 (50.6) 
118 (49.4) 
[26] 
 
 
 
0.260 
 
 
 
121 (54.5) 
101 (45.5) 
[166] 
 
 
 
30 (62.5) 
18 (37.5) 
[146] 
 
 
 
91 (52.3) 
83 (47.7) 
[20] 
 
 
 
0.207 
Gleason 
Pattern – n(%) 
  3+3 
  3+4 
  4+3 
  [Missing] 
 
 
 
65 (18.5) 
202 (57.6) 
84 (23.9) 
[304] 
 
 
14 [16.3) 
51 (59.3) 
21 (24.4) 
[304] 
 
 
51 (19.3) 
151 (57.0) 
63 (23.8) 
[0] 
 
 
0.078 
0.047 
0.015 
 
 
39 (15.9) 
145 (59.2) 
61 (24.9) 
[143] 
 
 
9 (17.7) 
29 (56.9) 
13 (25.5) 
[143] 
 
 
30 (15.5) 
116 (59.8) 
48 (24.7) 
[0] 
 
 
0.059 
0.060 
0.017 
RT Start Year 
– n(%) 
1999 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
2007 
2008 
2009 
2010 
 
 
5 (0.8) 
17 (2.6) 
44 (6.7) 
102 (15.6) 
84 (12.8) 
54 (8.2) 
50 (7.6) 
47 (7.2) 
55 (8.4) 
98 (15.0) 
73 (11.2) 
26 (4.0) 
 
 
0 (0) 
0 (0) 
10 (2.6) 
21 (5.4) 
20 (5.1) 
29 (7.4) 
27 (6.9) 
31 (8.0) 
55 (14.1) 
98 (25.1) 
73 (18.7) 
26 (6.7) 
 
 
5 (1.9) 
17 (6.4) 
34 (12.8) 
81 (30.6) 
64 (24.2) 
25 (9.4) 
23 (8.7) 
16 (6.0) 
0 (0)  
0 (0) 
0 (0) 
0 (0) 
 
 
0.196 
0.370 
0.392 
0.694 
0.559 
0.072 
0.066 
0.075 
0.573 
0.819 
0.679 
0.378 
 
 
4 (1.0) 
15 (3.9) 
31 (8.0) 
74 (19.1) 
50 (12.9) 
36 (9.3) 
35 (9.0) 
28 (7.2) 
25 (6.4) 
50 (12.9) 
28 (7.2) 
12 (3.1) 
 
 
0 (0) 
0 (0) 
6 (3.1) 
12 (6.2) 
12 (6.2) 
16 (8.3) 
15 (7.7) 
18 (9.3) 
25 (12.9) 
50 (25.8) 
28 (14.4) 
12 (6.2) 
 
 
4 (2.1) 
15 (7.7) 
25 (12.9) 
62 (32.0) 
38 (19.6) 
20 (10.3) 
20 (10.3) 
10 (5.2) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
 
0.205 
0.409 
0.367 
0.694 
0.408 
0.071 
0.090 
0.160 
0.544 
0.833 
0.581 
0.363 
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Treatment 
Centre – (n%) 
1 
2 
3 
4 
 
 
 
37 (5.7) 
228 (34.8) 
303 (46.3) 
87 (13.3) 
 
 
0 (0) 
0 (0) 
303 (77.7) 
87 (22.3) 
 
 
37 (14.0) 
228 (86.0) 
0 (0) 
0 (0) 
 
 
0.570 
3.511 
2.640 
0.758 
 
 
35 (9.0) 
159 (41.0) 
142 (36.6) 
52 (13.4) 
 
 
0 (0) 
0 (0) 
142 (73.2) 
52 (26.8) 
 
 
35 (18.0) 
159 (82.0) 
0 (0) 
0 (0) 
 
 
0.664 
3.014 
2.337 
0.856 
 Abbreviations: EBRT = external beam radiation therapy; HDR+EBRT = high dose rate 
brachytherapy with external beam radiation therapy; PSA = prostate specific antigen; RT = 
radiation therapy; S.D. = standardized difference; SDev = standard deviation 
 *Variable(s) used in propensity-score computation procedures (if NO asterisk(*) 
shown, then not used in propensity-score model). 
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 6.2 Survival Outcomes 
 
 Low-Risk LDR-BT vs. EBRT Match:  
 
 Kaplan-Meier curves comparing both OS and bFFS for LDR-BT and EBRT in 
low-risk PS matched prostate cancer patients are shown in Figures 6 and 7.  No 
significant difference was found comparing OS in the low-risk LDR-BT vs. EBRT match 
(hazard ratio = 1.41, 95% CI 0.52-3.86, p = 0.50).  The 5-year and 10-year actuarial 
percentages for OS were 96% and 88% for LDR-BT patients and 95% and 95% for 
EBRT patients, respectively.  However, LDR-BT was associated with a statistically 
significant improvement in bFFS when compared with EBRT (hazard ratio = 0.35, 95% 
CI 0.17-0.71, p=0.004).  The 5-year and 10-year actuarial percentages for bFFS were 
96% and 91% in the LDR-BT group and 89% and 78% in the EBRT group, respectively.  
In total, 17 (5.3%) LDR-BT patients and 10 (12.5%) EBRT patients experienced a 
biochemical failure, while 21 (6.6%) LDR-BT patients and 4 (5%) EBRT patients died. 
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Fig. 6. Overall survival for low-risk patients in LDR-BT vs. EBRT comparison group 
following propensity score match. 
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Fig. 7. Biochemical failure-free survival for low-risk patients in LDR-BT vs. EBRT 
comparison group following propensity score match. 
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 Intermediate-Risk LDR-BT vs. EBRT Match:  
 
 Kaplan-Meier curves comparing both OS and bFFS for LDR-BT and EBRT in 
intermediate-risk PS matched prostate cancer patients are shown in Figures 8 and 9.  No 
significant difference was found comparing OS in the intermediate-risk LDR-BT vs. 
EBRT match (hazard ratio = 0.79, 95% CI 0.24-2.53, p = 0.69).  The 5-year and 10-year 
actuarial percentages for OS were 97% and 83% for LDR-BT patient and 96% and 80% 
for EBRT patients, respectively.  LDR-BT was associated with a statistically significant 
improvement in bFFS when compared with EBRT (hazard ratio = 0.22, 95% CI 0.09-
0.50, p=0.001).  The 5-year and 10-year actuarial percentages for bFFS were 93% and 
93% in the LDR-BT group and 78% and 28% in the EBRT group, respectively.  In total, 
5 (3.9%) LDR-BT patients and 41 (32.3%) EBRT patients experienced a biochemical 
failure, while 4 (3.1%) LDR-BT patients and 12 (9.4%) EBRT patients died. 
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Fig. 8. Overall survival for intermediate-risk patients in LDR-BT vs. EBRT comparison 
group following propensity score match. 
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Fig. 9. Biochemical failure-free survival for intermediate-risk patients in LDR-BT vs. 
EBRT comparison group following propensity score match. 
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 Intermediate-Risk HDR-BT+EBRT vs. EBRT Match:  
 
 Kaplan-Meier curves comparing both OS and bFFS for HDR-BT+EBRT and 
EBRT in intermediate-risk PS matched prostate cancer patients are shown in Figures 10 
and 11.  No significant difference was found comparing OS in the intermediate-risk 
HDR-BT+EBRT vs. EBRT match (hazard ratio = 0.64, 95% CI 0.20-2.13, p = 0.47).  The 
5-year and 10-year actuarial percentages for OS were 99% and 95% for HDR-BT+EBRT 
patients and 96% and 75% for EBRT patients, respectively.  HDR-BT+EBRT was 
associated with a statistically significant improvement in bFFS when compared with 
EBRT (hazard ratio = 0.48, 95% CI 0.26-0.89, p=0.007).  The 5-year and 10-year 
actuarial percentages for bFFS were 89% and 84% in the HDR-BT+EBRT group and 
76% and 29% in the EBRT group, respectively.  In total, 13 (6.7%) HDR-BT+EBRT 
patients and 64 (33.0%) EBRT patients experienced a biochemical failure, while 3 (1.5%) 
HDR-BT+EBRT patients and 16 (8.2%) EBRT patients died. 
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Fig. 10. Overall survival for intermediate-risk patients in HDR-BT+EBRT vs. EBRT 
comparison group following propensity score match. 
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Fig. 11. Biochemical failure-free survival for intermediate-risk patients in HDR-
BT+EBRT vs. EBRT comparison group following propensity score match. 
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 6.3 Pre-Match Versus Post-Match Comparison 
 
 Kaplan-Meier survival curves showing differences in OS and bFFS in pre-
matched cohorts are shown in Figures 12-17.  The hazard ratio for pre-matched OS was 
0.60 (95% CI 0.31-1.16, p=0.13) for the low-risk cohort, 1.07 (95% CI 0.49-2.32, 
p=0.87) for the intermediate-risk LDR-BT vs. EBRT cohort, and 0.36 (95% CI 0.10-1.27, 
p=0.10) for the intermediate risk HDR-BT+EBRT vs. EBRT cohort.  The hazard ratio for 
pre-matched bFFS was 0.31 (95% CI 0.18-0.55, p<0.0001) for the low-risk cohort, 0.19 
(95% CI 0.10-0.36, p<0.0001) for the intermediate-risk LDR-BT vs. EBRT cohort, and 
0.52 (95% CI 0.34-0.80, p=0.003) for the HDR-BT+EBRT vs. EBRT cohort. 
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Fig. 12. Overall survival for low-risk patients in LDR-BT vs. EBRT comparison group 
prior to propensity score matching. 
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Fig. 13. Biochemical failure-free survival for low-risk patients in LDR-BT vs. EBRT 
comparison group prior to propensity score matching. 
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Fig. 14. Overall survival for intermediate-risk patients in LDR-BT vs. EBRT comparison 
group prior to propensity score matching. 
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Fig. 15. Biochemical failure-free survival for intermediate-risk patients in LDR-BT vs. 
EBRT comparison group prior to propensity score matching. 
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Fig. 16. Overall survival for intermediate-risk patients in HDR-BT+EBRT vs. EBRT 
comparison group prior to propensity score matching. 
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Fig. 17. Biochemical failure-free survival for intermediate-risk patients in HDR-
BT+EBRT vs. EBRT comparison group prior to propensity score matching. 
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7.0 Discussion 
 
 7.1 Survival Outcomes Assessment 
  
 Propensity score matched analysis demonstrated no difference in OS comparing 
BT options to EBRT in any of the comparison groups (LDR-BT vs. EBRT or HDR-
BT+EBRT vs. EBRT in low-risk or intermediate-risk matches) (Fig. 6, 8 and 10).  This 
matched analysis successfully adjusted for the baseline prognostic factors of age, PSA, 
Gleason total score and T-stage, which are the primary factors used to risk-stratify 
patients and tailor their radiation therapy (Keyes 2013, Rubin 2001, Thompson 2007).   
Prospective randomized data comparing OS in intermediate- to high-risk patients 
receiving combination BT with EBRT vs. EBRT alone have reported 5-year actuarial 
percentages of 94% vs. 92%, respectively (Santhya 2005).  Our PS matched analysis 
reported 5-year OS percentages of 99% HDR-BT+EBRT vs. 96% EBRT (p=0.47) in the 
intermediate-risk cohort (Fig. 10).  Similarly, observational data reporting on 
intermediate-risk LDR-BT vs. EBRT found no statistically significant OS difference with 
5-year actuarial percentages of 94% vs. 94% (Klein 2009).  Our results comparing LDR-
BT vs. EBRT in intermediate-risk patients found a similar 5-year OS result of 97% vs. 
96% (p=0.69), respectively (Fig. 8).  Results from observational studies show that OS for 
prostate cancer patients with favorable-risk disease is very high, with 5-year actuarial 
percentages reported at 97% (Wong 2009).  Results from our study showed no 
statistically significant OS difference in the low-risk matched cohort with survival rates 
of 96% LDR-BT vs. 95% EBRT (p=0.50) (Fig. 6).  
  
 A statistically significant difference in biochemical failure was found in both low-
risk and intermediate-risk matched cohorts comparing LDR-BT vs. EBRT, with BT 
providing superior bFFS in both cases (Fig. 7 and 9).  Observational studies comparing 
ASTRO Phoenix defined bFFS as their primary outcome have reported similar results 
when comparing LDR-BT to EBRT.  In strictly low-risk comparisons, literature reported 
5-year bFFS actuarial percentages of ≥ 94% for LDR-BT were constantly higher than 
EBRT compared values, ranging from 84% to 95% (Goldner 2012, Pe 2009, Pickles 
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2010, Wong 2009).  Results from our matched analysis of LDR-BT vs. EBRT in the low-
risk cohort demonstrated 5-year bFFS percentages of 96% LDR-BT vs. 89% EBRT 
(p=0.004) (Fig. 7).  Previously reported CER on entirely intermediate-risk patients 
comparing LDR-BT vs. EBRT have also reported improved bFFS in direct comparisons 
(Klein 2009, Pickles 2010, Vassil 2010, Wong 2009).  The results from our matched 
study are agreeable with the literature, with a hazard ratio of 0.22 (95% CI 0.09-0.50, 
p=0.001) favoring BT in the intermediate-risk LDR-BT vs. EBRT compared cohort (Fig. 
9).   
 
 In the combination HDR-BT+EBRT vs. EBRT PS matched, intermediate-risk 
comparison, statistically significant improvement in bFFS was observed in the HDR-
BT+EBRT group.  The 5-year bFFS percentages were 89% in the HDR-BT+EBRT group 
and 76% in the EBRT group, respectively (p=0.007) (Fig. 11).  Our results agree with 
other CER directly comparing HDR-BT+EBRT vs. EBRT in strictly intermediate-risk 
patients, which have reported similar results that favor combination therapy (Khor 2013, 
Deutsch 2010).  However, the results from one of these studies using Cox regression 
modeling for confounding adjustment, reported results on intermediate-risk in subgroup 
analysis but did not account for differences in ADT use between groups (Deutsch 2010).  
Results from our study on intermediate-risk HDR-BT+EBRT vs. EBRT patients was 
obtained from a homogenous intermediate-risk cohort that received no ADT use.  
Isolating the effect of radiation therapy alone on survival without hormone assistance was 
an advantage of our study over a large proportion of comparative RT outcome studies 
available.   
 
 Visually, in both intermediate-risk comparisons, no apparent difference in 
biochemical failure was observed until ≥3-years, at which point a sharp drop off in bFFS 
was noted in the EBRT cohorts (Fig. 9 and 11).  This visual trend was similar in the low-
risk comparison, where no observable difference in bFFS was seen until roughly 4-years 
post treatment (Fig. 7).  The need for PSA to reach nadir prior to any indication of 
biochemical failure using the ASTRO-RTOG Phoenix II definition (Roach 2006) is a 
likely explanation for this visual trend.  The time to reach PSA nadir following RT has 
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been demonstrated to take as long as 3-years (Shi 2013), which would agree with our 
results, where larger frequencies of biochemical failures were not present until roughly 3-
years after RT treatment was given.  These results demonstrate the importance of having 
follow-up times of at least 5-years to adequately assess PSA failure following RT in 
patients with prostatic cancer.  Another interesting discovery was that although a larger 
proportion of EBRT patients experienced biochemical failure, this did not correlate to a 
poorer overall survival probability.  A possible explanation for this discrepancy between 
biochemical failure and survival in the EBRT cohorts may be a result of salvage therapy. 
This would agree with current studies on BT salvage following EBRT, which have 
demonstrated adequate biochemical control at 5-years (Vargas 2014, Yamada 2013).   
 
 Upon literature review, only one other CER study directly comparing BT versus 
EBRT treatment survival outcomes was found that used PS matched analysis for 
confounding adjustment.  In their study, Khor et al matched 344 EBRT with 344 HDR-
BT+EBRT patients with intermediate- and high-risk disease, reporting a bFFS hazard 
ratio of 0.44 (95% CI 0.28-0.70, p<0.001), favoring combination therapy in intermediate-
risk subgroup analysis.  However, in this study ADT use was only effectively balanced 
between treatment groups in their primary match, which included both intermediate-risk 
and high-risk patients.  Therefore, among other factors included in their PS match model, 
ADT use in the intermediate-risk cohort was no longer balanced and may have 
confounded their subgroup analysis.  Results from our analysis of intermediate-risk 
HDR-BT+EBRT vs. EBRT showed a bFFS hazard ratio of 0.48 (95% CI 0.26-0.89, 
p=0.007) (Fig. 11) in favor of combination HDR-BT+EBRT.  Additionally, our results 
are from a matched, strictly intermediate-risk cohort that had balanced baseline 
prognostic factors with no ADT use in either group.    
 
 When comparing pre-matched, unadjusted survival curves to PS matched curves, 
some differences were observed.  For example, in the pre-match low-risk cohort, a slight 
visual difference in OS with borderline significance favoring LDR-BT was present (Fig. 
12).  This borderline visual difference in OS was no longer present in the low-risk PS 
matched curve (Fig. 6).  Visual comparison of additional pre-match to post-match curves 
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provided similar results.  In the intermediate-risk HDR-BT+EBRT vs. EBRT 
comparison, OS is borderline statistically significant pre-match (Fig. 16) but not 
following PS matching (Fig. 10).  Although reduced sample size in the matched cohorts 
compared to the original pre-matched population could explain this change in statistical 
significance, under visual inspection, survival between treatment groups appears to 
become more similar after PS matching.  This visual trend is also noticeable in the pre-
match and post-match bFFS curves in the intermediate-risk LDR-BT vs. EBRT cohort 
(Fig. 9 and 15) with a slight reduction in strength of difference between groups post-
match.  These results demonstrate that PS matching can be an effective tool at removing 
imbalances in baseline prognostic factors that impact survival and can provide results 
with a reduced amount of bias. 
 
 To our knowledge, this was the first multi-institutional Canadian study comparing 
primary BT vs. EBRT survival outcomes in separate prostate cancer risk groups using PS 
matched analysis.  Through retrospective data analysis, we were able to obtain results of 
biochemical failure and overall survival of patients treated at four major cancer 
institutions in Canada, with over 10-years of follow-up data.  Another advantage of this 
study was that it controlled for the phenomenon of PSA bounce, or the benign spike in 
PSA measurement that can occur following BT treatment (Mehta 2013).  An attempt to 
control for PSA bounce was either not mentioned or attempted in most comparative 
studies found in the literature.  In an exploratory analysis, we created additional Kaplan 
Meier curves that did not factor in PSA bounce in the matched cohorts and compared 
them to the original survival curves (see Appendix IV).  Under visual inspection of the 
bFFS curves, when PSA bounce was not accounted for, EBRT appeared to be initially 
protective compared with BT options over the first 1 to 3 years, until BT eventually 
became superior.  This initial protective effect of EBRT is no longer present when PSA 
bounce was factored into the biochemical survival analysis (Fig. 7, 9 and 11).  This 
demonstrates the potential effect PSA bounce can have on biochemical outcome analysis 
in prostate cancer, specifically when assessing PSA failures from BT treatments within 
the first few years of follow-up.  
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 7.2 Study Limitations 
 
1. Data Source: A major limitation to this study was that results were from a secondary 
analysis that was not originally planned during the creation of the ProCaRS database.  As 
a result, our analysis was restricted to the data originally present in the ProCaRS 
database.  Outcome data was restricted to survival and biochemical failure only.  There 
was no information on acute or late side effects available in the database, including data 
on GI or GU toxicities, impotency, or any measurement on patient reported quality of 
life.  Information on these additional patient important outcomes would have 
strengthened this study by allowing a more in depth assessment of the mortality and 
morbidity associated with the various RT treatments.  
 
2. Sample Size: Matching was restricted to patients with complete data for all variables 
included in the PS models (logistic regression models) and based on specific sets of 
exclusion criteria used to create homogenous comparison groups.  This resulted in a 
reduction in sample size and power in our matched comparisons.  
   
3. Confounding Variable Selection: Variable eligibility for inclusion in PS models was 
restricted to those readily available in the database and of sufficient level of 
completeness.  For example, information on both percent positive core biopsy and 
Gleason 7 sub-pattern (3+4 vs. 4+3) was generally incompletely entered and could not be 
controlled for in our analysis.  The variation in RT management of prostate cancer across 
different treatment centres could potentially impact outcomes (Cooperberg 2010), 
however, the method of data collection from the various cancer institutions made it 
impossible to include a ‘treatment centre’ variable in the PS models. 
 
4.  Comparisons:  Again, due to limitations in available data, no RT modality 
comparisons were made with high-risk prostate cancer patients.  Additionally, there were 
no comparisons of the RT treatments to conservative management strategies (watchful 
waiting or active surveillance) or radical prostatectomy.   
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 7.3 Future Work 
  
 Given the completion of this CER study on prostate cancer outcomes, and the 
effort expended in creating the ProCaRS database containing RT data on roughly 8000 
patients, additional uses for this database could be explored.  A potential retrospective 
study aimed at exploring the relationship between biochemical failure and overall 
survival is warranted.  Identifying patient characteristics that best predict survival 
following biochemical failure would help investigators better understand the relationship 
between these two important patient outcomes.  Additionally, identifying the importance 
of ADT use in LDR-BT patients could be explored to better understand the impact of 
hormone therapy in this patient population.  
 
 With respect to future work in the field of prostate cancer CER, expansion of the 
ProCaRS database to include more patients treated with higher doses of EBRT (>78 Gy) 
with more modern techniques, such as image guided IMRT, would allow for higher 
quality comparisons of BT versus dose escalated IMRT treatments.  Incorporating 
outcome data on acute and late toxicities, impotency and patient reported quality of life 
into the ProCaRS database would also be beneficial.  Exploring patient toxicities as well 
as other side effects from compared therapies could strengthen the quality of comparisons 
made between treatment groups.  Additionally, integrating information on health care 
costs into the ProCaRS database would enable economic assessment.  This could allow 
for a more complete understanding of strengths and weaknesses between therapies and 
ultimately aid decision-making by health policy makers.  Finally, improving the volume 
of high-risk patients in the ProCaRS database could allow for RT outcome comparisons 
to be made in this patient population that, as yet, were not achievable. 
 
 Potential randomized phase III trials comparing both survival and side effect 
outcomes in patients receiving BT or EBRT could be explored.  Results from our study 
indicate that BT treatments appear to lead to fewer treatment failures in low-risk and 
intermediate-risk patients.  However, confirmation of the overall benefit of BT compared 
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to EBRT from a treatment effectiveness standpoint that includes both survival and side-
effect data is not yet fully understood.   
 
 7.4 Conclusions 
 
 Propensity score matched analysis showed BT options significantly improved 
bFFS in low- and intermediate-risk prostate cancer patients after 10-years of follow-up, 
but did not lead to statistically significant improvements in OS.  The comparisons made 
demonstrated that LDR-BT led to relatively fewer treatment failures than EBRT in both 
low-risk and intermediate-risk patients.  Combination HDR-BT+EBRT was also found to 
have a superior benefit in reducing biochemical failures compared with EBRT in men 
with intermediate-risk prostate cancer.  The results of this study add to an increasing 
amount of evidence favoring BT over EBRT with respect to biochemical control in the 
treatment of localized prostate cancer.  Assuming this research question is still of interest 
to the radiation oncology community, our results also provide preliminary evidence for 
implementation of an RCT comparing RT survival outcomes of BT vs. EBRT in low-
risk, intermediate-risk and potentially high-risk prostate cancer patients.  
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Appendix I:  Summary of CER Articles on Primary RT Outcomes. 
Author Date Study Type  
 
Confounder 
Adjustment 
Comparison  
(n per treatment) 
RT Dose (Tx) % Prostate Cancer 
Risk Groups per 
treatment 
Abel-
Wahab et 
al 
2008 Retrospective Cox PH 
Regression 
BT (10214)  
vs.  
EBRT (28225)  
vs.  
BT+EBRT (9078) 
NR NR 
Aoki et al 2009 Retrospective Cox PH 
Regression 
LDR-BT (252)  
vs.  
LDR-BT+EBRT 
(44) 
LDR-BT: 
144 Gy I-125  
vs.  
LDR-BT+EBRT: 
110 Gy I-125 + 
44-46 Gy EBRT  
LDR-BT: 
(Low=65%;Int=33
%;High=2%) 
vs. 
LDR-BT+EBRT: 
(Int=75%;High=25
%) 
Beyer et 
al 
2000 Retrospective Cox PH 
Regression 
LDR-BT (595)  
vs.  
EBRT (1527) 
LDR-BT: 
120 Gy Pd-103 or 
160 Gy I-125  
vs.  
EBRT: 
66 Gy 
NR 
Burdick 
et al 
2009 Retrospective Cox PH 
Regression 
LDR-BT (127) 
vs.  
EBRT (268) 
LDR-BT: 
144 Gy I-125 
vs.  
EBRT: 
70 Gy 
NR 
Coen et al 2012 Retrospective Individual 
1:1 Case 
Match 
Proton + EBRT 
(141)  
vs.  
LDR-BT (141) 
Proton + EBRT: 
20 Gy to 29 Gy 
Proton EBRT + 
50 Gy Photon 
EBRT 
vs.  
LDR-BT: 
145 Gy I-125 or 
115 Gy Pd-103  
Proton EBRT: 
(Low=80%;Int=20
%) 
vs. 
LDR-BT: 
(Low=84%;Int=16
%) 
D'Amico 
et al 
1998 Retrospective Cox PH 
Regression 
LDR-BT (218)  
vs.  
EBRT (766) 
LDR-BT: 
115 Gy Pd-103  
vs.  
EBRT: 
66-72 Gy  
LDR-BT: 
(low=56%;int=23%
;high=20%)  
vs. 
EBRT: 
(low=29%;int=31%
;high=40%) 
da Silva 
Franca et 
al 
2010 Retrospective Cox PH 
Regression 
LDR-BT (72) 
vs.  
LDR-BT+EBRT 
(24) 
LDR-BT: 
145 Gy I-125  
vs.  
LDR-BT+EBRT: 
110 Gy I-125 + 
45 Gy EBRT 
LDR-BT: 
(Int=64%;High=36
%) 
vs.  
LDR-BT+EBRT: 
(Int=29%;High=71
%) 
Davis et 
al 
2001 Prospective None LDR-BT (142)  
vs.  
EBRT (222) 
LDR-BT: 
115 Gy Pd-103 
vs.  
EBRT: 
70 Gy  
NR 
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Deutsch 
et al 
2010 Retrospective Cox PH 
Regression 
EBRT (470)  
vs. 
HDR-BT+EBRT 
(160) 
EBRT:  
86 Gy  
vs.  
HDR-BT+EBRT: 
21 Gy Ir-192 + 50 
Gy EBRT  
EBRT: 
(Low=21%;Int=40
%;High=39%) 
vs. 
HDR-BT+EBRT: 
(Low=14%;Int=71
%;High=15%) 
Eade et al 2008 Retrospective Cox PH 
Regression 
LDR-BT (158)  
vs.  
EBRT (216) 
LDR-BT: 
145-166 Gy I-125  
vs.  
EBRT: 
70-78 Gy 
100% low 
Elliot et 
al 
2007 Retrospective Cox PH 
Regression 
BT (799)  
vs.  
EBRT (645) 
NR NR 
Ferrer et 
al 
2008 Prospective GEE LDR-BT (275) 
vs.  
EBRT (205) 
LDR-BT:  
144 Gy I-125  
vs.  
EBRT: 
74 Gy  
 
LDR-BT: 
(Low=88%;Int=11
%:High=1%) 
vs. 
EBRT: 
(Low=48%;Int=34
%;High=18%) 
Gelbium 
et al 
2000 Retrospective Cox PH 
Regression 
LDR-BT (685)  
vs.  
LDR-BT+EBRT 
(140) 
LDR-BT: 
144 Gy I-125 or 
120 Gy Pd-103 
vs.  
LDR-BT+EBRT: 
100 Gy I-125 or 
90 Gy Pd-103 + 
41-45 Gy EBRT  
NR 
Goldner 
et al 
2012 Retrospective Cox PH 
Regression 
LDR-BT (667)  
vs.  
70 Gy EBRT (82) 
vs.  
74 Gy EBRT 
(170) 
LDR-BT: 
144 Gy I-125  
vs. 
EBRT:  
70 Gy  
vs.  
EBRT: 
74 Gy  
100% low-risk 
patients 
Gondi et 
al 
2007 Retrospective Cox PH 
Regression 
LDR-BT or LDR-
BT+EBRT ± 
ADT (72)  
vs.  
EBRT+ADT (84) 
vs.  
EBRT only (141) 
LDR-BT or LDR-
BT+EBRT ± 
ADT: 
145 Gy I-125 or 
120 Gy Pd-103 or 
110 Gy I-125 + 
45 Gy EBRT or 
90 Gy Pd-103 + 
45 Gy EBRT   
vs. 
EBRT+ADT: 
66-70 Gy + ADT 
vs.  
EBRT: 
66-70 Gy 
100% Intermediate-
risk patients 
Huang et 
al 
2010 Retrospective Regression BT (219)  
vs.  
EBRT (154) 
NS BT: 
(Low=65%;Int=27
%;High=7%) 
vs. 
EBRT: 
(Low=25%;Int=38
%;High=37%) 
132	  
	  
Joseph et 
al 
2008 Prospective None EBRT (111)  
vs.  
HDR-BT+EBRT 
(23) 
EBRT: 
66-70 Gy 
vs. 
HDR-BT+EBRT: 
17 Gy Ir-192 + 40 
Gy EBRT 
 
NR - all int/high-
risk 
Kalakota 
et al 
2010 Prospective Cox PH 
Regression 
LDR-BT (62)  
vs.  
LDR-BT+EBRT 
(48) 
LDR-BT: 
144 Gy I-125  
vs.  
LDR-BT+EBRT: 
108 Gy I-125 + 
45 Gy EBRT  
NR 
Klein et 
al 
2009 Retrospective Cox PH 
Regression 
LDR-BT (204)  
vs.  
EBRT (321) 
LDR-BT: 
144 Gy I-125  
vs. 
EBRT: 
81 Gy  
100% Intermediate-
risk patients 
Khor et al 2013 Retrospective Propensity 
Score Match 
EBRT (344)  
vs.  
HDR-BT+EBT 
(344) 
EBRT: 
74 Gy   
vs. 
HDR-BT+EBRT: 
19.5 Gy Ir-192 + 
46 Gy EBRT  
EBRT: 
(Int=59%;High=41
%) 
vs.  
HDR-BT+EBRT: 
(Int=59%;High=41
%) 
Krestin et 
al 
2000 Retrospective Individual 
1:1 Case 
Match 
EBRT (161)  
vs.  
HDR+EBRT 
(161) 
EBRT: 
66 Gy  
vs. 
HDR-BT+EBRT: 
16-21 Gy Ir-192 + 
46 Gy EBRT   
NR 
Kupelian 
et al 
2004 Retrospective Cox PH 
Regression 
LDR-BT (950)  
vs.  
EBRT≥72Gy 
(301)  
vs. 
EBRT<72Gy 
(484)  
vs.  
LDR-BT+EBRT 
(222) 
LDR-BT: 
144 Gy I-125 or 
136 Gy Pd-103  
vs.  
EBRT≥72Gy: 
72-82 Gy  
vs. 
EBRT<72Gy 
 63-70 Gy  
vs. 
LDR-BT+EBRT: 
108 Gy I-125 + 
41 Gy EBRT or 
102 Gy Pd-103 + 
45 Gy EBRT  
NR - T1/T2 disease 
Lee et al 2001 Prospective None LDR-BT (44)  
vs.  
EBRT (23) 
LDR-BT: 
144 Gy I-125  
vs.  
EBRT:  
70-72 Gy  
LDR-BT: 
(100% low/int) 
vs. 
EBRT: 
(low/int/<10%high) 
Lev et al 2009 Prospective Regression LDR-BT+EBRT 
(61)  
vs.  
HDR-BT+EBRT 
(49) 
NR NR 
Nieder et 
al 
2008 Retrospective Cox PH 
Regression 
BT (22889)  
vs.  
EBRT (93059)  
vs.  
NR NR 
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BT+EBRT 
(17956) 
Ojha et al 2010 Retrospective Cox PH 
Regression 
BT (20259)  
vs.  
EBRT (41986) 
NR NR 
Pe et al 2009 Retrospective Cox PH 
Regression 
LDR-BT (171)  
vs.  
EBRT (189) 
LDR-BT: 
145 Gy I-125  
vs. 
EBRT: 
74 Gy  
100% low-risk 
patients 
Pickles et 
al 
2010 Retrospective Individual 
1:1 Case 
Match 
LDR-BT (139)  
vs.  
EBRT (139) 
LDR-BT: 
145 Gy I-125  
vs. 
EBRT: 
52-72 Gy  
LDR-BT: 
(Low=77%;Int=23
%) 
vs. 
EBRT: 
(Low=77%;Int=23
%) 
Pinkawa 
et al 
2010 Retrospective Cox PH 
Regression 
LDR-BT (94)  
vs.  
EBRT (135)  
vs.  
HDR-BT+EBRT 
(66) 
LDR-BT: 
145 Gy I-125  
vs. 
EBRT: 
70 Gy  
vs. 
HDR-BT+EBRT: 
18 Gy Ir-192 + 50 
Gy  
LDR-BT: 
(Low=65%;Int=35
%) 
vs. 
EBRT: 
(Low=27%;Int=24
%;High=49%) 
vs. 
HDR-BT+EBRT 
(Low=35%;Int=26
%;High=39%) 
Santhya 
et al 
2005 RCT Cox PH 
Regression 
HDR-BT+EBRT 
(51)  
vs.  
EBRT (53) 
HDR-BT+EBRT: 
35 Gy BT + 40 
Gy EBRT  
vs.  
EBRT: 
66 Gy  
HDR-BT+EBRT: 
(int=41%;high=59
%) 
vs. 
EBRT: 
(int=40%;high=60
%) 
Smith et 
al 
2009 Prospective Regression LDR-BT (58)  
vs.  
HDR-BT (47)  
vs.  
EBRT (123) 
NR NR 
Talcott et 
al 
2003 Prospective Regression BT (80)  
vs.  
EBRT (182) 
NR BT: 
(Low=35%;Int=32
%;High=33%;unkn
own=4%) 
vs. 
EBRT: 
(Low=55%;Int=22
%;High=23%;Unkn
own=7%) 
Vassil et 
al 
2010 Retrospective Cox PH 
Regression 
LDR-BT (256)  
vs.  
EBRT (305) 
LDR-BT: 
144 Gy I-125  
vs. 
EBRT: 
70-80 Gy  
100% Intermediate-
risk patients 
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Wong et 
al 
2009 Retrospective Cox PH 
Regression 
LDR-BT (225)  
vs.  
3D-CRT (270)  
vs.  
IMRT (314)  
vs.  
LDR-BT+EBRT 
(44) 
LDR-BT: 
144 Gy I-125 or 
120 Pd-103  
vs.  
3D-CRT: 
66-71 Gy  
vs.  
IMRT: 
75-77 Gy  
vs.  
LDR-BT_EBRT) 
110 Gy I-125 or 
90 Gy Pd-103 + 
45 Gy 3D-CRT  
LDR-BT: 
(Low=70%;Int=26
%;High=9%) 
vs. 
3D-CRT: 
(Low=44%;Int=41
%;High=15%);  
vs. 
IMRT: 
(Low=35%;Int=48
%;High=17%) 
vs. 
LDR-BT+EBRT 
(Low=32%;Int=52
%;High=16%) 
Zelefsky 
et al 
1999 Retrospective Cox PH 
Regression 
LDR-BT (145)  
vs.  
EBRT (137) 
LDR-BT: 
144 Gy I-125  
vs.  
EBRT: 
65-81 Gy 
100% low-risk 
patients 
Zelefsky 
et al 
2008 Retrospective Cox PH 
Regression 
LDR-BT (127)  
vs.  
LDR-BT+EBRT 
(216) 
LDR-BT: 
144 Gy I-125  
vs.  
LDR-BT+EBRT: 
110 Gy I-125 + 
50 Gy EBRT  
LDR-BT: 
(Low=28%;Int=64
%;High=8%) 
vs. 
LDR-BT+EBRT: 
(Low=88%;Int=12
%) 
Zelefsky 
et al 
2011 Retrospective Cox PH 
Regression 
LDR-BT (448)  
vs.  
EBRT (281) 
LDR-BT: 
144 Gy I-125  
vs. 
EBRT: 
81 Gy  
100% low-risk 
patients 
Zhou et al 2009 Retrospective Cox PH 
Regression 
BT (644)  
vs.  
EBRT (876) 
NR NR 
 
Appendix I:  Continued. 
Author ADT 
use? 
Primary 
Outcome 
Reported Result of 
Primary Outcome 
Secondary 
Outcomes  
Reported Result 
of Secondary 
Outcome (s) 
Country Multi-
centred
? 
Abel-
Wahab et 
al 
NR Secondary 
Cancer 
Incidence 
>5 years 
Actuarial 
percentages > 5 
years:  
4.7% (BT) vs. 
10.3% (EBRT) vs. 
5.7% (BT+EBRT), 
p<0.001 
No N/A USA Y 
Aoki et al No - 
ADT 
patients 
excluded 
Late Grade 
2 GI 
toxicity 
(rectal 
bleeding) 
9.1% (LDR-BT) vs. 
36% (LDR-
BT+EBRT),  
p <0.01 
No N/A Japan N 
Beyer et 
al 
Yes - 
Mixed 
use in 
both 
groups 
FFS Actuarial 
percentages > 5 
years: 71% (LDR-
BT) vs. 69% 
(EBRT), p=0.91 
No N/A USA N 
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Burdick 
et al 
Yes - 
Mixed 
use in 
both 
groups 
bFFS 
(Phoenix) 
Actuarial 
percentages @ 5 
years:  88% (95% 
CI 80-95%) LDR-
BT vs. 84% (95% 
CI 78-91%) EBRT 
No N/A USA N 
Coen et al No - 
ADT 
patients 
excluded 
bFFS 
(Phoenix) 
Actuarial 
percentages @ 8 
years: 92% (Proton 
EBRT) vs. 84% 
(LDR-BT), 
p=0.44[log-rank] 
OS Actuarial 
percentages @ 8 
years: 93% 
(Proton EBRT) 
vs. 96% (LDR-
BT), 
p=0.45[log-
rank] 
USA Y 
D'Amico 
et al 
Yes - 
used in 
LDR-BT 
group 
PSAF Relative Risk not 
reported; showed no 
significant 
difference in low-
risk (p=0.3), int-risk 
(p=0.6), or high-risk 
(0.5) 
No N/A USA Y 
da Silva 
Franca et 
al 
Yes - 
Mixed 
use in 
both 
groups 
bFFS 
(Phoenix) 
Actuarial 
percentages @ 5 
years: 96% (LDR-
BT) vs. 72% (LDR-
BT+EBRT) 
No N/A Brazil Y 
Davis et 
al 
Yes - 
Mixed 
use in 
both 
groups 
SF-36 Reported a variety 
of results from SF-
36 questionnaire 
No N/A USA N 
Deutsch 
et al 
Yes - 
Mixed in 
both 
groups 
bFFS 
(Phoenix) 
Actuarial 
percentages @ 5 
years: 82% (EBRT) 
vs. 98% (HDR-
BT+EBRT), 
p<0.001 
No N/A USA Y 
Eade et al No - 
ADT 
patients 
excluded 
bFFS 
(Phoenix) 
Actuarial 
percentages @ 4 
years: 99% (LDR-
BT) vs. 93% 
(EBRT), p=0.09 
Late 
Grade 2 or 
higher 
GI/GU 
toxicity 
Actuarial 
percentages @ 4 
years: GI: 7.8% 
(LDR-BT) vs. 
2.4% (EBRT), 
p=0.03; GU: 
19.2% (LDR-
BT) vs. 3.5% 
(EBRT), 
p<0.001 
USA N 
Elliot et 
al 
Yes - 
Mixed 
use in 
both 
groups 
Urethral 
Stricture 
Incidence 
Actuarial 
percentages at 4 
years: 1.8% (BT) 
vs. 1.7% (EBRT), 
p=NS 
No N/A USA Y 
Ferrer et 
al 
Yes - 
Mixed 
use in 
both 
groups 
EPIC EBRT led to 
significantly worse 
bowel (p<0.001), 
sexual (p<0.01), and 
hormonal (p<0.01) 
function than LDR-
BT 
No N/A Spain Y 
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Gelbium 
et al 
Yes - 
Mixed in 
both 
groups 
Late Grade 
2 or higher 
GI toxicity 
Actuarial 
percentages @ 4 
years: 6.9% (LDR-
BT) vs. 7.8%, 
p=NR 
No N/A USA N 
Goldner 
et al 
Yes- 
Mixed in 
all 
groups 
bFFS 
(Phoenix) 
Actuarial 
percentages @ 5 
years: 94% (LDR-
BT) vs. 91% (74 Gy 
EBRT) vs. 84% (70 
Gy EBRT), p<0.01 
No N/A Austria Y 
Gondi et 
al 
Yes - 
Mixed in 
LDR-BT 
group 
bFFS 
(ASTRO1) 
Actuarial 
percentages @ 5 
years: 88% (LDR-
BT or LDR-
BT+EBRT ± ADT) 
vs. 60% 
(EBRT+ADT) vs. 
49% (EBRT only), 
p<0.001 
bFFS 
(Phoenix) 
Actuarial 
percentages @ 5 
years: 81% 
(LDR-BT or 
LDR-
BT+EBRT ± 
ADT) vs. 85% 
(EBRT+ADT) 
vs. 64% (EBRT 
only), p=0.014 
USA N 
Huang et 
al 
NS SF-36 Primary Treatment 
was significant 
predictor of SF-36 
scoring of urinary, 
bowel and sexual 
function (all 
p<0.001) 
No N/A USA Y 
Joseph et 
al 
NR FACT-P Overall FACT-P 
scores @ 1 year: 98 
(EBRT) vs. 95 
(HDR-BT+EBRT), 
p=0.67 
No N/A Canada Y 
Kalakota 
et al 
Yes - 
Mixed 
use in 
both 
groups 
Late Grade 
2 GI 
toxicity 
Actuarial 
percentages @ 4 
years: 91% (LDR-
BT) vs. 82% (LDR-
BT+EBRT), p=0.30 
No N/A USA Y 
Klein et 
al 
No - 
ADT 
patients 
excluded 
bFFS 
(Phoenix) 
Actuarial 
percentages @ 5 
and 8 years: 82% 
and 82% (LDR-BT) 
vs. 80% and 75% 
(EBRT), p=NS 
RFS, OS Actuarial 
percentages for 
RFS @ 5 and 8 
years: 97% and 
81% (LDR-BT) 
vs. 95% and 
90% (EBRT), 
p=0.02; 
Actuarial 
percentages for 
OS @ 5 and 8 
years: 94% and 
94% (LDR-BT) 
vs. 93% and 
81% (EBRT), 
p=0.05 
USA Y 
Khor et al Yes - 
Equal 
use in 
both tx 
groups 
bFFS 
(Phoenix) 
Hazard Ratio for 
HDR-BT+EBRT vs. 
EBRT = 0.59 (95% 
CI 0.43-0.81, 
p<0.01) 
No N/A Australia N 
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Krestin et 
al 
NR bFFS 
(ASTRO1) 
Actuarial 
percentages @ 5 
years: 44% (EBRT) 
vs. 67% (HDR-
BT+EBRT) 
No N/A USA N 
Kupelian 
et al 
Yes - 
Mixed 
use in all 
groups 
bFFS 
(ASTRO1) 
Actuarial 
percentages @ 5 
and 7 years: 83% 
and 76% (LDR-BT) 
vs. 81% and 81% 
(EBRT) vs. 51% 
and 48% (EBRT) 
vs. 77% and 77% 
(LDR-BT+EBRT); 
When EBRT<72 Gy 
removed, no 
significant 
difference between 
treatment groups 
No N/A USA Y 
Lee et al Yes - 
Mixed 
use in 
both 
groups 
FACT-P Reported a variety 
of results from the 
FACT-P 
questionnaire 
No N/A USA N 
Lev et al NR HQoL RT treatment not a 
significant predictor 
of HQoL 
No N/A USA Y 
Nieder et 
al 
NR Secondary 
Cancer 
No significant 
difference between 
treatment groups 
No N/A USA Y 
Ojha et al NR Secondary 
Cancer 
HR = 1.68 (p=NS) 
favors BT 
No N/A USA Y 
Pe et al No - 
ADT 
patients 
excluded 
bFFS 
(Phoenix) 
Actuarial 
percentages @ 5 
years: 96% (LDR-
BT) vs. 95% 
(EBRT), p=0.70 
No N/A USA N 
Pickles et 
al 
Yes - 
Equal 
use in 
both tx 
groups 
bFFS(Phoe
nix) 
Actuarial 
percentages @ 5 
and 7 years: 95% 
and 95% (LDR-BT) 
vs. 85% and 75% 
(EBRT), p<0.001 
No N/A Canada N 
Pinkawa 
et al 
Yes - 
Mixed 
used in 
all 
groups 
bFFS 
(Phoenix) 
Hazard Ratios: 
LDR-BT vs. EBRT: 
0.5 (95% CI 0.3-
0.8, p<0.01); 
HDRT-BT+EBRT 
vs. EBRT: 0.6 (95% 
CI 0.4-0.97, p=0.04) 
No N/A Germany N 
Santhya 
et al 
Yes, 
Mixed 
use in 
both 
groups 
OS HR = 1.36 (p=0.54) 
favors EBRT 
BCF, 
GI/GU 
toxicity 
BCF: HR=0.42 
(p=0.02), favors 
HDR-
BT+EBRT; 
GI/GU toxicity: 
p=NS 
Canada No 
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Smith et 
al 
Yes - 
Mixed 
used in 
all 
groups 
HQoL Reported on a 
variety of results 
from their HQoL 
questionnaire 
No N/A Australia Y 
Talcott et 
al 
Yes - 
Mixed 
use in 
both 
groups 
SF-36 Reported on a 
variety of results 
from SF-36 
questionnaire  
No N/A USA Y 
Vassil et 
al 
Yes - 
Mixed 
use in 
both 
groups 
bFFS 
(Phoenix) 
LDR-BT vs. EBRT 
HR = 0.99 (95% CI 
0.62-1.58, p=0.97) 
No N/A USA Y 
Wong et 
al 
Yes - 
Mixed 
use in all 
groups 
bFFS 
(Phoenix) 
Actuarial 
percentages @ 5 
years: 94% (LDR-
BT) vs. 74% (3D-
CRT) vs. 87% 
(IMRT) vs. 94% 
(LDR-BT+EBRT), 
p<0.001 
OS Actuarial 
percentages @ 5 
years: 97% 
(LDR-BT) vs. 
97% (EBRT) 
vs. 97% (LDR-
BT+EBRT), 
p=NR 
USA N 
Zelefsky 
et al 
Yes - 
Mixed 
use in all 
groups 
bFFS 
(ASTRO1) 
Actuarial 
percentages @ 5 
years: 88% (LDR-
BT) vs. 82% 
(EBRT), p=0.09 
Urethral 
stricture 
incidence 
Actuarial 
percentages @ 5 
years: 12% 
(LDR-BT) vs. 
2% (EBRT), 
p<0.01 
USA N 
Zelefsky 
et al 
Yes - 
Mixed in 
both 
groups 
Late Grade 
2 GI/GU 
toxicity 
Hazard Ratios for 
LDR-BT vs. LDR-
BT+EBRT: Grade 2 
GI Toxicity: 8.9 
(p<0.001); Grade 2 
GU Toxicity: 2.3 
(p<0.01) 
No N/A USA Y 
Zelefsky 
et al 
Yes- 
Mixed 
use in 
both 
groups 
bFFS 
(Phoenix) 
Actuarial 
percentages @ 7 
years: 95% (LDR-
BT) vs. 89% 
(EBRT), p=0.04 
No N/A USA N 
Zhou et al NR OS Actuarial 
percentages @ 7 
years: 82% (BT) vs. 
72% (EBRT), 
p<0.001 
DSS Actuarial 
percentages @ 7 
years: 97% (BT) 
vs. 94% 
(EBRT), 
p<0.001  
USA Y 
 
Appendix I:  Continued. 
Author Mean/Median Follow-Up 
(months) 
Total  Follow-
Up Time 
(Years) 
Mean/Median 
Age of Patients 
(Years) 
Independent, low-, intermediate-, 
high-risk assessment? 
Abel-Wahab 
et al 
40 (BT) vs. 64 (EBRT) 
vs. 46 (BT+EBRT) 
16 years 67 (BT) vs. 71 
(EBRT) vs. 68 
(BT+EBRT) 
No 
Aoki et al NR >3 years 68 (LDR-BT) vs. 
71 (LDR-
BT+EBRT) 
No 
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Beyer et al 51 (LDR-BT) vs. 41 
(EBRT) 
8 years 74 for both No 
Burdick et al 54 (LDR-BT) vs. 54 
(EBRT) 
10 years 70 (LDR-BT) vs. 
69.5 (EBRT) 
No 
Coen et al 103 (Proton EBRT) vs. 89 
(LDR-BT) 
>10 years 67 (Proton EBRT) 
vs. 65 (LDR-BT) 
No significant difference in bFFS 
(Phoenix) in low-risk (p=0.74) or 
intermediate-risk (p=0.21) 
D'Amico et al 41 (LDR-BT) vs. 38 
(EBRT) 
5 years NR Yes - see primary outcome 
results 
da Silva 
Franca et al 
105 (LDR-BT) vs. 60 
(LDR-BT+EBRT) 
5 Years 66 (LDR-BT) vs. 
68 (LDR-
BT+EBRT) 
No 
Davis et al 22 (LDR-BT) vs. 30 
(EBRT) 
NR 67 (LDR-BT) vs. 
69 (EBRT) 
No 
Deutsch et al 53 (EBRT) 47 (HDR-
BT+EBRT) 
> 8 Years 68 (EBRT) vs. 65 
(HDR-
BT+EBRT) 
Actuarial percentages @ 5 years: 
Low-risk: 98% (EBRT) vs. 100% 
(HDR-BT+EBRT), p=0.71; 
Intermediate-risk: 84% (EBRT) 
vs. 100% (HDR-BT+EBRT), 
p<0.001; High-risk: 71% (EBRT) 
vs. 93% (HDR-BT+EBRT), 
p=0.23 
Eade et al 48 (LDR-BT) vs. 43 
(EBRT) 
4 years 65 (LDR-BT) vs. 
68 (EBRT) 
 
No 
Elliot et al 32 (BT) vs. 32 (EBRT) 4 years NR No 
Ferrer et al 24 (LDR-BT) vs. 24 
(EBRT) 
2 years 67 (LDR-BT) vs. 
69 (EBRT) 
 
No 
Gelbium et al 48 for all patients >4 years NR No 
Goldner et al 44 (LDR-BT) vs. 41 (74 
Gy EBRT) vs. 81 (70 Gy 
EBRT) 
10 years 64 (LDR-BT) vs. 
71 (EBRT) 
N/A - all low-risk patients 
Gondi et al 34 for all patients 5 years NR No 
Huang et al NR 4 Years NR No 
Joseph et al 12 for all patients 1 year 69 (EBRT) vs. 69 
(HDR-
BT+EBRT) 
No 
Kalakota et al 41 for all patients 4 years 65 (LDR-BT) vs. 
63 (LDR-
BT+EBRT) 
No 
Klein et al 39 (LDR-BT) vs. 58 
(EBRT) 
>8 years NR N/A - all intermediate-risk 
patients 
Khor et al 68 (EBRT) vs. 61 (HDR-
BT+EBRT) 
10 years 69 (EBRT) vs. 67 
(HDR-
BT+EBRT) 
Hazard Ratios for HDR-
BT+EBRT vs. EBRT: 
Intermediate-risk: 0.44 (95% CI 
0.28-0.70, p<0.001); High-risk: 
0.82 (95% CI 0.52-1.28, p=0.38) 
Krestin et al 30 (EBRT) vs. 30 (HDR-
BT+EBRT) 
6 years 74 (EBRT) vs. 69 
(HDR-
BT+EBRT) 
No 
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Kupelian et al 47 (LDR-BT) vs. 49 
(EBRT≥72Gy) vs. 75 
(EBRT<72Gy) vs. 46 
LDR-BT+EBRT 
7 Years 70 (LDR-BT) vs. 
68 (EBRT≥72Gy) 
vs. 70 
(EBRT<72Gy) vs. 
69 LDR-
BT+EBRT 
No 
Lee et al 12 (BT) vs. 12 (EBRT) 1 Year 67 (LDR-BT) vs. 
69 (EBRT) 
 
No 
Lev et al 12 for all patients 1 Year 67 (LDR-
BT+EBRT) vs. 68 
(HDR-
BT+EBRT) 
No 
Nieder et al 49 for all patients >10 years NR No 
Ojha et al 46 (BT) vs. 67 (EBRT) >10 years 67 (BT) vs. 71 
(EBRT) 
No 
Pe et al 37 (BT) vs. 51 (EBRT) 7 years 65 (LDR-BT) vs. 
70 (EBRT) 
 
N/A - all low-risk patients 
Pickles et al 68 (LDR-BT) vs. 67 
(EBRT) 
7 years 64 (LDR-BT) vs. 
71 (EBRT) (*did 
not match on age) 
Actuarial percentages @ 5 years: 
Low-risk: 94% (LDR-BT) vs. 
88% (EBRT), p<0.001; Int-risk: 
100% (LDR-BT) vs. 78% 
(EBRT), p=0.02 
Pinkawa et al 76 (BT) vs. 67 (EBRT) 5 years 69 (LDR-BT) vs. 
71 (EBRT) vs. 72 
(HDR-
BT+EBRT) 
 
No 
Santhya et al NR 10 years 65 HDR-
BT+EBRT vs. 66 
EBRT 
BCF favors HDR-BT+EBRT in 
both Int-risk and High-risk; Int-
risk: HR=0.30 (p=0.03); High-
risk: HR=0.47(p=0.03) 
Smith et al NR 3 years 60 (LDR-BT) vs. 
62 (HDR-BT) vs. 
64 (EBRT) 
No 
Talcott et al 24 (BT) vs. 24 (EBRT) 2 Years 65 (BT) vs. 69 
(EBRT) 
 
No 
Vassil et al 65 for all patients 5 years 69 (LDR-BT) vs. 
68 (EBRT) 
N/A - all intermediate-risk 
patients 
Wong et al 49 (LDR-BT) vs. 62 (3D-
CRT) vs. 56 (IMRT) vs. 
63 (LDR-BT+EBRT) 
5 years NR Actuarial percentages @ 5 years: 
Low-risk: 97% (LDR-BT) vs. 
92% (3D-CRT) vs. 93% (IMRT) 
vs. 100% (LDR-BT+EBRT), 
p=0.30; Intermediate-risk: 94% 
(LDR-BT) vs. 74% (3D-CRT) 
vs. 88% (IMRT) vs. 94% (LDR-
BT+EBRT), p<0.001; High-risk: 
50% (LDR-BT) vs. 55% (3D-
CRT) vs. 76% (IMRT) vs. 100% 
(LDR-BT+EBRT), p=0.18 
Zelefsky et al 24 (LDR-BT) vs. 36 
(EBRT) 
> 7 Years 68 (LDR-BT) vs. 
64 (EBRT) 
N/A - all low-risk patients 
Zelefsky et al 30 for all patients NR NR No 
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Zelefsky et al 77 (LDR-BT) vs. 76 
(EBRT) 
8 years 65 (LDR-BT) vs. 
66 (EBRT) 
N/A - all low-risk patients 
Zhou et al NR 7 years NR NR 
 Abbreviations: 3D-CRT = 3-dimensional conformal radiation therapy; 
BCF = biochemical or clinical failure: a PSA failure or clinical failure or death; bFFS(ASTRO1) = 
biochemical relapse-free survival, American Society for Therapeutic Radiology and Oncology definition: 
three consecutive rising PSA levels after nadir; bFFS(Phoenix) = biochemical failure-free survival, 
American Society for Therapeutic Radiology and Oncology Phoenix definition: a PSA level of 2ng/mL or 
more than nadir; BT = brachytherapy of unknown type; BT+EBRT = brachytherapy of unknown type with 
adjuvant external beam radiation therapy; DSS = disease specific survival: date from therapy to prostate 
cancer death; EBRT = external beam radiation therapy; EPIC = Expanded Prostate Cancer Index 
Composite Questionnaire: a 50 item instrument created at the University of California to assess prostate 
cancer patient reported urinary, bowel, sexual, and hormonal functioning; FACT-P= Functional 
Assessment of Cancer Therapy-Prostate: a 12 item questionnaire specifically designed to measure quality 
of life in prostate cancer patients; FFS = failure free survival: initiation of secondary therapy, positive 
biopsy post-treatment, PSA rise of 10 ng/dL or more even without three consecutive elevations, 
development of metastasis; GEE = generalized estimating equation modeling; Grade 2 GI Toxicity = 
Radiation Therapy Oncology Group defined grade 2 gastrointestinal side effect which includes any 
symptom of moderate nature requiring medical therapy eg. rectal bleeding requiring suppositories; Grade 2 
GU Toxicity = Radiation Therapy Oncology Group defined grade 2 genitourinary side effects which 
includes any symptom of moderate nature requiring medical therapy eg. urinary urgency or dysuria; HDR-
BT = high dose rate brachytherapy; HDR-BT+EBRT = high dose rate brachytherapy with adjuvant external 
beam radiation therapy; HQoL = health quality of life; IMRT = intensity modulated radiation therapy; 
LDR-BT = low dose rate brachytherapy; LDR-BT+EBRT = low dose rate brachytherapy with adjuvant 
external beam radiation therapy; N/A = Not Applicable; NR = not reported; NS = none significant; OS = 
overall survival: date from therapy to death from any cause; PSAF = prostate specific antigen failure = a 
patient must have 3 consecutive rising PSA values each obtained at least 3 months apart; RFS = recurrence 
free survival: date from treatment until clinically diagnosed recurrence under radiography or biopsy; SF-36 
= Medical Outcomes Study 36-Item Short Form Questionnaire: contains 36 items covering eight 
dimensions of health related quality of life including physical function, pain, general health, vitality, social, 
emotional, and mental health; Tx = treatment group;  
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Literature Search Strategy for CER Articles Comparing Different RT Modalities 
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Appendix II: Literature Search Strategy for CER Studies Comparing Primary RT 
Modalities 
 
 The literature search for CER articles directly comparing primary RT modalities 
was conducted using the electronic databases of Pubmed, MEDLINE (OVID), Cochrane 
Library, EMBASE, and Google Scholar; also the clinical trials registry at 
‘www.clinicaltrials.gov’ was searched to identify any potential RCTs.  The search period 
was from January 1, 1996 to December 2013 and was limited to English publications.  
The following key terms were used in combination to search the databases:  prostate, 
prostate cancer, cancer, comparative effectiveness, brachytherapy, external beam 
radiation therapy, external beam radiotherapy, versus, randomized trial, radiation therapy 
or radiotherapy, high-dose rate, low-dose rate, intensity modulated radiation therapy, 
survival, biochemical failure, PSA failure, toxicity, impotency, secondary cancer, and 
quality of life.  Relevant studies were also searched for in review articles or on reference 
lists of identified articles.  The relevant RT guideline websites such as the RTOG and the 
European Organization for Research and Treatment of Cancer were checked for 
systematic reviews and randomized trials.  All articles included in this review required a 
sample size ≥30 patients and must have directly compared at least two RT treatment 
modalities with respect to the outcomes of overall survival, biochemical or PSA failure, 
late toxicities or side effects, or patient reported outcomes.   
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Appendix III 
 
ProCaRS Variable List and Descriptions 
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PROCARS: Variable List (Last Updated December 2, 2013) 
 
# Variable Description 
1 ID Patient ID Number: Centre‐XX (e.g. BCCA‐1012) 
2 ID2 Patient ID Number: 1, 2, 3,...,7973, 7974 [For Sorting Purposes Only] 
3 ID_PMH Patients included in PMH cohorts only 
4 PMH_9907 Patients included in PMH Trial #9907 cohort only 
5 Centre Centre: 1, 2, 3, 4 
6 Centrex Centre: Description 
7 Cohort_7cat Cohort (7 categories): BCCA, PMH LDR, PMH Dose Escalation, PMH Trial #9907, Laval LDR, Laval HDR+EBRT, McGill 
8 Age Age 
9 BasePSA Baseline PSA (ng/mL) 
10 BasePSA_ROUND Baseline PSA (ng/mL) **ROUNDED TO NEAREST WHOLE NUMBER** 
11 Tstage T‐Stage: '4', '8' and '12' corresponding to Tstage '2', '3' and '4' coded as MISSING **IGNORE** 
12 Tstage_CRU T‐Stage: '4', '8' and '12' corresponding to Tstage '2', '3' and '4' RETAINED **IGNORE** 
13 Tstage_CORR T‐Stage (including Sub‐Type): n = 7839 (frequency missing = 135) 
14 Tstage_CORR_4cat T‐Stage (excluding Sub‐Type): n = 7839 (frequency missing = 135) 
15 Tstage_CORR_4catx T‐Stage (excluding Sub‐Type): n = 7860 (frequency missing = 114) 
16 TNMyear TNM Year 
17 GleasonPattern Gleason Pattern: 1, 2, 3,...24, 25 
18 GleasonPattern_CORR Gleason Pattern: 1+1, 1+2...5+4, 5+5 
19 GleasonMajor Gleason Major: 1st number in pattern **DO NOT USE** 
20 GleasonMajor_CORR Gleason Major: Re‐derived based on FIRST number in Gleason Pattern **CORRECTED** 
21 GleasonMinor Gleason Minor: 2nd number in pattern **DO NOT USE** 
22 GleasonMinor_CORR Gleason Minor: Re‐derived based on SECOND number in Gleason Pattern **CORRECTED** 
23 GleasonTotal Total Gleason Score: Add 2 numbers in pattern **DO NOT USE** 
24 GleasonTotal_CORR Total Gleason Score: Re‐derived based on corrected Gleason Major and Minor **CORRECTED** 
25 GleasonTotal_CORR_4cat Total Gleason Score (4 categories): (1) 2‐5, (2) 6, (3) 7, (4) 8‐10 
26 Cores_total Biopsy Cores: Total Number 
27 Cores_pos Biopsy Cores: Number of cores containing any cancer 
28 Cores_neg Biopsy Cores: Number of cores NOT containing any cancer 
29 Cores_rejected Biopsy Cores: Number of cores rejected 
30 PosCores_Percent Biopsy Cores: Percent of Positive Cores 
31 PosCores_ge50pct Biopsy Cores: Positive Cores: (1) ≥ 50 % , (0) < 50% 
32 Bilateral_biopsy_pos Bilateral Biopsy Status: 0, 1, 8, 9 
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PROCARS: Variable List (Last Updated December 2, 2013) 
 
# Variable Description 
33 Bilat_Biopsy_Status_CORR Bilateral Biopsy Status: No, Yes, Unknown, N/A 
34 Hormones Hormones: (1) Yes, (0) No 
35 HormStart Hormones: Start Date 
36 HormEnd Hormones: End Date 
37 AdjHT_months Adjuvant Hormone Therapy (Months): ZEROs coded as MISSING 
38 AdjHT_months_OLD Adjuvant Hormone Therapy (Months): ZEROs kept as ZEROs (for modeling) 
39 RTStart RT Start Date 
40 RTStart_Year RT Start Year 
41 RTStart_Year_4cat RT Start Year (4 categories): (1) 1994‐1999, (2) 2000‐2002, (3) 2003‐ 2005, (4) 2006‐2010 
42 RTEnd RT End Date 
43 RTdays Number of Days of RT 
44 EBRT EBRT: (1) Yes, (0) No 
45 EBRT_Dose EBRT Dose (cGy) 
46 EBRT_Dose_GT70 EBRT Dose: (1) > 70 Gy, (0) ≤ 70 Gy 
47 EBRT_Dose_GT70x EBRT Dose Label 
48 EBRT_Fractions EBRT: Number of Fractions 
49 EBRT_FractionDose EBRT: Dose per Fraction (cGy) 
50 EBRT_BED_Gy EBRT Biologic Equivalent Dose (Gy) 
51 LDR LDR: Low Dose Rate Brachytherapy 
52 LDR_Dose  
53 LDR_Fractions  
54 HDR HDR: High Dose Rate Brachytherapy 
55 HDR_Dose  
56 HDR_Fractions  
57 Brachy Brachytherapy: (1) Yes, (0) No 
58 Radiation_Type Radiation Type: Brachy + EBRT, Brachy only, EBRT only 
59 Radiation_Type_5cat Radiation Type (5 categories): Brachy(LDR) only, Brachy(HDR) only, EBRT only, Brachy(LDR) + EBRT, Brachy(HDR) + EBRT 
60 LocalRelapse Clin/Path confirmed Local Relapse 
61 LocalRelapseDate Date of Local Relapse 
62 PostRTHormStart Salvage Hormone Therapy Start Date 
63 Dead Dead: (1) Dead, (0) Alive 
64 Dead_5yr Dead (≤ 5 years): (1) Dead, (0) Alive 
65 Status  
66 StatDate  
67 Survival_months Survival in MONTHS 
68 Surmon  
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PROCARS: Variable List (Last Updated December 2, 2013) 
 
# Variable Description 
69 AliveDate  
70 DeathDate Date of Death 
71 DeathCause  
72 CauseofDeath Cause of Death 
73 CauseofDeath_CORR  
74 CauseofDeath_CORRx Denominator = 7974 
75 Date_data_pulled  
76 Notes  
77 PSADT2  
78 PSAvelocity  
79 PSADT  
80 npsa  
81 BrachyAINorm  
82 rownames  
83 Amico AMICO Classification: Low, Intermediate, High 
84 GUROC GUROC Classification: Low, Intermediate, High 
85 GUROC2 GUROC2 Classification: 1, 2, 3 
86 GUROC_OLD **UNCORRECTED VERSION (For Earlier Manuscript(s))** 
87 GUROC2_OLD **UNCORRECTED VERSION (For Earlier Manuscripts(s))** 
88 CAPSURE CAPSURE Classification: Low, Intermediate, High 
89 EAU EAU Classification: Low, Intermediate, High 
90 NICE NICE Classification: Low, Intermediate, High 
91 AUA AUA Classification: Low, Intermediate, High 
92 NCCN NCCN Classification: Very Low, Low, Intermediate, High, Very High 
93 NCCN_5cat NCCN_5cat: 1, 2, 3, 4, 5 
94 ESMO ESMO Classification: Low, Intermediate, High 
95 George George Classification: Low, Intermediate, High 
96 GeorgeII GeorgeII Classification: Low, Intermediate, High 
97 procars_6cat PROCARS 6 Classification: A, B, C, D, E, F 
98 procars_6catx PROCARS 6 Classification: Extr Low, Low, Inter Low, Inter High, High, Extr High 
99 procars_5cat PROCARS 5 Classification: AB, C, D, E, F 
100 procars_5catx PROCARS 5 Classification: Low, Inter Low, Inter High, High, Extr High 
101 procars_4cat PROCARS 4 Classification: AB, C, DE, F 
102 procars_4catx PROCARS 4 Classification: Low, Inter Low, Inter High, High 
103 Simplified  
104 Time  
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PROCARS: Variable List (Last Updated December 2, 2013) 
 
 
# Variable Description 
105 CRS Prostate Cancer Death (aka Cancer‐Related/Specific Survival): (1) Yes, (0) No (Equivalent to "CRStatus") 
106 CRS_5yr Prostate Cancer Death (≤ 5 years): (1) Yes, (0) No 
107 CRStatus  
108 CRS_months Cancer‐Related/Specific Survival in MONTHS 
109 CRTime  
110 AIBFStat  
111 AIBFTime  
112 AIBFFSStat  
113 AIBFFSTime  
114 AIBFFS2Stat  
115 AIBFFS2Time  
116 AIHSTBFStat  
117 AIHSTBFTime  
118 AIHSTBFFSStat  
119 AIHSTBFFSTime  
120 AIHSTBFFS2Stat  
121 AIHSTBFFS2Time  
122 PhBFStat  
123 PhBFTime  
124 PhBFFSStat  
125 PhBFFSTime  
126 BFFS2 Biochemical Failure (aka Biochemical‐Failure‐Free Survival): (1) Yes, (0) No (Equivalent to "PhBFFS2Stat" ‐ Phoenix Version #2) 
127 BFFS2_5yr Biochemical Failure (≤ 5 years): (1) Yes, (0) No 
128 PhBFFS2Stat  
129 BFFS2_months Biochemical‐Failure‐Free Survival in MONTHS 
130 PhBFFS2Time  
131 BFFS2_months_5yr Biochemical‐Failure‐Free Survival in MONTHS (corresponds with "BFFS2_5yr") 
132 BFFS2_to_CRS_months Time (months) from Biochemical Failure (BFFS2) to Prostate Cancer Death (CRS) 
133 BFFS2_CORR 
Biochemical Failure CORRECTED for PSA bounce (Brachytherapy 
patients with NO post‐RT hormone therapy meeting previous 
ASTRO II Phoenix definition censored if LAST PSA ≤ 0.5 ng/mL). 
134 BFFS2_CORR_months Biochemical‐Failure‐Free Survival CORRECTED in MONTHS 
135 PSA_Bounce 
PSA Bounce (assessed for brachytherapy patients with NO post‐RT 
hormone therapy and ASTRO II BF): (1) LAST PSA ≤ 0.5 ng/mL, 
(0) LAST PSA > 0.5 ng/mL [opposite to BFFS2_CORR] 
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PROCARS: Variable List (Last Updated December 2, 2013) 
 
 
# Variable Description 
136 Nadir_PSA Nadir PSA (ng/mL) 
137 Nadir_Months Time‐to‐Nadir in MONTHS 
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Appendix IV 
 
Kaplan Meier Curves of bFFS with and Without Accounting for PSA Bounce 
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Low-risk bFFS Match with or Without Accounting for PSA Bounce: 
 
 
(Accounting for PSA Bounce)  
 
(Not Accounting for PSA Bounce) 
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Intermediate-risk LDR-BT vs. EBRT Match with or Without Accounting for PSA 
Bounce: 
 
  
(Accounting for PSA bounce)   
 
(Not Accounting for PSA Bounce) 
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Intermediate-risk HDR-BT+EBRT vs. EBRT Match with or Without Accounting 
for PSA Bounce: 
 
  
(Accounting for PSA Bounce)    
 
 
(Not Accounting for PSA Bounce) 
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Appendix V 
 
SAS Code for Intermediate-Risk Cohort Selection 
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SAS Code for Selection Process (Intermediate-Risk): 
 
libname thesis 'P:\Graham\Thesis'; 
data Procars_Interm_Risky; 
set thesis.procars_final_03dec2013; 
where GUROC = 'Interm'; 
/*Adjust for T-Stage year, Remove Gleason total 2to5*/  
if TNMyear = '0' and Tstage_CORR = '2b' then delete; 
if GleasonTotal_CORR_4Cat = '1_2to5' then delete; 
if Tstage_CORR = '2b' and TNMyear = '1997' then Tstage_3cat = '3'; 
if Tstage_CORR = '2b' and TNMyear = '2002' then Tstage_3cat = '2'; 
if Tstage_CORR = '2b' and TNMyear = '1992' then Tstage_3cat = '2'; 
if Tstage_CORR = '2a' then Tstage_3cat = '2'; 
if Tstage_CORR = '2c' then Tstage_3cat = '3'; 
if Tstage_CORR = '1a' or Tstage_CORR = '1b' or Tstage_CORR = '1c' then Tstage_3cat = '1'; 
run; 
proc freq data=procars_interm_risky; 
tables Radiation_Type_5cat /list; 
run; 
 
Create T-Stage and Gleason Pattern Variables for Standardized Difference Testing: 
 
data thesis.procars_interm_risk; 
set procars_interm_risky; 
if Tstage_3cat = 1 then Tstage_T1 = 1; 
if Tstage_3cat = 2 or Tstage_3cat = 3 then Tstage_T1 = 0; 
if Tstage_3cat = 2 then Tstage_LowT2 = 1; 
if Tstage_3cat = 1 or Tstage_3cat = 3 then Tstage_LowT2 = 0; 
if Tstage_3cat = 3 then Tstage_HighT2 = 1; 
if Tstage_3cat = 1 or Tstage_3cat = 2 then Tstage_HighT2 = 0; 
if GleasonTotal_CORR_4cat = "2_6" then GleasonTotal_7 = 0; 
if GleasonTotal_CORR_4cat = "3_7" then GleasonTotal_7 = 1; 
if GleasonPattern_CORR = "3+4" then GleasonPattern_CORRx3plus4 = 1; 
if GleasonPattern_CORR = "4+3" or GleasonPattern_CORR = "3+3" or GleasonPattern_CORR = "." then 
GleasonPattern_CORRx3plus4 = 0; 
if GleasonPattern_CORR = "4+3" then GleasonPattern_CORRx4plus3 = 1; 
if GleasonPattern_CORR = "3+4" or GleasonPattern_CORR = "3+3" or GleasonPattern_CORR = "." then 
GleasonPattern_CORRx4plus3 = 0; 
if GleasonPattern_CORR = "3+3" then GleasonPattern_CORRx3plus3 = 1; 
if GleasonPattern_CORR = "3+4" or GleasonPattern_CORR = "4+3" or GleasonPattern_CORR = "." then 
GleasonPattern_CORRx3plus3 = 0; 
run; 
 
proc freq data=thesis.procars_interm_risk; 
table GleasonTotal_7*GleasonTotal_CORR_4cat Tstage_T1*Tstage_3cat Tstage_LowT2*Tstage_3cat 
Tstage_HighT2*Tstage_3cat/list; 
run; 
 
Initial Selection of intermediate-risk cohort, including ensuring patients have info on outcomes, 
important baseline factors, adequate RT dose and NO hormones: 
 
libname thesis 'P:\Graham\Thesis'; 
data thesis.Interm_Risk_PS; 
set thesis.Procars_Interm_Risk; 
if Tstage = '.' then delete; 
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if Age = '.' then delete; 
if BasePSA = '.' then delete; 
if GleasonTotal_CORR = '.' then delete; 
if Dead = '.' then delete; 
if Survival_months = '.' then delete; 
if BFFS2_months = '.' then delete; 
if BFFS2 = '.' then delete; 
if Radiation_Type_5cat = 'EBRT_only' and EBRT_Dose = '.' then delete; 
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = '.' then delete; 
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and HDR_Dose = '.' then delete; 
if Radiation_Type_5cat = 'Brachy(LDR)_only' and LDR_Dose = '.' then delete; 
if Radiation_Type_5cat = 'Brachy(HDR)_only' or Radiation_Type_5cat = 'Brachy(LDR)_and_EBRT' then 
delete; 
if Radiation_Type_5cat = 'EBRT_only' and EBRT_Dose < 7400 then delete; 
if Radiation_Type_5cat = 'EBRT_only' and EBRT_Dose = 7524 then delete; 
if Radiation_Type_5cat = 'Brachy(LDR)_only' and LDR_Dose < 14400 then delete; 
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4400 and HDR_Dose = 1000 
then delete; 
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4400 and HDR_Dose = 1800 
then delete; 
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4400 and HDR_Dose = 1900 
then delete; 
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4200 and HDR_Dose = 2000 
then delete; 
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4500 and HDR_Dose = 2000 
then delete; 
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4600 and HDR_Dose = 2000 
then delete; 
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4700 and HDR_Dose = 2000 
then delete; 
where hormones = 0; 
run; 
proc freq data=thesis.Interm_Risk_PS; 
tables Radiation_Type_5cat Radiation_Type_5cat*Centre Radiation_Type_5cat*RTStart_year/list; 
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Appendix VI 
 
SAS Code for Low-Risk Cohort Selection 
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SAS Code for Selection Process (Low-Risk): 
 
libname thesis 'P:\Graham\Thesis'; 
data Procars_Low_Risky; 
set thesis.procars_final_03dec2013; 
if GUROC = 'Low'; 
/*Adjust for T-Stage Year, Restrict RT-Start Year*/ 
if TNMyear = '0' and Tstage_CORR = '2b' then delete; 
if RTStart_Year < 1999 then delete; 
if RTStart_Year > 2006 then delete; 
if Tstage_CORR = '2b' and TNMyear = '1997' then Tstage_3cat = '3'; 
if Tstage_CORR = '2b' and TNMyear = '2002' then Tstage_3cat = '2'; 
if Tstage_CORR = '2b' and TNMyear = '1992' then Tstage_3cat = '2'; 
if Tstage_CORR = '2a' then Tstage_3cat = '2'; 
if Tstage_CORR = '2c' then Tstage_3cat = '3'; 
if Tstage_CORR = '1a' or Tstage_CORR = '1b' or Tstage_CORR = '1c' then Tstage_3cat = '1';  
run; 
proc freq data=Procars_Low_Risky; 
tables Tstage_CORR*TNMyear*Tstage_3cat/list; 
run; 
 
Create T-Stage, Gleason Total, RT-Start Year and Treatment Centre Variables for Standardized 
Difference Testing: 
 
data thesis.Procars_Low_Risk; 
set Procars_Low_Risky; 
if Tstage_3cat = 1 then Tstage_T1 = 1; 
if Tstage_3cat = 2 or Tstage_3cat = 3 then Tstage_T1 = 0; 
if Tstage_3cat = 2 then Tstage_LowT2 = 1; 
if Tstage_3cat = 1 or Tstage_3cat = 3 then Tstage_LowT2 = 0; 
if Tstage_3cat = 3 then Tstage_HighT2 = 1; 
if Tstage_3cat = 1 or Tstage_3cat = 2 then Tstage_HighT2 = 0; 
if GleasonTotal_CORR_4cat = "1_2to5" then GleasonTotal_6 = 0; 
if GleasonTotal_CORR_4cat = "2_6" then GleasonTotal_6 = 1; 
if RTStart_Year = 1999 then RTStart_Year_1999 = 1; 
if RTStart_Year > 1999 then RTStart_Year_1999 = 0; 
if RTStart_Year = 2000 then RTStart_Year_2000 = 1; 
if RTStart_Year > 2000 then RTStart_Year_2000 = 0; 
if RTStart_Year < 2000 then RTStart_Year_2000 = 0; 
if RTStart_Year = 2001 then RTStart_Year_2001 = 1; 
if RTStart_Year > 2001 then RTStart_Year_2001 = 0; 
if RTStart_Year < 2001 then RTStart_Year_2001 = 0; 
if RTStart_Year = 2002 then RTStart_Year_2002 = 1; 
if RTStart_Year > 2002 then RTStart_Year_2002 = 0; 
if RTStart_Year < 2002 then RTStart_Year_2002 = 0; 
if RTStart_Year = 2003 then RTStart_Year_2003 = 1; 
if RTStart_Year > 2003 then RTStart_Year_2003 = 0; 
if RTStart_Year < 2003 then RTStart_Year_2003 = 0; 
if RTStart_Year = 2004 then RTStart_Year_2004 = 1; 
if RTStart_Year > 2004 then RTStart_Year_2004 = 0; 
if RTStart_Year < 2004 then RTStart_Year_2004 = 0; 
if RTStart_Year = 2005 then RTStart_Year_2005 = 1; 
if RTStart_Year > 2005 then RTStart_Year_2005 = 0; 
if RTStart_Year < 2005 then RTStart_Year_2005 = 0; 
if RTStart_Year = 2006 then RTStart_Year_2006 = 1; 
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if RTStart_Year > 2006 then RTStart_Year_2006 = 0; 
if RTStart_Year < 2006 then RTStart_Year_2006 = 0; 
if centre = 1 then centre1 = 1; 
if centre = 2 or centre = 3 then centre1 = 0; 
if centre = 2 then centre2 = 1; 
if centre = 1 or centre = 3 then centre2 = 0; 
if centre = 3 then centre3 = 1; 
if centre = 2 or centre = 1 then centre3 = 0; 
run; 
 
proc freq data=thesis.Procars_Low_Risk; 
table GleasonTotal_6*GleasonTotal_CORR_4cat Tstage_T1*Tstage_3cat Tstage_LowT2*Tstage_3cat 
Tstage_HighT2*Tstage_3cat/list; 
run; 
 
Initial Selection of low-risk cohort, including ensuring patients have info  
on outcomes, important baseline factors, adequate RT dose and NO hormones: 
 
Title 'Low Risk Propensity Score'; 
libname thesis 'P:\Graham\Thesis'; 
data thesis.Low_Risk_PS; 
set thesis.Procars_Low_Risk; 
if Tstage = '.' then delete; 
if Age = '.' then delete; 
if BasePSA = '.' then delete; 
if GleasonTotal_CORR = '.' then delete; 
if Dead = '.' then delete; 
if Survival_months = '.' then delete; 
if BFFS2_months = '.' then delete; 
if BFFS2 = '.' then delete; 
if Radiation_Type_5cat = 'EBRT_only' and EBRT_Dose = '.' then delete; 
if Radiation_Type_5cat = 'Brachy(LDR)_only' and LDR_Dose = '.' then delete; 
if Radiation_Type_5cat = 'Brachy(HDR)_only' or Radiation_Type_5cat = 'Brachy(LDR)_and_EBRT' or 
Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' then delete; 
if Radiation_Type_5cat = 'EBRT_only' and EBRT_Dose < 7000 then delete; 
if Radiation_Type_5cat = 'Brachy(LDR)_only' and LDR_Dose < 14400 then delete; 
where Hormones = 0; 
run; 
proc freq data=thesis.Low_Risk_PS; 
tables Radiation_Type_5cat*Hormones EBRT_Dose*Radiation_Type_5cat LDR_Dose 
Radiation_Type_5cat/list; 
run; 
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Appendix VII 
 
SAS Code for PS Model and Matching Intermediate-risk LDR-BT vs. EBRT 
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Code for LDR-BT vs. EBRT Intermediate-risk PS match: 
 
Title 'Intermediate Risk EBRT vs. LDR'; 
libname thesis 'P:\Graham\Thesis'; 
Data Thesis.IR_PS_EBRTvsLDR; 
set thesis.Interm_Risk_PS; 
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' then delete; 
if Radiation_Type_5cat = 'EBRT_only' then Tx = 0; 
if Radiation_type_5cat = 'Brachy(LDR)_only' then Tx = 1; 
/*Create RT Start Year and Treatment Centre Variables for Standardized Difference Testing*/ 
if RTStart_Year = 1996 then RTStart_Year_1996 = 1; 
if RTStart_Year > 1996 then RTStart_Year_1996 = 0; 
if RTStart_Year = 1997 then RTStart_Year_1997 = 1; 
if RTStart_Year > 1997 then RTStart_Year_1997 = 0; 
if RTStart_Year < 1997 then RTStart_Year_1997 = 0; 
if RTStart_Year = 1998 then RTStart_Year_1998 = 1; 
if RTStart_Year > 1998 then RTStart_Year_1998 = 0; 
if RTStart_Year < 1998 then RTStart_Year_1998 = 0; 
if RTStart_Year = 1999 then RTStart_Year_1999 = 1; 
if RTStart_Year > 1999 then RTStart_Year_1999 = 0; 
if RTStart_Year < 1999 then RTStart_Year_1999 = 0; 
if RTStart_Year = 2000 then RTStart_Year_2000 = 1; 
if RTStart_Year > 2000 then RTStart_Year_2000 = 0; 
if RTStart_Year < 2000 then RTStart_Year_2000 = 0; 
if RTStart_Year = 2000 then RTStart_Year_2000 = 1; 
if RTStart_Year > 2000 then RTStart_Year_2000 = 0; 
if RTStart_Year < 2000 then RTStart_Year_2000 = 0; 
if RTStart_Year = 2001 then RTStart_Year_2001 = 1; 
if RTStart_Year > 2001 then RTStart_Year_2001 = 0; 
if RTStart_Year < 2001 then RTStart_Year_2001 = 0; 
if RTStart_Year = 2002 then RTStart_Year_2002 = 1; 
if RTStart_Year > 2002 then RTStart_Year_2002 = 0; 
if RTStart_Year < 2002 then RTStart_Year_2002 = 0; 
if RTStart_Year = 2003 then RTStart_Year_2003 = 1; 
if RTStart_Year > 2003 then RTStart_Year_2003 = 0; 
if RTStart_Year < 2003 then RTStart_Year_2003 = 0; 
if RTStart_Year = 2004 then RTStart_Year_2004 = 1; 
if RTStart_Year > 2004 then RTStart_Year_2004 = 0; 
if RTStart_Year < 2004 then RTStart_Year_2004 = 0; 
if RTStart_Year = 2005 then RTStart_Year_2005 = 1; 
if RTStart_Year > 2005 then RTStart_Year_2005 = 0; 
if RTStart_Year < 2005 then RTStart_Year_2005 = 0; 
if RTStart_Year = 2006 then RTStart_Year_2006 = 1; 
if RTStart_Year > 2006 then RTStart_Year_2006 = 0; 
if RTStart_Year < 2006 then RTStart_Year_2006 = 0; 
if RTStart_Year = 2007 then RTStart_Year_2007 = 1; 
if RTStart_Year > 2007 then RTStart_Year_2007 = 0; 
if RTStart_Year < 2007 then RTStart_Year_2007 = 0; 
if RTStart_Year = 2008 then RTStart_Year_2008 = 1; 
if RTStart_Year > 2008 then RTStart_Year_2008 = 0; 
if RTStart_Year < 2008 then RTStart_Year_2008 = 0; 
if RTStart_Year = 2009 then RTStart_Year_2009 = 1; 
if RTStart_Year > 2009 then RTStart_Year_2009 = 0; 
if RTStart_Year < 2009 then RTStart_Year_2009 = 0; 
if RTStart_Year = 2010 then RTStart_Year_2010 = 1; 
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if RTStart_Year > 2010 then RTStart_Year_2010 = 0; 
if RTStart_Year < 2010 then RTStart_Year_2010 = 0; 
if centre = 1 then centre1 = 1; 
if centre = 2 or centre = 3 then centre1 = 0; 
if centre = 2 then centre2 = 1; 
if centre = 1 or centre = 3 then centre2 = 0; 
if centre = 3 then centre3 = 1; 
if centre = 2 or centre = 1 then centre3 = 0; 
run; 
proc freq data=Thesis.IR_PS_EBRTvsLDR; 
tables Tstage_CORR*tx GleasonTotal*tx Radiation_Type_5cat*tx GleasonTotal_CORR_4cat*tx 
Tstage_3cat*tx /list; 
run; 
 
 
Create PS model for LDR vs. EBRT Intermediate-risk match: 
 
proc logistic descending data=Thesis.IR_PS_EBRTvsLDR; 
  class GleasonTotal_CORR_4cat (param=ref ref="2_6"); 
  class Tstage_3cat (param=ref ref="1"); 
    model Tx = Age BasePSA GleasonTotal_CORR_4cat Tstage_3cat/lackfit rsquare; 
  output out=Propensity_Scores predprobs=Individual; 
run; 
 
 
Create 1:1 and 2:1 PS matches for LDR vs. EBRT intermediate-risk match – Caliper 0.01: 
 
data thesis.Pscores_IR_EBRTvsLDR; 
  set Propensity_Scores; 
  Pscore=IP_1;  
  drop _from_ _into_ IP_0 IP_1; 
run; 
 
proc sort data=Thesis.Pscores_IR_EBRTvsLDR;  
  by ID2; 
run; 
 
data Brachy_LDR_pscores_C1; 
  set Thesis.Pscores_IR_EBRTvsLDR; 
  where Tx=1; 
  Brachy_LDR_ID=ID2; 
  Brachy_LDR_Pscore=Pscore; 
  keep Brachy_LDR_ID Brachy_LDR_Pscore; 
run; 
data EBRT_pscores_C1; 
  set Thesis.Pscores_IR_EBRTvsLDR; 
  where Tx=0; 
  EBRT_ID=ID2; 
  EBRT_Pscore=Pscore; 
  keep EBRT_ID EBRT_Pscore; 
run; 
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/*==========================================================*/ 
/*==== Caliper Matching (Without Replacement): Wave 1 =================*/ 
/*================== Caliper = 0.01 ============================*/ 
/*==========================================================*/ 
 
data Matched_C025_W1(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w1); 
    length ebrt_pscore 8; 
 length EBRT_ID 8; 
 if _N_= 1 then do; 
      declare hash h(dataset: "EBRT_pscores_C1", ordered: 'no'); 
      declare hiter iter('h'); 
      h.defineKey('EBRT_ID'); 
   h.defineData('EBRT_Pscore', 'EBRT_ID'); 
      h.defineDone(); 
      call missing(EBRT_ID, EBRT_Pscore); 
    end; 
    set Brachy_LDR_pscores_C1; 
    retain BestDistance 99; 
    rc= iter.first(); 
    if (rc=0) then BestDistance= 99; 
    do while (rc= 0); 
      if (Brachy_LDR_Pscore - 0.01) <= EBRT_Pscore <= (Brachy_LDR_Pscore + 0.01) then do; 
        ScoreDistance= abs(Brachy_LDR_Pscore - EBRT_Pscore); 
      if ScoreDistance < BestDistance then do; 
        BestDistance= ScoreDistance; 
        EBRT_ID_matched= EBRT_ID; 
        Brachy_LDR_ID_matched= Brachy_LDR_ID; 
        C025_w1=1; 
       end; 
     end; 
     rc= iter.next(); 
     if (rc~= 0) and BestDistance~= 99 then do; 
       output; 
         rc1= h.remove(key: EBRT_ID_matched); 
     end; 
     end; 
run; 
 
/*==========================================================*/ 
/*======== Remove EBRT Patients Selected in Wave 1 ==================*/ 
/*==========================================================*/ 
 
data C025_W1_EBRT_ID; 
  set Matched_C025_W1; 
  EBRT_ID=EBRT_ID_matched; 
  keep EBRT_ID C025_w1; 
run; 
 
proc sort data=C025_W1_EBRT_ID; 
  by EBRT_ID; 
run; 
 
data C025_W2_EBRT_pscores; 
  merge EBRT_pscores_C1 (in=EBRT_pscores_C1) 
        C025_W1_EBRT_ID (in=C025_W1_EBRT_ID); 
  by EBRT_ID; 
164	  
	  
    if EBRT_pscores_C1; 
run; 
 
data C025_W2_EBRT_pscoresB; 
  set C025_W2_EBRT_pscores; 
  if C025_w1=1 then delete; 
run; 
 
/*==========================================================*/ 
/*==== Caliper Matching (Without Replacement): Wave 2 =================*/ 
/*================== Caliper = 0.01 ============================*/ 
/*==========================================================*/ 
 
 
data Matched_C025_W2(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w2); 
length EBRT_ID 8; 
length EBRT_pscore 8; 
      if _N_= 1 then do; 
      declare hash h(dataset: "C025_W2_EBRT_pscoresB", ordered: 'no'); 
      declare hiter iter('h'); 
      h.defineKey('EBRT_ID'); 
      h.defineData('EBRT_pscore', 'EBRT_ID'); 
      h.defineDone(); 
          call missing(EBRT_ID, EBRT_pscore); 
    end; 
    set Brachy_LDR_pscores_C1; 
    retain BestDistance 99; 
    rc= iter.first(); 
    if (rc=0) then BestDistance= 99; 
    do while (rc= 0); 
      if (Brachy_LDR_pscore - 0.01) <= EBRT_pscore <= (Brachy_LDR_pscore + 0.01) then do; 
        ScoreDistance= abs(Brachy_LDR_pscore - EBRT_pscore); 
      if ScoreDistance < BestDistance then do; 
        BestDistance= ScoreDistance; 
        EBRT_ID_matched= EBRT_ID; 
        Brachy_LDR_ID_matched= Brachy_LDR_ID; 
        C025_w2=1; 
      end; 
    end; 
    rc= iter.next(); 
    if (rc~= 0) and BestDistance~= 99 then do; 
      output; 
        rc1= h.remove(key: EBRT_ID_matched); 
    end; 
    end; 
run; 
 
/*==========================================================*/ 
/*====== Remove EBRT Patients Selected in Wave 1 or 2 =================*/ 
/*==========================================================*/ 
 
data C025_W2_EBRT_ID; 
  set Matched_C025_W2; 
  EBRT_ID=EBRT_ID_matched; 
  keep EBRT_ID C025_w2; 
run; 
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proc sort data=C025_W2_EBRT_ID; 
  by EBRT_ID; 
run; 
 
data C025_W3_EBRT_pscores; 
  merge EBRT_pscores_C1 (in=EBRT_pscores_C1) 
        C025_W2_EBRT_ID (in=C025_W2_EBRT_ID) 
        C025_W1_EBRT_ID (in=C025_W1_EBRT_ID); 
  by EBRT_ID; 
    if EBRT_pscores_C1; 
run; 
 
 
/*==========================================================*/ 
/*============ Re-Import Matched ID Datasets ======================*/ 
/*==========================================================*/ 
 
data Matched_C025_W1_F; 
  set Matched_C025_W1; 
  Brachy_LDR_ID=Brachy_LDR_ID_matched; 
  EBRT_ID1=EBRT_ID_matched; 
  drop Brachy_LDR_ID_matched EBRT_ID_matched; 
run; 
 
data Matched_C025_W2_F; 
  set Matched_C025_W2; 
  Brachy_LDR_ID=Brachy_LDR_ID_matched; 
  EBRT_ID2=EBRT_ID_matched; 
  drop Brachy_LDR_ID_matched EBRT_ID_matched; 
run; 
 
/*==========================================================*/ 
/*======== Merge Datasets and Fix Variable Order =====================*/ 
/*==========================================================*/ 
 
data Matched_C025; 
  merge Matched_C025_W1_F (in=Matched_C025_W1_F) 
        Matched_C025_W2_F (in=Matched_C025_W2_F) 
 
; 
  by Brachy_LDR_ID; 
    if Matched_C025_W1_F; 
run; 
 
data Matched_C025B; 
  retain Brachy_LDR_ID 
         EBRT_ID1 C025_W1 
         EBRT_ID2 C025_w2 
  set Matched_C025; 
run; 
 
/*==========================================================*/ 
/*========== Re-Import Updated ID Matched Flags ====================*/ 
/*==========================================================*/ 
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data matched_C025B_F;  
  set matched_C025B; 
run; 
 
*Caliper=0.025, 1:1; 
data C025_1to1;  
  set matched_C025B_F; 
  if C025_w1=1; C025_1to1=1; 
  pair = _N_; 
run; 
data C025_1to1_Brachy_LDR; 
  set C025_1to1;  
  ID2=Brachy_LDR_ID;  
  keep ID2 C025_1to1 pair; 
run; 
data C025_1to1_EBRT1; 
  set C025_1to1;  
  ID2=EBRT_ID1;  
  keep ID2 C025_1to1 pair; 
run; 
data C025_1to1x; 
  set C025_1to1_Brachy_LDR  
      C025_1to1_EBRT1; 
run; 
proc sort data=C025_1to1x; 
  by ID2; 
run; 
 
 
data IR_PS_EBRTvsLDR; 
set Thesis.IR_PS_EBRTvsLDR; 
run; 
data C025_EBRT_LDR_IR; 
  merge C025_1to1x (in=C025_1to1x) 
        IR_PS_EBRTvsLDR (in=IR_PS_EBRTvsLDR); 
  by ID2; 
    if C025_1to1x; 
run; 
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Appendix VIII 
 
SAS code for PS Model and Matching Intermediate-risk HDR-BT+EBRT vs. EBRT 
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Code for HDR-BT+EBRT vs. EBRT Intermediate-risk PS match: 
 
Title 'Intermediate Risk: EBRT vs. HDR+EBRT'; 
libname thesis 'P:\Graham\Thesis'; 
Data Thesis.IR_PS_EBRTvsHDRandEBRT; 
set thesis.Interm_Risk_PS; 
if Radiation_Type_5cat = 'Brachy(LDR)_only' then delete; 
if Radiation_Type_5cat = 'EBRT_only' then Tx = 0; 
if Radiation_type_5cat = 'Brachy(HDR)_and_EBRT' then Tx = 1; 
/*Create RT Start Year and Treatment Centre Variables for Standardized Difference Analysis*/ 
if RTStart_Year = 1996 then RTStart_Year_1996 = 1; 
if RTStart_Year > 1996 then RTStart_Year_1996 = 0; 
if RTStart_Year = 1997 then RTStart_Year_1997 = 1; 
if RTStart_Year > 1997 then RTStart_Year_1997 = 0; 
if RTStart_Year < 1997 then RTStart_Year_1997 = 0; 
if RTStart_Year = 1998 then RTStart_Year_1998 = 1; 
if RTStart_Year > 1998 then RTStart_Year_1998 = 0; 
if RTStart_Year < 1998 then RTStart_Year_1998 = 0; 
if RTStart_Year = 1999 then RTStart_Year_1999 = 1; 
if RTStart_Year > 1999 then RTStart_Year_1999 = 0; 
if RTStart_Year < 1999 then RTStart_Year_1999 = 0; 
if RTStart_Year = 2000 then RTStart_Year_2000 = 1; 
if RTStart_Year > 2000 then RTStart_Year_2000 = 0; 
if RTStart_Year < 2000 then RTStart_Year_2000 = 0; 
if RTStart_Year = 2000 then RTStart_Year_2000 = 1; 
if RTStart_Year > 2000 then RTStart_Year_2000 = 0; 
if RTStart_Year < 2000 then RTStart_Year_2000 = 0; 
if RTStart_Year = 2001 then RTStart_Year_2001 = 1; 
if RTStart_Year > 2001 then RTStart_Year_2001 = 0; 
if RTStart_Year < 2001 then RTStart_Year_2001 = 0; 
if RTStart_Year = 2002 then RTStart_Year_2002 = 1; 
if RTStart_Year > 2002 then RTStart_Year_2002 = 0; 
if RTStart_Year < 2002 then RTStart_Year_2002 = 0; 
if RTStart_Year = 2003 then RTStart_Year_2003 = 1; 
if RTStart_Year > 2003 then RTStart_Year_2003 = 0; 
if RTStart_Year < 2003 then RTStart_Year_2003 = 0; 
if RTStart_Year = 2004 then RTStart_Year_2004 = 1; 
if RTStart_Year > 2004 then RTStart_Year_2004 = 0; 
if RTStart_Year < 2004 then RTStart_Year_2004 = 0; 
if RTStart_Year = 2005 then RTStart_Year_2005 = 1; 
if RTStart_Year > 2005 then RTStart_Year_2005 = 0; 
if RTStart_Year < 2005 then RTStart_Year_2005 = 0; 
if RTStart_Year = 2006 then RTStart_Year_2006 = 1; 
if RTStart_Year > 2006 then RTStart_Year_2006 = 0; 
if RTStart_Year < 2006 then RTStart_Year_2006 = 0; 
if RTStart_Year = 2007 then RTStart_Year_2007 = 1; 
if RTStart_Year > 2007 then RTStart_Year_2007 = 0; 
if RTStart_Year < 2007 then RTStart_Year_2007 = 0; 
if RTStart_Year = 2008 then RTStart_Year_2008 = 1; 
if RTStart_Year > 2008 then RTStart_Year_2008 = 0; 
if RTStart_Year < 2008 then RTStart_Year_2008 = 0; 
if RTStart_Year = 2009 then RTStart_Year_2009 = 1; 
if RTStart_Year > 2009 then RTStart_Year_2009 = 0; 
if RTStart_Year < 2009 then RTStart_Year_2009 = 0; 
if RTStart_Year = 2010 then RTStart_Year_2010 = 1; 
if RTStart_Year > 2010 then RTStart_Year_2010 = 0; 
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if RTStart_Year < 2010 then RTStart_Year_2010 = 0; 
if centre = 1 then centre1 = 1; 
if centre = 2 or centre = 3 or centre = 4 then centre1 = 0; 
if centre = 2 then centre2 = 1; 
if centre = 1 or centre = 3 or centre = 4 then centre2 = 0; 
if centre = 3 then centre3 = 1; 
if centre = 2 or centre = 1 or centre = 4 then centre3 = 0; 
if centre = 4 then centre4 = 1; 
if centre = 3 or centre = 2 or centre = 1 then centre4 = 0; 
run; 
proc freq data=Thesis.IR_PS_EBRTvsHDRandEBRT; 
tables Tstage_CORR*tx GleasonTotal*tx Radiation_Type_5cat*tx GleasonTotal_CORR_4cat*tx 
Tstage_3cat*tx /list; 
run; 
 
Create PS model for HDR+EBRT vs EBRT Intermediate-risk match: 
 
proc logistic descending data=Thesis.IR_PS_EBRTvsHDRandEBRT; 
  class GleasonTotal_CORR_4cat (param=ref ref="2_6"); 
  class Tstage_3cat (param=ref ref="1"); 
    model Tx = Age BasePSA GleasonTotal_CORR_4cat Tstage_3cat/lackfit rsquare; 
  output out=Propensity_Scores predprobs=Individual xbeta=logitps; 
run; 
proc means data=Propensity_Scores std; 
run; 
 
Create 1:1 and 2:1 PS matches for HDR+EBRT vs EBRT intermediate-risk match – Caliper -
1STD[logit]*(0.2): 
 
 
data thesis.Pscores_IR_EBRTvsHDR; 
  set Propensity_Scores; 
  Pscore=logitps;  
  drop _from_ _into_ IP_0 IP_1; 
run; 
 
proc sort data=Thesis.Pscores_IR_EBRTvsHDR;  
  by ID2; 
run; 
 
data Brachy_LDR_pscores_C1; 
  set Thesis.Pscores_IR_EBRTvsHDR; 
  where Tx=0; 
  Brachy_LDR_ID=ID2; 
  Brachy_LDR_Pscore=Pscore; 
  keep Brachy_LDR_ID Brachy_LDR_Pscore; 
run; 
data EBRT_pscores_C1; 
  set Thesis.Pscores_IR_EBRTvsHDR; 
  where Tx=1; 
  EBRT_ID=ID2; 
  EBRT_Pscore=Pscore; 
  keep EBRT_ID EBRT_Pscore; 
run; 
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/*=============================================================*/ 
/*==== Caliper Matching (Without Replacement): Wave 1 ===================*/ 
/*================== Caliper =1STD[logit]*(0.2)=======================*/ 
/*=============================================================*/ 
 
data Matched_C025_W1(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w1); 
    length ebrt_pscore 8; 
 length EBRT_ID 8; 
 if _N_= 1 then do; 
      declare hash h(dataset: "EBRT_pscores_C1", ordered: 'no'); 
      declare hiter iter('h'); 
      h.defineKey('EBRT_ID'); 
   h.defineData('EBRT_Pscore', 'EBRT_ID'); 
      h.defineDone(); 
      call missing(EBRT_ID, EBRT_Pscore); 
    end; 
    set Brachy_LDR_pscores_C1; 
    retain BestDistance 99; 
    rc= iter.first(); 
    if (rc=0) then BestDistance= 99; 
    do while (rc= 0); 
      if (Brachy_LDR_Pscore - (1.0143704*0.2)) <= EBRT_Pscore <= (Brachy_LDR_Pscore + 
(1.0143704*0.2)) then do; 
        ScoreDistance= abs(Brachy_LDR_Pscore - EBRT_Pscore); 
      if ScoreDistance < BestDistance then do; 
        BestDistance= ScoreDistance; 
        EBRT_ID_matched= EBRT_ID; 
        Brachy_LDR_ID_matched= Brachy_LDR_ID; 
        C025_w1=1; 
       end; 
     end; 
     rc= iter.next(); 
     if (rc~= 0) and BestDistance~= 99 then do; 
       output; 
         rc1= h.remove(key: EBRT_ID_matched); 
     end; 
     end; 
run; 
 
/*==========================================================*/ 
/*======== Remove EBRT Patients Selected in Wave 1 ================*/ 
/*==========================================================*/ 
 
data C025_W1_EBRT_ID; 
  set Matched_C025_W1; 
  EBRT_ID=EBRT_ID_matched; 
  keep EBRT_ID C025_w1; 
run; 
 
proc sort data=C025_W1_EBRT_ID; 
  by EBRT_ID; 
run; 
 
data C025_W2_EBRT_pscores; 
  merge EBRT_pscores_C1 (in=EBRT_pscores_C1) 
        C025_W1_EBRT_ID (in=C025_W1_EBRT_ID); 
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  by EBRT_ID; 
    if EBRT_pscores_C1; 
run; 
 
data C025_W2_EBRT_pscoresB; 
  set C025_W2_EBRT_pscores; 
  if C025_w1=1 then delete; 
run; 
 
 
 
/*===========================================================*/ 
/*==== Caliper Matching (Without Replacement): Wave 2 ==================*/ 
/*============= Caliper 1STD[logit]*(0.2)===========================*/ 
/*==========================================================*/ 
 
 
data Matched_C025_W2(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w2); 
length EBRT_ID 8; 
length EBRT_pscore 8; 
      if _N_= 1 then do; 
      declare hash h(dataset: "C025_W2_EBRT_pscoresB", ordered: 'no'); 
      declare hiter iter('h'); 
      h.defineKey('EBRT_ID'); 
      h.defineData('EBRT_pscore', 'EBRT_ID'); 
      h.defineDone(); 
          call missing(EBRT_ID, EBRT_pscore); 
    end; 
    set Brachy_LDR_pscores_C1; 
    retain BestDistance 99; 
    rc= iter.first(); 
    if (rc=0) then BestDistance= 99; 
    do while (rc= 0); 
      if (Brachy_LDR_pscore – (1.0143704*0.2) <= EBRT_pscore <= (Brachy_LDR_pscore + 
(1.0143704*0.2) then do; 
        ScoreDistance= abs(Brachy_LDR_pscore - EBRT_pscore); 
      if ScoreDistance < BestDistance then do; 
        BestDistance= ScoreDistance; 
        EBRT_ID_matched= EBRT_ID; 
        Brachy_LDR_ID_matched= Brachy_LDR_ID; 
        C025_w2=1; 
      end; 
    end; 
    rc= iter.next(); 
    if (rc~= 0) and BestDistance~= 99 then do; 
      output; 
        rc1= h.remove(key: EBRT_ID_matched); 
    end; 
    end; 
run; 
 
/*==========================================================*/ 
/*====== Remove EBRT Patients Selected in Wave 1 or 2 ==============*/ 
/*==========================================================*/ 
 
data C025_W2_EBRT_ID; 
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  set Matched_C025_W2; 
  EBRT_ID=EBRT_ID_matched; 
  keep EBRT_ID C025_w2; 
run; 
 
proc sort data=C025_W2_EBRT_ID; 
  by EBRT_ID; 
run; 
 
data C025_W3_EBRT_pscores; 
  merge EBRT_pscores_C1 (in=EBRT_pscores_C1) 
        C025_W2_EBRT_ID (in=C025_W2_EBRT_ID) 
        C025_W1_EBRT_ID (in=C025_W1_EBRT_ID); 
  by EBRT_ID; 
    if EBRT_pscores_C1; 
run; 
 
 
/*==========================================================*/ 
/*============ Re-Import Matched ID Datasets =====================*/ 
/*==========================================================*/ 
 
data Matched_C025_W1_F; 
  set Matched_C025_W1; 
  Brachy_LDR_ID=Brachy_LDR_ID_matched; 
  EBRT_ID1=EBRT_ID_matched; 
  drop Brachy_LDR_ID_matched EBRT_ID_matched; 
run; 
 
data Matched_C025_W2_F; 
  set Matched_C025_W2; 
  Brachy_LDR_ID=Brachy_LDR_ID_matched; 
  EBRT_ID2=EBRT_ID_matched; 
  drop Brachy_LDR_ID_matched EBRT_ID_matched; 
run; 
 
/*==========================================================*/ 
/*======== Merge Datasets and Fix Variable Order ===================*/ 
/*==========================================================*/ 
 
data Matched_C025; 
  merge Matched_C025_W1_F (in=Matched_C025_W1_F) 
        Matched_C025_W2_F (in=Matched_C025_W2_F) 
; 
  by Brachy_LDR_ID; 
    if Matched_C025_W1_F; 
run; 
 
data Matched_C025B; 
  retain Brachy_LDR_ID 
         EBRT_ID1 C025_W1 
         EBRT_ID2 C025_w2 
  set Matched_C025; 
run; 
 
 
173	  
	  
/*==========================================================*/ 
/*========== Re-Import Updated ID Matched Flags ===================*/ 
/*==========================================================*/ 
 
data matched_C025B_F;  
  set matched_C025B; 
run; 
 
Caliper=1STDlogit*0.2, 1:1; 
data C025_1to1;  
  set matched_C025B_F; 
  if C025_w1=1; C025_1to1=1; 
  pair = _N_; 
run; 
data C025_1to1_Brachy_LDR; 
  set C025_1to1;  
  ID2=Brachy_LDR_ID;  
  keep ID2 C025_1to1 pair; 
run; 
data C025_1to1_EBRT1; 
  set C025_1to1;  
  ID2=EBRT_ID1;  
  keep ID2 C025_1to1 pair; 
run; 
data C025_1to1x; 
  set C025_1to1_Brachy_LDR  
      C025_1to1_EBRT1; 
run; 
proc sort data=C025_1to1x; 
  by ID2; 
run; 
 
data IR_PS_EBRTvsHDR; 
set Thesis.IR_PS_EBRTvsHDRandEBRT; 
run; 
data C025_EBRT_HDR_IR; 
  merge C025_1to1x (in=C025_1to1x) 
        IR_PS_EBRTvsHDR (in=IR_PS_EBRTvsHDR); 
  by ID2; 
    if C025_1to1x; 
run; 
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Appendix IX 
 
SAS Code for PS Model and Matching Low-risk LDR-BT vs. EBRT 
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Code for LDR vs. EBRT Low-risk PS match: 
 
libname thesis 'P:\Graham\Thesis'; 
Data Thesis.LR_PS_EBRTvsLDR; 
set thesis.Low_Risk_PS; 
if Radiation_Type_5cat = 'EBRT_only' then Tx = 0; 
if Radiation_type_5cat = 'Brachy(LDR)_only' then Tx = 1; 
run; 
proc freq data=Thesis.LR_PS_EBRTvsLDR; 
tables Tstage_CORR*tx GleasonTotal*tx Radiation_Type_5cat*tx GleasonTotal_CORR_4cat*tx 
Tstage_3cat*tx /list; 
Title 'Low Risk Propensity Score Match EBRT vs LDR'; 
run; 
 
Create PS model for LDR vs EBRT Low-risk match: 
 
proc logistic descending data=Thesis.LR_PS_EBRTvsLDR; 
   class GleasonTotal_CORR_4cat (param=ref ref="2_6"); 
   class Tstage_3cat (param=ref ref="1"); 
   class RTStart_Year (param=ref ref="1999"); 
    model Tx = Age BasePSA GleasonTotal_CORR_4cat Tstage_3cat RTStart_Year/lackfit rsquare; 
  output out=Propensity_Scores predprobs=Individual xbeta=logitps; 
run; 
 
Create 1:1, 2:1, 3:1 and 4:1 (LDR:EBRT) PS matches for LDR vs EBRT Low-risk match – Caliper -
1STD[logit]*(0.2): 
 
data Thesis.LR_PS_EBRTvsLDR; 
  set Propensity_Scores; 
  Pscore=logitps;  
  drop _from_ _into_ IP_0 IP_1; 
run; 
 
proc sort data=Thesis.LR_PS_EBRTvsLDR;  
  by ID2; 
run; 
 
data Brachy_LDR_pscores_C1; 
  set Thesis.LR_PS_EBRTvsLDR; 
  where Tx=0; 
  Brachy_LDR_ID=ID2; 
  Brachy_LDR_Pscore=Pscore; 
  keep Brachy_LDR_ID Brachy_LDR_Pscore; 
run; 
data EBRT_pscores_C1; 
  set Thesis.LR_PS_EBRTvsLDR; 
  where Tx=1; 
  EBRT_ID=ID2; 
  EBRT_Pscore=Pscore; 
  keep EBRT_ID EBRT_Pscore; 
run; 
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/*===========================================================*/ 
/*==== Caliper Matching (Without Replacement): Wave 1 ==================*/ 
/*============= Caliper = 1STD[logit]*(0.2)==========================*/ 
/*===========================================================*/ 
 
data Matched_C025_W1(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w1); 
    length ebrt_pscore 8; 
 length EBRT_ID 8; 
 if _N_= 1 then do; 
      declare hash h(dataset: "EBRT_pscores_C1", ordered: 'no'); 
      declare hiter iter('h'); 
      h.defineKey('EBRT_ID'); 
   h.defineData('EBRT_Pscore', 'EBRT_ID'); 
      h.defineDone(); 
      call missing(EBRT_ID, EBRT_Pscore); 
    end; 
    set Brachy_LDR_pscores_C1; 
    retain BestDistance 99; 
    rc= iter.first(); 
    if (rc=0) then BestDistance= 99; 
    do while (rc= 0); 
      if (Brachy_LDR_Pscore - (1.1565042*0.2)) <= EBRT_Pscore <= (Brachy_LDR_Pscore + 
(1.1565042*0.2)) then do; 
        ScoreDistance= abs(Brachy_LDR_Pscore - EBRT_Pscore); 
      if ScoreDistance < BestDistance then do; 
        BestDistance= ScoreDistance; 
        EBRT_ID_matched= EBRT_ID; 
        Brachy_LDR_ID_matched= Brachy_LDR_ID; 
        C025_w1=1; 
       end; 
     end; 
     rc= iter.next(); 
     if (rc~= 0) and BestDistance~= 99 then do; 
       output; 
         rc1= h.remove(key: EBRT_ID_matched); 
     end; 
     end; 
run; 
 
/*==========================================================*/ 
/*======== Remove EBRT Patients Selected in Wave 1 ==================*/ 
/*==========================================================*/ 
 
data C025_W1_EBRT_ID; 
  set Matched_C025_W1; 
  EBRT_ID=EBRT_ID_matched; 
  keep EBRT_ID C025_w1; 
run; 
 
proc sort data=C025_W1_EBRT_ID; 
  by EBRT_ID; 
run; 
 
data C025_W2_EBRT_pscores; 
  merge EBRT_pscores_C1 (in=EBRT_pscores_C1) 
        C025_W1_EBRT_ID (in=C025_W1_EBRT_ID); 
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  by EBRT_ID; 
    if EBRT_pscores_C1; 
run; 
 
data C025_W2_EBRT_pscoresB; 
  set C025_W2_EBRT_pscores; 
  if C025_w1=1 then delete; 
run; 
 
/*==========================================================*/ 
/*==== Caliper Matching (Without Replacement): Wave 2 =================*/ 
/=========== Caliper = 1STD[logit]*(0.2) ===========================*/ 
/*==========================================================*/ 
 
 
data Matched_C025_W2(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w2); 
length EBRT_ID 8; 
length EBRT_pscore 8; 
      if _N_= 1 then do; 
      declare hash h(dataset: "C025_W2_EBRT_pscoresB", ordered: 'no'); 
      declare hiter iter('h'); 
      h.defineKey('EBRT_ID'); 
      h.defineData('EBRT_pscore', 'EBRT_ID'); 
      h.defineDone(); 
          call missing(EBRT_ID, EBRT_pscore); 
    end; 
    set Brachy_LDR_pscores_C1; 
    retain BestDistance 99; 
    rc= iter.first(); 
    if (rc=0) then BestDistance= 99; 
    do while (rc= 0); 
      if (Brachy_LDR_pscore - (1.1565042*0.2)) <= EBRT_pscore <= (Brachy_LDR_pscore + 
(1.1565042*0.2)) then do; 
        ScoreDistance= abs(Brachy_LDR_pscore - EBRT_pscore); 
      if ScoreDistance < BestDistance then do; 
        BestDistance= ScoreDistance; 
        EBRT_ID_matched= EBRT_ID; 
        Brachy_LDR_ID_matched= Brachy_LDR_ID; 
        C025_w2=1; 
      end; 
    end; 
    rc= iter.next(); 
    if (rc~= 0) and BestDistance~= 99 then do; 
      output; 
        rc1= h.remove(key: EBRT_ID_matched); 
    end; 
    end; 
run; 
 
/*==========================================================*/ 
/*====== Remove EBRT Patients Selected in Wave 1 or 2 ==============*/ 
/*==========================================================*/ 
 
data C025_W2_EBRT_ID; 
  set Matched_C025_W2; 
  EBRT_ID=EBRT_ID_matched; 
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  keep EBRT_ID C025_w2; 
run; 
 
proc sort data=C025_W2_EBRT_ID; 
  by EBRT_ID; 
run; 
 
data C025_W3_EBRT_pscores; 
  merge EBRT_pscores_C1 (in=EBRT_pscores_C1) 
        C025_W2_EBRT_ID (in=C025_W2_EBRT_ID) 
        C025_W1_EBRT_ID (in=C025_W1_EBRT_ID); 
  by EBRT_ID; 
    if EBRT_pscores_C1; 
run; 
 
 
data C025_W3_EBRT_pscoresB; 
  set C025_W3_EBRT_pscores; 
  if C025_w1=1 or C025_w2=1 then delete; 
run; 
 
/*==========================================================*/ 
/*==== Caliper Matching (Without Replacement): Wave 3 =================*/ 
/*========== Caliper = 1STD[logit]*(0.2) ===========================*/ 
/*==========================================================*/ 
 
 
data Matched_C025_W3(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w3); 
length EBRT_ID 8; 
length EBRT_pscore 8; 
      if _N_= 1 then do; 
      declare hash h(dataset: "C025_W3_EBRT_pscoresB", ordered: 'no'); 
      declare hiter iter('h'); 
      h.defineKey('EBRT_ID'); 
      h.defineData('EBRT_pscore', 'EBRT_ID'); 
      h.defineDone(); 
          call missing(EBRT_ID, EBRT_pscore); 
    end; 
    set Brachy_LDR_pscores_C1; 
    retain BestDistance 99; 
    rc= iter.first(); 
    if (rc=0) then BestDistance= 99; 
    do while (rc= 0); 
      if (Brachy_LDR_pscore - (1.1565042*0.2)) <= EBRT_pscore <= (Brachy_LDR_pscore + 
(1.1565042*0.2)) then do; 
        ScoreDistance= abs(Brachy_LDR_pscore - EBRT_pscore); 
      if ScoreDistance < BestDistance then do; 
        BestDistance= ScoreDistance; 
        EBRT_ID_matched= EBRT_ID; 
        Brachy_LDR_ID_matched= Brachy_LDR_ID; 
        C025_w3=1; 
      end; 
    end; 
    rc= iter.next(); 
    if (rc~= 0) and BestDistance~= 99 then do; 
      output; 
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        rc1= h.remove(key: EBRT_ID_matched); 
    end; 
    end; 
run; 
 
 
/*==========================================================*/ 
/*====== Remove EBRT Patients Selected in Wave 1 or 2 or 3 ===========*/ 
/*==========================================================*/ 
 
data C025_W3_EBRT_ID; 
  set Matched_C025_W3; 
  EBRT_ID=EBRT_ID_matched; 
  keep EBRT_ID C025_w3; 
run; 
 
proc sort data=C025_W3_EBRT_ID; 
  by EBRT_ID; 
run; 
 
data C025_W4_EBRT_pscores; 
  merge EBRT_pscores_C1 (in=EBRT_pscores_C1) 
        C025_W2_EBRT_ID (in=C025_W2_EBRT_ID) 
        C025_W1_EBRT_ID (in=C025_W1_EBRT_ID) 
  C025_W3_EBRT_ID (in=C025_W3_EBRT_ID); 
  by EBRT_ID; 
    if EBRT_pscores_C1; 
run; 
 
 
data C025_W4_EBRT_pscoresB; 
  set C025_W4_EBRT_pscores; 
  if C025_w1=1 or C025_w2=1 or C025_w3 then delete; 
run; 
/*==========================================================*/ 
/*==== Caliper Matching (Without Replacement): Wave 4 =================*/ 
/*========== Caliper = 1STD[logit]*(0.2)  ===========================*/ 
/*==========================================================*/ 
 
 
data Matched_C025_W4(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w4); 
length EBRT_ID 8; 
length EBRT_pscore 8; 
      if _N_= 1 then do; 
      declare hash h(dataset: "C025_W4_EBRT_pscoresB", ordered: 'no'); 
      declare hiter iter('h'); 
      h.defineKey('EBRT_ID'); 
      h.defineData('EBRT_pscore', 'EBRT_ID'); 
      h.defineDone(); 
          call missing(EBRT_ID, EBRT_pscore); 
    end; 
    set Brachy_LDR_pscores_C1; 
    retain BestDistance 99; 
    rc= iter.first(); 
    if (rc=0) then BestDistance= 99; 
    do while (rc= 0); 
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      if (Brachy_LDR_pscore - (1.1565042*0.2)) <= EBRT_pscore <= (Brachy_LDR_pscore + 
(1.1565042*0.2)) then do; 
        ScoreDistance= abs(Brachy_LDR_pscore - EBRT_pscore); 
      if ScoreDistance < BestDistance then do; 
        BestDistance= ScoreDistance; 
        EBRT_ID_matched= EBRT_ID; 
        Brachy_LDR_ID_matched= Brachy_LDR_ID; 
        C025_w4=1; 
      end; 
    end; 
    rc= iter.next(); 
    if (rc~= 0) and BestDistance~= 99 then do; 
      output; 
        rc1= h.remove(key: EBRT_ID_matched); 
    end; 
    end; 
run; 
/*==========================================================*/ 
/*============ Re-Import Matched ID Datasets =====================*/ 
/*==========================================================*/ 
 
data Matched_C025_W1_F; 
  set Matched_C025_W1; 
  Brachy_LDR_ID=Brachy_LDR_ID_matched; 
  EBRT_ID1=EBRT_ID_matched; 
  drop Brachy_LDR_ID_matched EBRT_ID_matched; 
run; 
 
data Matched_C025_W2_F; 
  set Matched_C025_W2; 
  Brachy_LDR_ID=Brachy_LDR_ID_matched; 
  EBRT_ID2=EBRT_ID_matched; 
  drop Brachy_LDR_ID_matched EBRT_ID_matched; 
run; 
 
data Matched_C025_W3_F; 
  set Matched_C025_W3; 
  Brachy_LDR_ID=Brachy_LDR_ID_matched; 
  EBRT_ID3=EBRT_ID_matched; 
  drop Brachy_LDR_ID_matched EBRT_ID_matched; 
run; 
 
data Matched_C025_W4_F; 
  set Matched_C025_W4; 
  Brachy_LDR_ID=Brachy_LDR_ID_matched; 
  EBRT_ID4=EBRT_ID_matched; 
  drop Brachy_LDR_ID_matched EBRT_ID_matched; 
run; 
 
/*==========================================================*/ 
/*======== Merge Datasets and Fix Variable Order =====================*/ 
/*==========================================================*/ 
 
data Matched_C025; 
  merge Matched_C025_W1_F (in=Matched_C025_W1_F) 
        Matched_C025_W2_F (in=Matched_C025_W2_F) 
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  Matched_C025_W3_F (in=Matched_C025_W3_F) 
  Matched_C025_W4_F (in=Matched_C025_W4_F); 
 
  by Brachy_LDR_ID; 
    if Matched_C025_W1_F; 
run; 
 
data Matched_C025B; 
  retain Brachy_LDR_ID 
         EBRT_ID1 C025_W1 
         EBRT_ID2 C025_w2 
  EBRT_ID3 C025_w3 
  EBRT_ID4 C025_w4; 
 
  set Matched_C025; 
run; 
 
/*==========================================================*/ 
/*========== Re-Import Updated ID Matched Flags ====================*/ 
/*==========================================================*/ 
 
data matched_C025B_F;  
  set matched_C025B; 
run; 
 
*Caliper=0.02logit, 1:1; 
data C025_1to1;  
  set matched_C025B_F; 
  if C025_w1=1; C025_1to1=1; 
  pair = _N_; 
run; 
data C025_1to1_Brachy_LDR; 
  set C025_1to1;  
  ID2=Brachy_LDR_ID;  
  keep ID2 C025_1to1 pair; 
run; 
data C025_1to1_EBRT1; 
  set C025_1to1;  
  ID2=EBRT_ID1;  
  keep ID2 C025_1to1 pair; 
run; 
data C025_1to1x; 
  set C025_1to1_Brachy_LDR  
      C025_1to1_EBRT1; 
run; 
proc sort data=C025_1to1x; 
  by ID2; 
run; 
 
*Caliper=0.2logit, 1:2; 
data C025_1to2;  
  set matched_C025B; 
  if C025_w1=1 and C025_w2=1;  
  C025_1to2=1; 
  pair = _N_; 
run; 
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data C025_1to2_Brachy_LDR; 
  set C025_1to2;  
  ID2=Brachy_LDR_ID;  
  keep ID2 C025_1to2 pair; 
run; 
data C025_1to2_EBRT1; 
  set C025_1to2;  
  ID2=EBRT_ID1;  
  keep ID2 C025_1to2 pair; 
run; 
data C025_1to2_EBRT2; 
  set C025_1to2;  
  ID2=EBRT_ID2;  
  keep ID2 C025_1to2 pair; 
run; 
data C025_1to2x; 
  set C025_1to2_Brachy_LDR  
      C025_1to2_EBRT1  
      C025_1to2_EBRT2; 
run; 
proc sort data=C025_1to2x; 
  by ID2; 
run; 
*Caliper=0.2logit, 1:3; 
data C025_1to3;  
  set matched_C025B; 
  if C025_w1=1 and C025_w2=1 and C025_w3=1;  
  C025_1to3=1; 
  pair = _N_; 
run; 
 
data C025_1to3_Brachy_LDR; 
  set C025_1to3;  
  ID2=Brachy_LDR_ID;  
  keep ID2 C025_1to3 pair; 
run; 
data C025_1to3_EBRT1; 
  set C025_1to3;  
  ID2=EBRT_ID1;  
  keep ID2 C025_1to3 pair; 
run; 
data C025_1to3_EBRT2; 
  set C025_1to3;  
  ID2=EBRT_ID2;  
  keep ID2 C025_1to3 pair; 
run; 
data C025_1to3_EBRT3; 
  set C025_1to3;  
  ID2=EBRT_ID3;  
  keep ID2 C025_1to3 pair; 
run; 
data C025_1to3x; 
  set C025_1to3_Brachy_LDR  
      C025_1to3_EBRT1  
      C025_1to3_EBRT2 
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   C025_1to3_EBRT3; 
run; 
proc sort data=C025_1to3x; 
  by ID2; 
run; 
*Caliper=0.2logit, 1:4; 
data C025_1to4;  
  set matched_C025B; 
  if C025_w1=1 and C025_w2=1 and C025_w3=1 and C025_w4=1;  
  C025_1to4=1; 
  pair = _N_; 
run; 
data C025_1to4_Brachy_LDR; 
  set C025_1to4;  
  ID2=Brachy_LDR_ID;  
  keep ID2 C025_1to4 pair; 
run; 
data C025_1to4_EBRT1; 
  set C025_1to4;  
  ID2=EBRT_ID1;  
  keep ID2 C025_1to4 pair; 
run; 
data C025_1to4_EBRT2; 
  set C025_1to4;  
  ID2=EBRT_ID2;  
  keep ID2 C025_1to4 pair; 
run; 
data C025_1to4_EBRT3; 
  set C025_1to4;  
  ID2=EBRT_ID3;  
  keep ID2 C025_1to4 pair; 
run; 
data C025_1to4_EBRT4; 
  set C025_1to4;  
  ID2=EBRT_ID4;  
  keep ID2 C025_1to4 pair; 
run; 
data C025_1to4x; 
  set C025_1to4_Brachy_LDR  
      C025_1to4_EBRT1  
      C025_1to4_EBRT2 
   C025_1to4_EBRT3 
   C025_1to4_EBRT4; 
run; 
proc sort data=C025_1to4x; 
  by ID2; 
run; 
data LR_PS_EBRTvsLDR; 
set Thesis.LR_PS_EBRTvsLDR; 
run; 
data C025_EBRT_LDR_LR; 
  merge C025_1to4x (in=C025_1to4x) 
        LR_PS_EBRTvsLDR (in=LR_PS_EBRTvsLDR); 
  by ID2; 
    if C025_1to4x; 
run; 
184	  
	  
 
 
 
 
 
 
 
 
 
 
 
Appendix X 
 
SAS Code for Standardized Difference Testing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
185	  
	  
Standardized Difference Testing: 
 
Intermediate-risk LDR vs EBRT Match: 
 
proc sort data=C025_EBRT_LDR_IR; 
by Tx; 
run; 
 
/*== Macro for computing standardized difference for continuous variables ===*/ 
 
%macro cont(var=,label=); 
proc means mean stddev data=C025_EBRT_LDR_IR noprint; 
var &var; 
by Tx; 
output out=outmean (keep = Tx mean stddev) mean = mean stddev=stddev; 
run; 
 
data EBRT; 
set outmean; 
if Tx = 0; 
mean_0 = mean; 
s_0 = stddev; 
keep mean_0 S_0; 
run; 
 
data Brachy; 
set outmean; 
if Tx = 1; 
mean_1 = mean; 
s_1 = stddev; 
keep mean_1 s_1; 
run; 
 
data newdata; 
length label $ 25; 
merge EBRT Brachy; 
d = (mean_1 - mean_0)/sqrt((s_1*S_1 + S_0*s_0)/2); 
d = round(abs(d),0.00001); 
label = &label; 
keep d label; 
run; 
 
proc append data=newdata base=standiff force; 
run; 
 
%mend cont; 
 
/*== Macro for computing standardized difference for categorical variables ===*/ 
 
%macro binary(var=,label=); 
proc means mean data=C025_EBRT_LDR_IR noprint; 
var &var; 
by Tx; 
output out=outmean (keep = Tx mean) mean = mean; 
186	  
	  
run; 
 
data EBRT; 
set outmean; 
if Tx = 0; 
mean_0 = mean; 
keep mean_0; 
run; 
 
data Brachy; 
set outmean; 
if Tx = 1; 
mean_1 = mean; 
keep mean_1; 
run; 
 
data newdata; 
length label $ 25; 
merge EBRT Brachy; 
 
d = (mean_1 - mean_0)/sqrt((mean_1*(1-mean_1) + mean_0*(1-mean_0))/2); 
d = round(abs(d),0.0001); 
 
label = &label; 
 
keep d label; 
run; 
 
proc append data=newdata base=standiff force; 
run; 
 
%mend binary; 
 
%cont(var=age,label="Age"); 
%cont(var=BasePSA,label="Baseline PSA ng/mL"); 
 
%binary(var=Tstage_T1,label="Any T1"); 
%binary(var=Tstage_LowT2,label="Low T2"); 
%binary(var=Tstage_HighT2,label="High T2"); 
%binary(var=GleasonTotal_7,label="Gleason Total 7 vs 6"); 
%binary(var=PosCores_ge50pct,label="Percent Positive Cores > 50"); 
%binary(var=GleasonPattern_CORRx3plus3,label="Gleason Pattern 3+3"); 
%binary(var=GleasonPattern_CORRx3plus4,label="Gleason Pattern 3+4"); 
%binary(var=GleasonPattern_CORRx4plus3,label="Gleason Pattern 4+3"); 
%binary(var=RTStart_Year_1996;,label="RT Start YR 1996"); 
%binary(var=RTStart_Year_1997;,label="RT Start YR 1997"); 
%binary(var=RTStart_Year_1998;,label="RT Start YR 1998"); 
%binary(var=RTStart_Year_1999;,label="RT Start YR 1999"); 
%binary(var=RTStart_Year_2000;,label="RT Start YR 2000"); 
%binary(var=RTStart_Year_2001;,label="RT Start YR 2001"); 
%binary(var=RTStart_Year_2002;,label="RT Start YR 2002"); 
%binary(var=RTStart_Year_2003;,label="RT Start YR 2003"); 
%binary(var=RTStart_Year_2004;,label="RT Start YR 2004"); 
%binary(var=RTStart_Year_2005;,label="RT Start YR 2005"); 
%binary(var=RTStart_Year_2006;,label="RT Start YR 2006"); 
%binary(var=RTStart_Year_2007;,label="RT Start YR 2007"); 
187	  
	  
%binary(var=RTStart_Year_2008;,label="RT Start YR 2008"); 
%binary(var=RTStart_Year_2009;,label="RT Start YR 2009"); 
%binary(var=RTStart_Year_2010;,label="RT Start YR 2010"); 
%binary(var=centre1;,label="Centre 1"); 
%binary(var=centre2;,label="Centre 2"); 
%binary(var=centre3;,label="Centre 3"); 
proc print data=standiff; 
title "Standard Difference in Matched Sample"; 
run; 
 
proc freq data=C025_EBRT_LDR_IR; 
table RTStart_Year*tx centre*tx PosCores_ge50pct*tx GleasonPattern_CORR*tx Tstage_3cat*tx 
GleasonTotal_7*Tx Tstage_T1*Tx Tstage_LowT2*Tx Tstage_HighT2*tx/list chisq; 
run; 
proc freq data=C025_EBRT_LDR_IR; 
table PosCores_ge50pct*tx GleasonPattern_CORR*Tx GleasonTotal_CORR /missprint; 
run; 
data BrachyC025_Age_PSA; 
set C025_EBRT_LDR_IR; 
where Tx = 1; 
run; 
proc means data=brachyC025_Age_PSA N mean median std max min; 
var age basePSA; 
Title 'Mean AGE and BASELINE PSA in Brachytherapy Group'; 
run; 
 
data EBRTC025_Age_PSA; 
set C025_EBRT_LDR_IR; 
where tx = 0; 
run; 
proc means data=EBRTC025_Age_PSA N mean median std max min; 
var age basePSA; 
Title 'Mean AGE and BASELINE PSA in EBRT Group'; 
run; 
 
proc ttest data=C025_EBRT_LDR_IR; 
class tx; 
var age basePSA; 
run; 
 
Proc means data=C025_EBRT_LDR_IR N mean median std max min; 
var age basePSA; 
run; 
 
data Thesis.Final_LDRvsEBRT_Int_PS; 
set C025_EBRT_LDR_IR; 
Survival_Years = Survival_Months/12; 
BFFS2_Years = BFFS2_months/12; 
CRS_Years = CRS_months/12; 
run; 
 
Intermediate-risk HDR+EBRT vs EBRT Match: 
 
proc sort data=C025_EBRT_HDR_IR; 
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by Tx; 
run; 
 
/*== Macro for computing standardized difference for continuous variables ===*/ 
 
%macro cont(var=,label=); 
proc means mean stddev data=C025_EBRT_HDR_IR noprint; 
var &var; 
by Tx; 
output out=outmean (keep = Tx mean stddev) mean = mean stddev=stddev; 
run; 
 
data EBRT; 
set outmean; 
if Tx = 0; 
mean_0 = mean; 
s_0 = stddev; 
keep mean_0 S_0; 
run; 
 
data Brachy; 
set outmean; 
if Tx = 1; 
mean_1 = mean; 
s_1 = stddev; 
keep mean_1 s_1; 
run; 
 
data newdata; 
length label $ 25; 
merge EBRT Brachy; 
d = (mean_1 - mean_0)/sqrt((s_1*S_1 + S_0*s_0)/2); 
d = round(abs(d),0.00001); 
label = &label; 
keep d label; 
run; 
 
proc append data=newdata base=standiff force; 
run; 
 
%mend cont; 
 
/*== Macro for computing standardized difference for categorical variables ===*/ 
 
%macro binary(var=,label=); 
proc means mean data=C025_EBRT_HDR_IR noprint; 
var &var; 
by Tx; 
output out=outmean (keep = Tx mean) mean = mean; 
run; 
 
data EBRT; 
set outmean; 
if Tx = 0; 
mean_0 = mean; 
keep mean_0; 
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run; 
 
data Brachy; 
set outmean; 
if Tx = 1; 
mean_1 = mean; 
keep mean_1; 
run; 
 
data newdata; 
length label $ 25; 
merge EBRT Brachy; 
 
d = (mean_1 - mean_0)/sqrt((mean_1*(1-mean_1) + mean_0*(1-mean_0))/2); 
d = round(abs(d),0.0001); 
 
label = &label; 
 
keep d label; 
run; 
 
proc append data=newdata base=standiff force; 
run; 
 
%mend binary; 
 
%cont(var=age,label="Age"); 
%cont(var=BasePSA,label="Baseline PSA ng/mL"); 
 
%binary(var=Tstage_T1,label="Any T1"); 
%binary(var=Tstage_LowT2,label="Low T2"); 
%binary(var=Tstage_HighT2,label="High T2"); 
%binary(var=GleasonTotal_7,label="Gleason Total 7 vs 6"); 
%binary(var=PosCores_ge50pct,label="Percent Positive Cores > 50"); 
%binary(var=GleasonPattern_CORRx3plus3,label="Gleason Pattern 3+3"); 
%binary(var=GleasonPattern_CORRx3plus4,label="Gleason Pattern 3+4"); 
%binary(var=GleasonPattern_CORRx4plus3,label="Gleason Pattern 4+3"); 
%binary(var=RTStart_Year_1996;,label="RT Start YR 1996"); 
%binary(var=RTStart_Year_1997;,label="RT Start YR 1997"); 
%binary(var=RTStart_Year_1998;,label="RT Start YR 1998"); 
%binary(var=RTStart_Year_1999;,label="RT Start YR 1999"); 
%binary(var=RTStart_Year_2000;,label="RT Start YR 2000"); 
%binary(var=RTStart_Year_2001;,label="RT Start YR 2001"); 
%binary(var=RTStart_Year_2002;,label="RT Start YR 2002"); 
%binary(var=RTStart_Year_2003;,label="RT Start YR 2003"); 
%binary(var=RTStart_Year_2004;,label="RT Start YR 2004"); 
%binary(var=RTStart_Year_2005;,label="RT Start YR 2005"); 
%binary(var=RTStart_Year_2006;,label="RT Start YR 2006"); 
%binary(var=RTStart_Year_2007;,label="RT Start YR 2007"); 
%binary(var=RTStart_Year_2008;,label="RT Start YR 2008"); 
%binary(var=RTStart_Year_2009;,label="RT Start YR 2009"); 
%binary(var=RTStart_Year_2010;,label="RT Start YR 2010"); 
%binary(var=centre1;,label="Centre 1"); 
%binary(var=centre2;,label="Centre 2"); 
%binary(var=centre3;,label="Centre 3"); 
%binary(var=centre4;,label="Centre 4"); 
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proc print data=standiff; 
title "Standard Difference in Matched Sample"; 
run; 
 
proc freq data=C025_EBRT_HDR_IR; 
table GleasonPattern_CORR*Tx PosCores_ge50pct*tx /missprint; 
run; 
 
proc freq data=C025_EBRT_HDR_IR; 
table RTStart_Year*tx centre*tx PosCores_ge50pct*tx GleasonPattern_CORR*tx 
PosCores_ge50pct*centre GleasonPattern_CORR*centre Tstage_3cat*tx GleasonTotal_7*Tx 
Tstage_T1*Tx Tstage_LowT2*Tx Tstage_HighT2*tx/list chisq missprint; 
run; 
 
data BrachyC025_Age_PSA; 
set C025_EBRT_HDR_IR; 
where Tx = 1; 
run; 
proc means data=brachyC025_Age_PSA N mean median std max min; 
var age basePSA; 
Title 'Mean AGE and BASELINE PSA in Brachytherapy Group'; 
run; 
 
data EBRTC025_Age_PSA; 
set C025_EBRT_HDR_IR; 
where tx = 0; 
run; 
proc means data=EBRTC025_Age_PSA N mean median std max min; 
var age basePSA; 
Title 'Mean AGE and BASELINE PSA in EBRT Group'; 
run; 
Proc means data=C025_EBRT_HDR_IR N mean median std max min; 
var age basePSA; 
run; 
proc ttest data=C025_EBRT_HDR_IR; 
class tx; 
var age basePSA; 
run; 
 
data Thesis.Final_HDRplusEBRTvsEBRT_Int_PS; 
set C025_EBRT_HDR_IR; 
Survival_Years = Survival_Months/12; 
BFFS2_Years = BFFS2_months/12; 
CRS_Years = CRS_months/12; 
run; 
 
Low-risk LDR vs EBRT Match: 
 
proc sort data=C025_EBRT_LDR_LR; 
by Tx; 
run; 
 
/*== Macro for computing standardized difference for continuous variables ===*/ 
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%macro cont(var=,label=); 
proc means mean stddev data=C025_EBRT_LDR_LR noprint; 
var &var; 
by Tx; 
output out=outmean (keep = Tx mean stddev) mean = mean stddev=stddev; 
run; 
 
data EBRT; 
set outmean; 
if Tx = 0; 
mean_0 = mean; 
s_0 = stddev; 
keep mean_0 S_0; 
run; 
 
data Brachy; 
set outmean; 
if Tx = 1; 
mean_1 = mean; 
s_1 = stddev; 
keep mean_1 s_1; 
run; 
 
data newdata; 
length label $ 25; 
merge EBRT Brachy; 
d = (mean_1 - mean_0)/sqrt((s_1*S_1 + S_0*s_0)/2); 
d = round(abs(d),0.00001); 
label = &label; 
keep d label; 
run; 
 
proc append data=newdata base=standiff force; 
run; 
 
%mend cont; 
 
/*== Macro for computing standardized difference for categorical variables ===*/ 
 
%macro binary(var=,label=); 
proc means mean data=C025_EBRT_LDR_LR noprint; 
var &var; 
by Tx; 
output out=outmean (keep = Tx mean) mean = mean; 
run; 
 
data EBRT; 
set outmean; 
if Tx = 0; 
mean_0 = mean; 
keep mean_0; 
run; 
 
data Brachy; 
set outmean; 
if Tx = 1; 
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mean_1 = mean; 
keep mean_1; 
run; 
 
data newdata; 
length label $ 25; 
merge EBRT Brachy; 
 
d = (mean_1 - mean_0)/sqrt((mean_1*(1-mean_1) + mean_0*(1-mean_0))/2); 
d = round(abs(d),0.0001); 
 
label = &label; 
 
keep d label; 
run; 
 
proc append data=newdata base=standiff force; 
run; 
 
%mend binary; 
 
%cont(var=age,label="Age"); 
%cont(var=BasePSA,label="Baseline PSA ng/mL"); 
 
%binary(var=Tstage_T1,label="Any T1"); 
%binary(var=Tstage_LowT2,label="Low T2"); 
%binary(var=GleasonTotal_6,label="Gleason Total 6 vs 2to5"); 
%binary(var=RTStart_Year_1999,label="RT Start Year 1999"); 
%binary(var=RTStart_Year_2000,label="RT Start Year 2000"); 
%binary(var=RTStart_Year_2001,label="RT Start Year 2001"); 
%binary(var=RTStart_Year_2002,label="RT Start Year 2002"); 
%binary(var=RTStart_Year_2003,label="RT Start Year 2003"); 
%binary(var=RTStart_Year_2004,label="RT Start Year 2004"); 
%binary(var=RTStart_Year_2005,label="RT Start Year 2005"); 
%binary(var=RTStart_Year_2006,label="RT Start Year 2006"); 
%binary(var=PosCores_ge50pct,label="Percent Positive Cores > 50"); 
%binary(var=centre1,label="Treatment Centre 1"); 
%binary(var=centre2,label="Treatment Centre 2"); 
%binary(var=centre3,label="Treatment Centre 3"); 
 
 
proc print data=standiff; 
title "Standard Difference in Matched Sample"; 
run; 
 
proc freq data=C025_EBRT_LDR_LR; 
table centre*tx PosCores_ge50pct*tx RTStart_Year*tx Tstage_3cat*tx GleasonTotal_6*Tx Tstage_T1*Tx 
Tstage_LowT2*Tx Tstage_HighT2*tx/list chisq; 
run; 
proc freq data=C025_EBRT_LDR_LR; 
table PosCores_ge50pct*tx /missprint; 
run; 
 
data BrachyC025_Age_PSA; 
set C025_EBRT_LDR_LR; 
where Tx = 1; 
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run; 
proc means data=brachyC025_Age_PSA N mean median std max min; 
var age basePSA; 
Title 'Mean AGE and BASELINE PSA in Brachytherapy Group'; 
run; 
 
data EBRTC025_Age_PSA; 
set C025_EBRT_LDR_LR; 
where tx = 0; 
run; 
proc means data=EBRTC025_Age_PSA N mean median std max min; 
var age basePSA; 
Title 'Mean AGE and BASELINE PSA in EBRT Group'; 
run; 
 
proc ttest data=C025_EBRT_LDR_LR; 
class tx; 
var age basePSA; 
run; 
 
proc datasets lib=work nolist; 
delete C025_1to1 C025_1to1x C025_1to1_Brachy_LDR C025_1to1_EBRT1 C025_1to2 C025_1to2x 
C025_1to2_Brachy_LDR C025_1to2_EBRT1 C025_1to2_EBRT2 C025_1to3 C025_1to3x 
C025_1to3_EBRT1 C025_1to3_EBRT2; 
run; 
 
proc means data=C025_EBRT_LDR_LR N mean median std max min; 
var age basePSA; 
run; 
 
data Thesis.Final_LDRvsEBRT_LOW_PS; 
set C025_EBRT_LDR_LR; 
Survival_Years = Survival_Months/12; 
BFFS2_Years = BFFS2_months/12; 
CRS_Years = CRS_months/12; 
run; 
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Appendix XI 
 
SAS Code for Kaplan Meier Curves, Cox Adjusted and Extended Models (Time 
Dependent Covariate Models), and Model Assumption Tests (Visual and Global Tests) 
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OS Comparison Intermediate-risk LDR vs EBRT PS Matched Cohort: 
 
ods graphics on; 
libname thesis 'P:\Graham\Thesis'; 
Title "Intermediate Risk: LDR vs EBRT (Propensity Score Match)"; 
proc lifetest data=Thesis.Final_LDRvsEBRT_INT_PS outsurv=S_INT_LDRvsEBRT_PS maxtime=120 
notable 
plots=(survival(atrisk=0 to 120 by 24)); 
time Survival_Months*Dead(0); 
label Survival_Months = 'Time (Months)'; 
strata Radiation_Type_5cat / group=pair; 
run; 
 
 
/*Creating Kaplan Meier Curves*/ 
goptions cback=white; 
symbol1 line=1 color=black width=2 i=stepj; 
symbol2 line=4 color=black width=2 i=stepj; 
axis1 label=(angle=90 'Survival (%)' 
font="Swiss/bold") 
order=(0 to 1 by 0.2) 
major=(height=3) minor=none color=black; 
axis2 label=('Time (Months)' 
font="Swiss/bold") 
order=(0 to 120 by 24) 
major=(height=3) minor=none color=black; 
legend1 label=none mode=protect position=(bottom left inside) 
offset=(-8 -4) across=1 
value=(tick=1 justify=L "LDR" font="Swiss/bold" 
tick=2 justify=L "EBRT" font="Swiss/bold"); 
ods pdf startpage=now; 
proc gplot data=thesis.survival_INT_LDR; 
plot SURVIVAL*Survival_Months = Radiation_Type_5cat / 
vaxis=axis1 haxis=axis2 legend=legend1; 
format survival percent12.; 
run; 
 
/*Cox PH Regression of Treatment Type Stratified by Matched Pair with Kolmogorov-Supremum 
Test*/ 
proc phreg data=Thesis.Final_LDRvsEBRT_INT_PS covs(aggregate); 
class Radiation_Type_5cat (param=ref ref="EBRT_only"); 
model Survival_Months*Dead(0) = Radiation_Type_5cat /rl; 
id pair; 
assess proportionalhazards / resample seed=1004; 
output out=outRT ressch=Radiation_Type_5cat; 
run; 
 
/*Log of Negative Log of Estimated Survival Visual Test*/ 
proc lifetest data=Thesis.Final_LDRvsEBRT_INT_PS notable maxtime=120 
  plots=(lls);  
  time Survival_Months*Dead(0); 
  strata Radiation_Type_5cat; 
  label Survival_Months = 'Time (Months)'; 
  survival out=out1; 
run; 
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/*Schoenfeld Residual Plot*/ 
proc sgplot data=outRT; 
loess x=Survival_Months y=Radiation_Type_5cat2; 
title 'Schoenfeld residuals plot for Radiation_5cat'; 
run; 
 
/*Schoenfeld Global Test*/ 
proc corr data=outRT; 
var Radiation_Type_5cat2; 
with Survival_Months; 
run; 
 
/*Test for Radiation Type as Time Dependent Covariate for OS Using Extended Cox PH Model*/ 
data TDC_LDRvsEBRT_INT2; 
  set Thesis.Final_LDRvsEBRT_INT_PS; 
If Radiation_Type_5cat = "EBRT_only" then Radiation_Type_Num = 1; 
If Radiation_Type_5cat = "Brachy(LDR)_only" then Radiation_Type_Num = 2; 
run; 
proc phreg data=TDC_LDRvsEBRT_INT2; 
class Radiation_Type_Num (param=ref ref="1"); 
model Survival_months*Dead(0) = Radiation_Type_Num RT5cat_Log_Surv/rl; 
RT5cat_Log_Surv=Radiation_Type_Num*LOG(Survival_months); 
run; 
 
 
BFFS Comparison Intermediate-risk LDR vs EBRT PS Matched: 
 
 
proc lifetest data=Thesis.Final_LDRvsEBRT_INT_PS  notable outsurv=BFFS_INT_LDRvsEBRT_PS 
maxtime=120 
  plots=(survival(atrisk=0 to 120 by 24));  
  time BFFS2_CORR_months*BFFS2_CORR(0); 
  strata Radiation_Type_5cat / test=logrank; 
  label BFFS2_CORR_months = 'Time (Months)'; 
run; 
proc lifetest data=Thesis.Final_LDRvsEBRT_INT_PS  notable outsurv=BFFS_INT_LDRvsEBRT_PS 
maxtime=120 
  plots=(survival(atrisk=0 to 120 by 24));  
  time BFFS2_CORR_months*BFFS2_CORR(0); 
  strata Radiation_Type_5cat / group=pair; 
  label BFFS2_CORR_months = 'Time (Months)'; 
run; 
 
/*Creating Kaplan Meier Curves*/ 
goptions cback=white; 
symbol1 line=1 color=black width=2 i=stepj; 
symbol2 line=4 color=black width=2 i=stepj; 
axis1 label=(angle=90 'Survival (%)' 
font="Swiss/bold") 
order=(0 to 1 by 0.2) 
major=(height=3) minor=none color=black; 
axis2 label=('Time (Months)' 
font="Swiss/bold") 
order=(0 to 120 by 24) 
major=(height=3) minor=none color=black; 
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legend1 label=none mode=protect position=(bottom left inside) 
offset=(-8 -4) across=1 
value=(tick=1 justify=L "LDR" font="Swiss/bold" 
tick=2 justify=L "EBRT" font="Swiss/bold"); 
ods pdf startpage=now; 
proc gplot data=thesis.bff_INT_LDR; 
plot SURVIVAL*bffs2_CORR_Months = Radiation_Type_5cat / 
vaxis=axis1 haxis=axis2 legend=legend1; 
format survival percent12.; 
run; 
 
/*Cox PH Regression of Treatment Type Stratified by Matched Pair with Kolmogorov-Supremum 
Test*/ 
proc phreg data=Thesis.Final_LDRvsEBRT_INT_PS covs(aggregate); 
class Radiation_Type_5cat (param=ref ref="EBRT_only"); 
model BFFS2_CORR_months*BFFS2_CORR(0) = Radiation_Type_5cat /rl; 
id pair; 
assess proportionalhazards / resample seed=1004; 
output out=outRT2 ressch=Radiation_Type_5cat; 
run; 
 
/*Log of Negative Log of Estimated Survival Visual Test*/ 
proc lifetest data=Thesis.Final_LDRvsEBRT_INT_PS notable maxtime=120 
  plots=(lls);  
time BFFS2_CORR_months*BFFS2_CORR(0); 
  strata Radiation_Type_5cat; 
  label BFFS2_CORR_months = 'Time (Months)'; 
survival out=out2; 
run; 
 
/*Schoenfeld Residual Plot*/ 
proc sgplot data=outRT2; 
loess x=BFFS2_CORR_Months y=Radiation_Type_5cat2; 
title 'Schoenfeld residuals plot for Radiation_5cat'; 
run; 
 
/*Schoenfeld Global Test*/ 
proc corr data=outRT2; 
var Radiation_Type_5cat2; 
with BFFS2_CORR_Months; 
run; 
 
/*Test for Radiation Type as Time Dependent Covariate for BFFS Using Extended Cox PH Model */ 
data TDC_LDRvsEBRT_INT1; 
  set Thesis.Final_LDRvsEBRT_INT_PS; 
If Radiation_Type_5cat = "EBRT_only" then Radiation_Type_Num = 1; 
If Radiation_Type_5cat = "Brachy(LDR)_only" then Radiation_Type_Num = 2; 
run; 
proc phreg data=TDC_LDRvsEBRT_INT1; 
class Radiation_Type_Num (param=ref ref="1"); 
model BFFS2_CORR_months*BFFS2_CORR(0) = Radiation_Type_Num RT5cat_Log_BFFS2/rl; 
RT5cat_Log_BFFS2=Radiation_Type_Num*LOG(BFFS2_CORR_months); 
run; 
 
ods graphics off; 
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OS Comparison Intermediate-risk HDR+EBRT vs EBRT PS Matched Cohort: 
 
 
ods graphics on; 
libname thesis 'P:\Graham\Thesis'; 
Title "Intermediate Risk: HDR+EBRT vs EBRT (Propensity Score Match)"; 
proc lifetest data=Thesis.Final_HDRplusEBRTvsEBRT_INT_PS outsurv=S_INT_HDRvsEBRT_PS 
maxtime=120 notable 
plots=(survival(atrisk=0 to 120 by 24)); 
time Survival_Months*Dead(0); 
label Survival_Months = 'Time (Months)'; 
strata Radiation_Type_5cat / group=pair; 
run; 
 
/*Creating Kaplan Meier Curves*/ 
goptions cback=white; 
symbol1 line=1 color=black width=2 i=stepj; 
symbol2 line=4 color=black width=2 i=stepj; 
axis1 label=(angle=90 'Survival (%)' 
font="Swiss/bold") 
order=(0 to 1 by 0.2) 
major=(height=3) minor=none color=black; 
axis2 label=('Time (Months)' 
font="Swiss/bold") 
order=(0 to 120 by 24) 
major=(height=3) minor=none color=black; 
legend1 label=none mode=protect position=(bottom left inside) 
offset=(-8 -4) across=1 
value=(tick=1 justify=L "HDR+EBRT" font="Swiss/bold" 
tick=2 justify=L "EBRT" font="Swiss/bold"); 
ods pdf startpage=now; 
proc gplot data=thesis.survival_INT_HDR; 
plot SURVIVAL*Survival_Months = Radiation_Type_5cat / 
vaxis=axis1 haxis=axis2 legend=legend1; 
format survival percent12.; 
run; 
 
/*Cox PH Regression of Treatment Type Stratified by Matched Pair with Kolmogorov-Supremum 
Test*/ 
proc phreg data=Thesis.Final_HDRplusEBRTvsEBRT_INT_PS covs(aggregate); 
class Radiation_Type_5cat (param=ref ref="EBRT_only"); 
model Survival_Months*Dead(0) = Radiation_Type_5cat / rl; 
id pair; 
assess proportionalhazards / resample seed=1004; 
output out=outRT ressch=Radiation_Type_5cat; 
run; 
 
/*Log of Negative Log of Estimated Survival Visual Test*/ 
proc lifetest data=Thesis.Final_HDRplusEBRTvsEBRT_INT_PS notable maxtime=120 
  plots=(lls);  
time Survival_Months*Dead(0); 
label Survival_Months = 'Time (Months)'; 
strata Radiation_Type_5cat; 
survival out=out1; 
run; 
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/*Schoenfeld Residual Plot*/ 
proc sgplot data=outRT; 
loess x=Survival_Months y=Radiation_Type_5cat2; 
title 'Schoenfeld residuals plot for Radiation_5cat'; 
run; 
 
/*Schoenfeld Global Test*/ 
proc corr data=outRT; 
var Radiation_Type_5cat2; 
with Survival_Months; 
run; 
 
/*Test for Radiation Type as Time Dependent Covariate for OS Using Extended Cox PH Model*/ 
data TDC_HDRvsEBRT_INT; 
  set Thesis.Final_HDRplusEBRTvsEBRT_INT_PS; 
If Radiation_Type_5cat = "EBRT_only" then Radiation_Type_Num = 1; 
If Radiation_Type_5cat = "Brachy(HDR)_and_EBRT" then Radiation_Type_Num = 2; 
run; 
proc phreg data=TDC_HDRvsEBRT_INT; 
class Radiation_Type_Num (param=ref ref="1"); 
model Survival_months*Dead(0) = Radiation_Type_Num RT5cat_Log_Surv/rl; 
RT5cat_Log_Surv=Radiation_Type_Num*LOG(Survival_months); 
run; 
 
 
BFFS Comparison Intermediate-risk HDR+EBRT vs EBRT PS Matched Cohort: 
 
proc lifetest data=Thesis.Final_HDRplusEBRTvsEBRT_INT_PS  notable 
outsurv=BFFS_INT_HDRvsEBRT_PS maxtime=120 
  plots=(survival(atrisk=0 to 120 by 24));  
  time BFFS2_CORR_months*BFFS2_CORR(0); 
  strata Radiation_Type_5cat / group=pair; 
  label BFFS2_CORR_months = 'Time (Months)'; 
run; 
 
/*Creating Kaplan Meier Curves*/ 
goptions cback=white; 
symbol1 line=1 color=black width=2 i=stepj; 
symbol2 line=4 color=black width=2 i=stepj; 
axis1 label=(angle=90 'Survival (%)' 
font="Swiss/bold") 
order=(0 to 1 by 0.2) 
major=(height=3) minor=none color=black; 
axis2 label=('Time (Months)' 
font="Swiss/bold") 
order=(0 to 120 by 24) 
major=(height=3) minor=none color=black; 
legend1 label=none mode=protect position=(bottom left inside) 
offset=(-8 -4) across=1 
value=(tick=1 justify=L "HDR+EBRT" font="Swiss/bold" 
tick=2 justify=L "EBRT" font="Swiss/bold"); 
ods pdf startpage=now; 
proc gplot data=thesis.bff_INT_HDR; 
plot SURVIVAL*bffs2_CORR_Months = Radiation_Type_5cat / 
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vaxis=axis1 haxis=axis2 legend=legend1; 
format survival percent12.; 
run; 
 
/*Cox PH Regression of Treatment Type Stratified by Matched Pair with Kolmogorov-Supremum 
Test*/ 
proc phreg data=Thesis.Final_HDRplusEBRTvsEBRT_INT_PS covs(aggregate); 
class Radiation_Type_5cat (param=ref ref="EBRT_only"); 
model BFFS2_CORR_months*BFFS2_CORR(0) = Radiation_Type_5cat /rl; 
id pair; 
assess proportionalhazards / resample seed=1004; 
output out=outRT2 ressch=Radiation_Type_5cat; 
run; 
 
/*Log of Negative Log of Estimated Survival Visual Test*/ 
proc lifetest data=Thesis.Final_HDRplusEBRTvsEBRT_INT_PS notable maxtime=120 
  plots=(lls);  
  time BFFS2_CORR_months*BFFS2_CORR(0); 
  strata Radiation_Type_5cat; 
  label BFFS2_CORR_months = 'Time (Months)'; 
  survival out=out2; 
run; 
 
/*Schoenfeld Residual Plot*/ 
proc sgplot data=outRT2; 
loess x=BFFS2_CORR_Months y=Radiation_Type_5cat2; 
title 'Schoenfeld residuals plot for Radiation_5cat'; 
run; 
 
/*Schoenfeld Global Test*/ 
proc corr data=outRT2; 
var Radiation_Type_5cat2; 
with BFFS2_CORR_Months; 
run; 
 
/*Test for Radiation Type as Time Dependent Covariate for BFFS Using Extended Cox PH Model*/ 
data TDC_HDRvsEBRT_INT; 
  set Thesis.Final_HDRplusEBRTvsEBRT_INT_PS; 
If Radiation_Type_5cat = "EBRT_only" then Radiation_Type_Num = 1; 
If Radiation_Type_5cat = "Brachy(HDR)_and_EBRT" then Radiation_Type_Num = 2; 
run; 
proc phreg data=TDC_HDRvsEBRT_INT; 
class Radiation_Type_Num (param=ref ref="1"); 
model BFFS2_CORR_months*BFFS2_CORR(0) = Radiation_Type_Num RT5cat_Log_BFFS2/rl; 
RT5cat_Log_BFFS2=Radiation_Type_Num*LOG(BFFS2_CORR_months); 
run; 
 
ods graphics off; 
 
OS Comparison Low-risk LDR vs EBRT PS Matched Cohort: 
 
ods graphics on; 
libname thesis 'P:\Graham\Thesis'; 
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Title "Low Risk: LDR vs EBRT (Propensity Score Match)"; 
 
 
proc lifetest data=Thesis.Final_LDRvsEBRT_LOW_PS outsurv=S_LOW_LDRvsEBRT_PS maxtime=120 
notable 
plots=(survival(atrisk=0 to 120 by 24)); 
time Survival_Months*Dead(0); 
label Survival_Months = 'Time (Months)'; 
strata Radiation_Type_5cat / group=pair; 
run; 
 
/*Creating Kaplan Meier Curves*/ 
goptions cback=white; 
symbol1 line=1 color=black width=2 i=stepj; 
symbol2 line=4 color=black width=2 i=stepj; 
axis1 label=(angle=90 'Survival (%)' 
font="Swiss/bold") 
order=(0 to 1 by 0.2) 
major=(height=3) minor=none color=black; 
axis2 label=('Time (Months)' 
font="Swiss/bold") 
order=(0 to 120 by 24) 
major=(height=3) minor=none color=black; 
legend1 label=none mode=protect position=(bottom left inside) 
offset=(-8 -4) across=1 
value=(tick=1 justify=L "LDR" font="Swiss/bold" 
tick=2 justify=L "EBRT" font="Swiss/bold"); 
ods pdf startpage=now; 
proc gplot data=thesis.survival_lr; 
plot SURVIVAL*Survival_Months = Radiation_Type_5cat / 
vaxis=axis1 haxis=axis2 legend=legend1; 
format survival percent12.; 
run; 
 
/*Cox PH Regression of Treatment Type Stratified by Matched Pair with Kolmogorov-Supremum 
Test*/ 
proc phreg data=Thesis.Final_LDRvsEBRT_LOW_PS covs(aggregate); 
  class Radiation_Type_5cat (param=ref ref="EBRT_only"); 
  model Survival_Months*Dead(0) = Radiation_Type_5cat /rl; 
  id pair; 
assess proportionalhazards / resample seed=1004; 
output out=outRT ressch=Radiation_Type_5cat; 
run; 
 
/*Log of Negative Log of Estimated Survival Visual Test*/ 
proc lifetest data=Thesis.Final_LDRvsEBRT_LOW_PS notable maxtime=120 
  plots=(lls);  
  time Survival_Months*Dead(0); 
  strata Radiation_Type_5cat; 
  label Survival_Months = 'Time (Months)'; 
  survival out=out; 
run; 
 
/*Schoenfeld Residual Plot*/ 
proc sgplot data=outRT; 
loess x=Survival_Months y=Radiation_Type_5cat2; 
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title 'Schoenfeld residuals plot for Radiation_5cat'; 
run; 
 
/*Schoenfeld Global Test*/ 
proc corr data=outRT; 
var Radiation_Type_5cat2; 
with Survival_Months; 
run; 
 
/*Test for Radiation Type as Time Dependent Covariate for OS Using Extended Cox PH Model*/ 
data TDC_LDRvsEBRT_low; 
  set Thesis.Final_LDRvsEBRT_LOW_PS; 
If Radiation_Type_5cat = "EBRT_only" then Radiation_Type_Num = 1; 
If Radiation_Type_5cat = "Brachy(LDR)_only" then Radiation_Type_Num = 2; 
run; 
proc phreg data=TDC_LDRvsEBRT_low; 
class Radiation_Type_Num (param=ref ref="1"); 
model Survival_months*Dead(0) = Radiation_Type_Num RT5cat_Log_Surv/rl; 
RT5cat_Log_Surv=Radiation_Type_Num*LOG(Survival_months); 
run; 
data thesis.S_LOW_LDRvsEBRT_PS; 
set S_LOW_LDRvsEBRT_PS; 
run; 
 
 
BFFS Comparison Low-risk LDR vs EBRT PS Matched Cohort: 
 
proc lifetest data=Thesis.Final_LDRvsEBRT_LOW_PS  notable outsurv=BFFS_LOW_LDRvsEBRT_PS 
maxtime=120 
  plots=(survival(atrisk=0 to 120 by 24));  
  time BFFS2_CORR_months*BFFS2_CORR(0); 
  strata Radiation_Type_5cat / group=pair; 
  label BFFS2_CORR_months = 'Time (Months)'; 
run; 
 
/*Creating Kaplan Meier Curves*/ 
goptions cback=white; 
symbol1 line=1 color=black width=2 i=stepj; 
symbol2 line=4 color=black width=2 i=stepj; 
axis1 label=(angle=90 'Survival (%)' 
font="Swiss/bold") 
order=(0 to 1 by 0.2) 
major=(height=3) minor=none color=black; 
axis2 label=('Time (Months)' 
font="Swiss/bold") 
order=(0 to 120 by 24) 
major=(height=3) minor=none color=black; 
legend1 label=none mode=protect position=(bottom left inside) 
offset=(-8 -4) across=1 
value=(tick=1 justify=L "LDR" font="Swiss/bold" 
tick=2 justify=L "EBRT" font="Swiss/bold"); 
ods pdf startpage=now; 
proc gplot data=thesis.bff_lr; 
plot SURVIVAL*bffs2_CORR_Months = Radiation_Type_5cat / 
vaxis=axis1 haxis=axis2 legend=legend1; 
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format survival percent12.; 
run; 
 
/*Cox PH Regression of Treatment Type Stratified by Matched Pair with Kolmogorov-Supremum 
Test*/ 
proc phreg data=Thesis.Final_LDRvsEBRT_LOW_PS covs(aggregate); 
class Radiation_Type_5cat (param=ref ref="EBRT_only"); 
model BFFS2_CORR_months*BFFS2_CORR(0) = Radiation_Type_5cat /rl; 
id pair; 
assess proportionalhazards / resample seed=1004; 
output out=outRT2 ressch=Radiation_Type_5cat; 
run; 
/*Log of Negative Log of Estimated Survival Visual Test*/ 
proc lifetest data=Thesis.Final_LDRvsEBRT_LOW_PS notable maxtime=120 
  plots=(lls);  
  time BFFS2_CORR_months*BFFS2_CORR(0); 
  strata Radiation_Type_5cat; 
  label BFFS2_CORR_months = 'Time (Months)'; 
  survival out=out2; 
run; 
 
/*Schoenfeld Residual Plot*/ 
proc sgplot data=outRT2; 
loess x=BFFS2_CORR_Months y=Radiation_Type_5cat2; 
title 'Schoenfeld residuals plot for Radiation_5cat'; 
run; 
 
/*Schoenfeld Global Test*/ 
proc corr data=outRT2; 
var Radiation_Type_5cat2; 
with BFFS2_CORR_Months; 
run; 
 
/*Test for Radiation Type as Time Dependent Covariate for bFFS Using Extended Cox PH Model */ 
data TDC_LDRvsEBRT_low; 
  set Thesis.Final_LDRvsEBRT_LOW_PS; 
If Radiation_Type_5cat = "EBRT_only" then Radiation_Type_Num = 1; 
If Radiation_Type_5cat = "Brachy(LDR)_only" then Radiation_Type_Num = 2; 
run; 
proc phreg data=TDC_LDRvsEBRT_low; 
class Radiation_Type_Num (param=ref ref="1"); 
model BFFS2_CORR_months*BFFS2_CORR(0) = Radiation_Type_Num RT5cat_Log_BFFS2/rl; 
RT5cat_Log_BFFS2=Radiation_Type_Num*LOG(BFFS2_CORR_months); 
run; 
 
data thesis.BFFS_LOW_LDRvsEBRT_PS; 
set BFFS_LOW_LDRvsEBRT_PS; 
run; 
 
 
 
 
204	  
	  
 
 
 
 
 
 
 
 
 
 
 
Appendix XII 
 
Results of Global and Visual Tests for Proportional Hazards Assumption and Testing of 
Extended Cox Models Using Time Dependent Covariates 
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Results of PH Assumption Tests and Test for Treatment as Time Dependent 
Covariate Using Log(Survival Time in Months) in Intermediate-Risk LDR vs EBRT 
Comparison:  
 
Overall Survival: 
 
Visual Tests: 
Schoenfeld Plot:        Log(-Log) Survival Plot: 
    
 
Global Tests: 
Proportional Hazard Assumption Global Test Used  p-value 
Schoenfeld Test 0.8958 
Suprmum-Kolmogorov Test 0.8030 
Test Using Extended Cox PH Regression Including Treatment as 
TDC using Scale of Log(Survival Months) 
0.9075 
Reported p-value (from Adjusted Cox PH, with no TDC) 0.6867 
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Biochemical Failure Free Survival: 
 
Visual Tests: 
Schoenfeld Plot:        Log(-Log) Survival Plot: 
  
 
Global Tests: 
Proportional Hazard Assumption Test Used  p-value 
Schoenfeld Test 0.5993 
Suprmum-Kolmogorov Test 0.7160 
Test Using Extended Cox PH Regression Including Treatment as 
TDC using Scale of Log(Survival Months) 
0.6944 
Reported p-value (from Adjusted Cox PH, with no TDC) 0.0012 
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Results of PH Assumption Tests and Test for Treatment as Time Dependent 
Covariate Using Log(Survival Time in Months) in Intermediate-Risk HDR+EBRT 
vs EBRT Comparison:  
 
Overall Survival: 
Visual Tests: 
Schoenfeld Plot:        Log(-Log) Survival Plot: 
  
 
Global Tests: 
Proportional Hazard Assumption Test Used  p-value 
Schoenfeld Test 0.5176 
Suprmum-Kolmogorov Test 0.2020 
Test Using Extended Cox PH Regression Including Treatment as 
TDC using Scale of Log(Survival Months) 
0.2714 
Reported p-value (from Adjusted Cox PH, with no TDC) 0.4696 
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Biochemical Failure Free Survival: 
 
Visual Tests: 
Schoenfeld Plot:        Log(-Log) Survival Plot: 
  
 
Global Tests: 
Proportional Hazard Assumption Test Used  p-value 
Schoenfeld Test 0.1184 
Suprmum-Kolmogorov Test 0.0840 
Test Using Extended Cox PH Regression Including Treatment as 
TDC using Scale of Log(Survival Months) 
0.0654 
*Reported p-value (from Extended Cox PH, with TDC, using 
Likelihood Ratio Tests with 2 degrees of freedom) 
0.0066 
Reported p-value (from Adjusted Cox PH, with no TDC, from 
Sensitivity Analysis) 
0.0185 
 *p-value reported in study for this comparison 
 
 
209	  
	  
 
Results of PH Assumption Tests and Test for Treatment as Time Dependent 
Covariate Using Log(Survival Time in Months) in Low-Risk LDR vs EBRT 
Comparison:  
 
Overall Survival: 
Visual Tests: 
Schoenfeld Plot:        Log(-Log) Survival Plot: 
  
 
Global Tests: 
Proportional Hazard Assumption Test Used  p-value 
Schoenfeld Test 0.1471 
Suprmum-Kolmogorov Test 0.1350 
Test Using Extended Cox PH Regression Including Treatment as 
TDC using Scale of Log(Survival Months) 
0.2004 
Reported p-value (from Adjusted Cox PH, with no TDC) 0.4999 
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Biochemical Failure Free Survival: 
 
Visual Tests: 
Schoenfeld Plot:        Log(-Log) Survival Plot: 
  
 
Global Tests: 
Proportional Hazard Assumption Test Used  p-value 
Schoenfeld Test 0.5897 
Suprmum-Kolmogorov Test 0.6380 
Test Using Extended Cox PH Regression Including Treatment as 
TDC using Scale of Log(Survival Months) 
0.3594 
Reported p-value (from Adjusted Cox PH, with no TDC) 0.0041 
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Appendix XIII 
 
SAS Code Used for Power Calculations 
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Intermediate-risk LDR vs EBRT Power Calculation: 
 
proc power; 
twosamplesurvival test=logrank 
curve("control") = (1 2) : (0.86 0.81) 
refsurvival = "control" 
hazardratio = 0.1 to 0.95 by 0.05 
accrualtime = 1 
followuptime = 1 
ntotal = 254 
power = .; 
run; 
proc power; 
twosamplesurvival test=logrank 
curve("control") = (1 2) : (0.86 0.75) 
refsurvival = "control" 
hazardratio = 0.1 to 0.95 by 0.05 
accrualtime = 1 
followuptime = 1 
ntotal = 254 
power = .; 
run; 
 
Intermediate-risk HDR+EBRT vs EBRT Power Calculation: 
 
proc power; 
twosamplesurvival test=logrank 
curve("control") = (1 2) : (0.86 0.81) 
refsurvival = "control" 
hazardratio = 0.1 to 0.95 by 0.05 
accrualtime = 1 
followuptime = 1 
ntotal = 388 
power = .; 
run; 
proc power; 
twosamplesurvival test=logrank 
curve("control") = (1 2) : (0.86 0.75) 
refsurvival = "control" 
hazardratio = 0.1 to 0.95 by 0.05 
accrualtime = 1 
followuptime = 1 
ntotal = 388 
power = .; 
run; 
 
Low-risk LDR vs EBRT Power Calculation: 
 
proc power; 
twosamplesurvival test=logrank 
curve("control") = (1 2) : (0.95 0.89) 
refsurvival = "control" 
hazardratio = 0.2 to 0.95 by 0.05 
accrualtime = 1 
followuptime = 1 
groupweights = (1 4) 
213	  
	  
ntotal = 400 
power = .; 
run; 
proc power; 
twosamplesurvival test=logrank 
curve("control") = (1 2) : (0.95 0.75) 
refsurvival = "control" 
hazardratio = 0.2 to 0.95 by 0.05 
accrualtime = 1 
followuptime = 1 
groupweights = (1 4) 
ntotal = 400 
power = .; 
run; 
proc power; 
twosamplesurvival test=logrank 
curve("control") = (1 2) : (0.84 0.75) 
refsurvival = "control" 
hazardratio = 0.2 to 0.95 by 0.05 
accrualtime = 1 
followuptime = 1 
groupweights = (1 4) 
ntotal = 400 
power = .; 
run; 
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